Oficina de Patentes Y Marcas de Estados Unidos

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS
OFICINA DE PATENTES Y MARCAS DE ESTADOS UNIDOS
Dirección: COMISIONADO DE PATENTES
P.O. BOX 1450
Alexandria, Virginia 22313-1450
www.uspto.gow

AVISO DE CONCESIÓN Y TASA (S) DEBIDA

115777 7590 02/18/2016

Jennifer I. Kisko
GrayRobinson, P.A.
301 E. CALLE PINO
SUITE 1400
Orlando, FL 32801

EXAMINADOR
MCINTOSH III, TRAISS C

UNIDAD DE ARTE	NÙMERO DE PAPEL
1673	

FECHA DE ENVÍO: 02/18/2016

No. DE SOLICITUD	FECHA DE PRESENTACIÓN	PRIMER NOMBRE DE INVENTOR	No. EXPEDIENTE DE ABOGADO	No. DE CONFIRMACIÓN
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TÍTULO DE LA INVENCIÓN: Derivados Nucleósido Sustituidos de 4'-Difluorometilo como inhibidores de la replicación del ARN de la influenza.

TIPO DE SOLICITUD	ESTADO DE LA ENTIDAD	TASA DE EMISIÓN DEBIDA	TASA DE PUBLICACIÓN DEBIDA	TASA DE EMISIÓN PAGADA	TOTAL TASA(S) DEBIDA	FECHA DE VCTO
No provisional	No contado	$960	$0	$0	$960	05/18/2016

LA SOLICITUD ANTERIORMENTE IDENTIFICADA HA SIDO EXAMINADA Y SE PERMITE LA EMISIÓN COMO PATENTE. EL INDEMNIZACÌON SOBRE EL

MÈRITO ESTÁ CERRADO. ESTE AVISO DE CONCESIÓN NO ES UNA CONCESIÓN DE DERECHOS DE PATENTE. ESTA SOLICITUD ESTÁ SUJETA A LA RETIRADA DE LA EMISIÓN POR INICIATIVA DE LA OFICINA O POR PETICIÓN DEL SOLICITANTE. VER 37 CFR 1.313 Y MPEP 1308.

LA TASA DE EMISIÓN Y LA TASA DE PUBLICACIÓN (SI SE REQUIERE) DEBEN SER PAGADAS DENTRO DE LOS TRES MESES A PARTIR DE LA FECHA DE ENVÍO DE ESTE AVISO O ESTA SOLICITUD SE CONSIDERA ABANDONADA. ESTE PERIODO ESTATUTARIO NO PUEDE SER EXTENDIDO. VÉASE 35 U.S.C. 151. LA TASA DE EMISIÓN QUE DEBE INDICADA ANTERIORMENTE NO REFLEJA UN CRÉDITO POR NINGUNA TASA DE EMISIÓN ANTERIORMENTE PAGADA EN ESTA SOLICITUD. SI UNA TASA DE EMISIÓN HA SIDO PAGADA ANTERIORMENTE EN ESTA SOLICITUD (COMO SE MUESTRA ANTERIORMENTE), LA DEVOLUCIÓN DE LA PARTE B DE ESTE FORMULARIO SERÁ CONSIDERADA UNA SOLICITUD PARA REAPLICAR LA TASA DE EMISIÓN ANTERIORMENTE PAGADA HACIA LA TASA DE EMISIÓN AHORA DADA.

CÓMO RESPONDER A ESTA NOTIFICACIÓN:

I. Revise el ESTADO DE ENTIDAD mostrado anteriormente, si el ESTADO DE ENTIDAD se muestra como PEQUEÑO o MICRO, verifique si el derecho a ese estado de entidad sigue siendo válido.

Si el ESTADO DE ENTIDAD es el mismo que se muestra arriba, pague la(s)TASA(S) TOTAL(ES) DEBIDA(AS) mostrada(s) arriba.

Si se cambia el ESTADO DE LA ENTIDAD por la mostrada arriba, en la PARTE B- TASA (S) DE TRANSMISIÓN, complete la sección número 5 titulada " Cambio en el estado de la entidad (por el estado indicado arriba)".

Para propósitos de este aviso, los honorarios de entidad pequeña son la 1/2 de la cantidad de tarifas no descontadas, y los honorarios de micro entidad son la 1/2 de la cantidad de honorarios de entidad pequeña.

II. PARTE B- TASA(S) DE TRANSMISIÓN, o su equivalente, debe ser completado y devuelto a la Oficina de Marcas de Patentes de los Estados Unidos (USPTO) con su TASA DE EMISIÓN y TASA DE PUBLICACIÓN (si es necesario). Si usted está cobrando la tasa(s) a su cuenta de depósito, se debe completar la sección "4b" de la Parte B- Tasa(s) de Transmisión y se debe enviar una copia adicional

del formulario. Si se presenta un equivalente de la Parte B, se debe hacer claramente una solicitud para volver a aplicar una tasa de emisión pagada previamente y se pueden producir retrasos en el procesamiento debido a la dificultad de reconocer el documento como un equivalente de la Parte B.

III. Todas las comunicaciones relativas a esta solicitud deben dar el número de solicitud. Por favor dirija todas las comunicaciones antes de la expedición de la TASA DE EMISIÓN Paro del Correo, a menos que se le indique lo contrario.

NOTA IMPORTANTE: Las patentes de utilidad que se emiten en solicitudes presentadas el 12 de diciembre de 1980 o después pueden requerir el pago de tasas de mantenimiento. Es la responsabilidad del titular de la patente asegurar el pago puntual de las tasas de mantenimiento cuando se vencen.

PTOL-85 (Rev. 02/11)

PARTE B-TARIFA (S) DE TRANSMISIÓN

Complete y envíe este formulario, junto con los honorarios aplicables, a: Correo

Correo TASA DE EMISIÓN
Comisario de Patentes
P.O. Caja 1450
Alexandria, Virginia 22314-1450
or Fax (571) -273-2885

INSTRUCCIONES: Este formulario debe utilizarse para transmitir la TASA DE EMISIÓN y la TASA DE PUBLICACIÓN (si es necesario). Los bloques 1 a 5 deben completarse cuando sea apropiado. Toda la correspondencia adicional incluyendo la Patente, órdenes anticipadas y notificación de tasas de mantenimiento serán enviadas a la dirección de correspondencia actual como se indica a menos que sea corregida abajo o dirigida de otra manera en el Bloque 1, (a) especificando una nueva dirección de correspondencia; y/o (b) indicando un "DIRECCION DE TASA" diferente para notificaciones de tarifas de mantenimiento.

PRESENTE DIRECCIÓN DE CORRESPONDENCIA (Nota Utilice el bloque 1 para cualquier cambio de dirección)

115777 7590 02/18/2016

Jennifer I. Kisko
GrayRobinson, P.A.
301 E. CALLE PINO
SUITE 1400
Orlando, FL 32801

Nota: Un certificado de envío solo puede ser usado para envío de la Tasa (s) de Transmisión. Este certificado no puede utilizarse Para cualquier otro documento de acompañamiento. Cada papel adicional, como una cesión o un sorteo formal, debe tener su propio certificado de envío o transmisión.

Certificado de envío o transmisión

Por la presente certifico que esta Tasa (s) de Transmisión está siendo depositada con el Servicio Postal de los Estados Unidos con el franqueo suficiente para la primera clase envía en un sobre dirigido a la dirección de TASA DE PUBLICACIÓN de Correo anterior, EFS-WEB transmitido, o el facsímil transmitido al USPTO (571) 273-2885, en la fecha indicada a continuación.

(Nombre del Depositante)
(Firma)
(Fecha)

No. DE SOLICITUD	FECHA DE PRESENTACIÓN	PRIMER NOMBRE DEL INVENTOR	No. EXPEDIENTE DE ABOGADO	No. DE CONFIRMACIÓN
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TÍTULO DE LA INVENCIÓN: Derivados Nucleósido Sustituidos de 4'-Difluorometilo como inhibidores de la replicación del ARN de la influenza.

TIPO DE SOLICITUD	ESTADO DE LA ENTIDAD	TASA DE EMISIÓN DEBIDA	TASA DE PUBLICACIÓN DEBIDA	TASA DE EMISIÓN ANTER. PAGADA	TOTAL TASA(S) DEBIDA	FECHA DE VCTO
No provisional	No contado	$960	$0	$0	$960	05/18/2016

EXAMINADOR	UNIDAD DE ARTE	CLASE-SUBCLASE
MCINTOSH III. TRAVISS C	1673	514-047000

1. Cambio de dirección de correspondencia o indicación de "Dirección de Tasa" (37CFR 1.363). □ Cambio de dirección de correspondencia (o Formulario de Cambio de Dirección de Correspondencia PTO/SB/122) adjunto. □ Indicación de "Dirección de tasa" (o "Indicación de Formulario de "Dirección de tasa" PTO/SB/47; Rev. 03-02 o más reciente) adjunto. **Se requiere uso de un número de cliente.**	2. Para imprimir en la primera página de patente, (1) Los nombres de hasta 3 abogados de patentes registrados o agentes O, alternativamente, (2) El nombre de una sola empresa (teniendo como miembro un abogado registrado o agente) y los nombres de 2 abogados o agentes registrados. Si no hay nombre en listado, no se imprimirá ningún nombre. 1._____ 2._____ 3._____

3. DATOS DEL NOMBRE Y RESIDENCIA DEL CESIONARIO QUE DEBERÁN IMPRIMIRSE EN LA PATENTE (imprimir o escribir)

ATENCIÓN: A menos que se identifique un cesionario a continuación, no aparecerán datos de cesionario en la patente. Si un cesionario se identifica a continuación, el documento ha sido archivado para la grabación como se establece en 37 CFR 3.11. La terminación de este formulario NO es un sustituto de la presentación de una cesión.

(A) NOMBRE DEL ASESOR (B) RESIDENCIA: (CIUDAD Y ESTADO O PAIS)

Por favor, consulte las categorías apropiadas de cesionario (no se imprimirá en la patente): ☐ Individual ☐ Corporación u otra entidad del grupo privado ☐ Gobierno

4a. Se presentan las siguientes tasa(s): ☐Tasa de Emisión ☐Tasa de publicación (No se permite un descuento de entidad pequeña) ☐Orden de adelanto - # de	4b. Pago de la (s) tasa (s): (**Por favor primero reaplicar y pago previamente la tasa mostrada arriba**) ☐Un cheque adjunto ☐El pago debe ser con tarjeta de

copias_____	crédito. El formulario PTO-2038 está adjunto ☐El director está aquí autorizado a cobrar la(s) tasa(s) requerida(s), cualquier deficiencia, o créditos, cualquier sobrepago, al Número de Cuenta de Depósito _____ (adjunte una copia adicional de este formulario).

5. **Cambio del estado de la entidad** (del estado indicado arriba) ☐ Solicitante que certifica el estado de micro entidad. Véase 37 CFR 1.29 ☐ Solicitante que afirma el estado de entidad pequeña. Véase 37 CFR 1.27 NOTA: Si la solicitud se encontraba previamente en estado de micro entidad, se marcará esta casilla para ser una notificación de pérdida del derecho a la condición de micro entidad. ☐ Solicitante cambiando al estado regular de la tarifa no descontada.	NOTA: A falta de una certificación válida de Estado de Micro Entidad (ver los formularios PTO/SB/15A y 15B), emita el pago de cuotas en el monto de la micro entidad no será aceptado por el riesgo de abandono de la solicitud. NOTA: Si la solicitud se encontraba anteriormente en estado de entidad micro, marcar esta casilla se tomará Para ser una notificación de pérdida del derecho a la condición de micro entidad. NOTA: El chequeo de este recuadro se tomará como notificación de pérdida de derecho a pequeños o micro Entidad, según corresponda.

NOTA: Este formulario debe ser firmado de acuerdo con 37 CFR 1.31 y 1.33. Ver 37 CFR 1.4 para requisitos de la firma y certificaciones.

Firma Autorizada _____

Nombre registrado o impreso_____

Fecha_____

No. De Registro_____

PTOL-85 Parte B (10-13) Aprobado para su uso a través de 10/31/2013

OMB 0651-0033

Oficina de Patentes y Marcas de los Estados Unidos; DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS.

Oficina de Patentes Y Marcas de Estados Unidos

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS
OFICINA DE PATENTES Y MARCAS DE ESTADOS UNIDOS
Dirección: COMISIONADO DE PATENTES
P.O. BOX 1450
Alexandria, Virginia 22313-1450
www.uspto.gow

No. DE SOLICITUD	FECHA DE PRESENTACIÓN	PRIMER NOMBRE DE INVENTOR	No. EXPEDIENTE DE ABOGADO	No. DE CONFIRMACIÓN
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

115777 7590 02/18/2016

Jennifer I. Kisko
GrayRobinson, P.A.
301 E. CALLE PINO
SUITE 1400
Orlando, FL 32801

EXAMINADOR
MCINTOSH III, TRAISS C

UNIDAD DE ARTE	NÙMERO DE PAPEL
1673	

FECHA DE ENVÍO: 02/18/2016

Determinación del Ajuste del Periodo de Patente bajo 35 U.S.C. 154 (b)

(Solicitudes presentadas a partir del 29 de mayo de 2000)

La Oficina ha dejado de proporcionar un cálculo del Ajuste al Término de Patente (PTA) con el Aviso de Concesión.

La sección 1(h)(2) de la Ley de Correcciones Técnicas AIA enmendada 35 U.S.C. 154 (b) (3) (B) (i) para eliminar el requisito de que la Oficina proporcione una determinación del ajuste al término de la patente con el aviso de concesión. Véanse las Revisiones al Ajuste al Término de la Patente, 78 Fed. Reg. 19416, 19417 (1 de abril de 2013). Por lo tanto, la Oficina ya no está proporcionando una determinación inicial de ajuste al término de patente con el aviso de concesión. La Oficina continuará proporcionando una determinación de ajuste al término de la patente con la Carta de Notificación de Emisión que se envía por correo al solicitante aproximadamente tres semanas antes de la fecha de emisión de la patente e incluirá el ajuste de la patente en la patente. Toda solicitud de reconsideración de la determinación del ajuste de la duración de la patente (o el restablecimiento del ajuste de la duración de la patente) debería seguir el proceso descrito en 37 CPR 1.705.

Cualquier pregunta relacionada con la extensión término de patente o la determinación de ajuste debe dirigirse a la Oficina de Administración Jurídica de Patentes al (571) -272-7702. Las preguntas relacionadas con los pagos de tasas de emisión y publicación deben dirigirse al Centro de Servicio al Cliente de la Oficina de Publicación de Patentes al 1- (888) -786-0101 o (571) -272-4200.

Despacho OMB y Declaración de carga PRA para PTOL-85 Parte B

La Ley de Reducción de Trámites (PRA) de 1995 requiere que las agencias federales Oficina de Administración y aprobación del presupuesto antes de solicitar la mayoría de los tipos de información del público. Cuando la OMB aprueba una solicitud de agencia para recopilar información del público, la OMB (i) proporciona un número de control OMB válido y fecha de vencimiento para que la agencia muestre en el instrumento que se usará para recolectar la información y (ii) Informa al público sobre el significado legal del Número de Control OMB de acuerdo con 5 CFR 1320.5 (b).

La información recogida por PTOL-85 Parte B es requerida por 37 CFR 1.311. La información es requerida para obtener o retener un beneficio por parte del público

que debe presentar (y por la USPTO para procesar) una solicitud. La confidencialidad está gobernada por 35 U.S.C. 122 y 37 CFR 1.14. Se estima que esta colección tardará 12 minutos en completarse, incluyendo recolectar, preparar y enviar el formulario de solicitud completo a la USPTO. El tiempo variará dependiendo del caso individual. Cualquier comentario sobre la cantidad de tiempo que usted requiere para completar este formulario y/o sugerencias para reducir esta carga, debe ser enviado a la Oficial Principal de Información, Oficina de Patentes y Marcas de los Estados Unidos, Departamento de Comercio de los Estados Unidos, P.O. Box 1450, Alexandria, Virginia 22313 - 1450. NO ENVÍE TASAS O FORMULARIOS COMPLETADOS A ESTA DIRECCIÓN. ENVIAR A: Comisionado de Patentes, P.O. Box 1450, Alexandria, Virginia 22313 - 1450. Bajo la Ley de Reducción de Trámites de 1995, ninguna persona está obligada a responder a una recopilación de información a menos que muestre un número de control OMB válido.

Declaración de la Ley de Privacidad

La **Ley de Privacidad de 1974** (P.L. 93-579) requiere que se le dé cierta información en relación con su presentación del formulario adjunto relacionado con una solicitud de patente o patente. En consecuencia, de conformidad con los requisitos de la Ley, se debe informar que: (1) la autoridad general para la recopilación de esta información es 35 U.S.C. 2(b)(2); (2) el suministro de la información solicitada es voluntario; y (3) el propósito principal para el cual la información es utilizada por la Oficina de Patentes y Marcas de los Estados Unidos es procesar y/o examinar su presentación relacionada con una solicitud de patente o patente. Si no proporciona la información solicitada, la Oficina de Patentes y Marcas de los Estados Unidos puede no ser capaz de procesar y/o examinar su envío, lo cual puede resultar en la terminación de los procedimientos o el abandono de la solicitud o vencimiento de la patente.

La información proporcionada por usted en este formulario estará sujeta a los siguientes usos de rutina:

1. La información en este formulario será tratada confidencialmente en la medida permitida por la Ley de Libertad de Información (5 U.S.C. 552) y la Ley de Privacidad (5 U.S.C 552a). Los registros de este sistema de registros pueden ser revelados al Departamento de Justicia para determinar si la divulgación de estos registros es requerida por la Ley de Libertad de Información.

2. Un registro de este sistema de registros puede ser revelado, como un uso rutinario, en el curso de la presentación de pruebas a un tribunal, magistrado, o tribunal administrativo, incluyendo revelaciones a abogados opositores en el curso de negociaciones de asentamiento.
3. Un registro en este sistema de registros puede ser revelado, como uso de rutina, a un Miembro del Congreso que envíe una solicitud que involucre a un individuo, a quien pertenece el expediente, cuando el individuo ha solicitado asistencia al Miembro con respecto al tema del record.
4. Un registro en este sistema de registros puede ser revelado, como un uso rutinario, a un contratista de la Agencia que tenga la necesidad de la información para realizar un contrato. Los destinatarios de la información deberán cumplir con los requisitos de la Ley de Privacidad de 1974, según enmendada, de conformidad con 5 U.S.C. 552a (m).
5. Un expediente relacionado con una solicitud internacional presentada en virtud del Tratado de Cooperación en materia de Patentes en este sistema de registros podrá ser divulgado, como uso rutinario, a la Oficina Internacional de la Organización Mundial de la Propiedad Intelectual, de conformidad con el Tratado de Cooperación en materia de Patentes.
6. Un registro en este sistema de registros puede ser revelado, como un uso rutinario, a otra agencia federal para los propósitos de la revisión de la Seguridad Nacional (35 U.S.C. 181) y para la revisión según la Ley de Energía Atómica (42 U.S.C. 218 (c)).
7. Un registro de este sistema de registros puede ser revelado, como un uso de rutina, al Administrador, Servicios Generales o su designado, durante una inspección de los expedientes realizados por GSA como parte de la responsabilidad de dicha agencia de recomendar mejoras en la gestión de registros Prácticas y programas, bajo la autoridad de 44 USC 2904 y 2906. Dicha divulgación se realizará de conformidad con los reglamentos de la GSA que rigen la inspección de los registros con este fin y cualquier otra directiva pertinente (es decir, GSA o Comercio). Dicha divulgación no se utilizará para hacer determinaciones sobre individuos
8. Un registro de este sistema de registros puede ser revelado, como un uso de rutina, al público después de la publicación de la solicitud de conformidad con 35 U.S.C. 122 (b) o la emisión de una patente de conformidad con 35 U.S.C. 151. Además, un registro puede ser revelado al público, sujeto a las limitaciones de 37 CFR 1.14, como uso de rutina, si el registro se presentó en una solicitud que se abandonó o en la que se dio por concluido el proceso y cuya solicitud se hace referencia ya sea por una

solicitud publicada, una solicitud abierta a inspección pública o una patente expedida.

9. Un registro de este sistema de registros puede ser revelado, como un uso rutinario, a una agencia federal, estatal o local de solicitud de la ley, si la USPTO se da cuenta de una violación o posible violación de la ley o regulación.

<table>
<tr><td rowspan="2">Aviso de Concesión</td><td>No. de Solicitud
14/615,928</td><td colspan="2">Solicitante(s)
SMITH ET AL.</td></tr>
<tr><td>Examinador
TRAVISS C. MCINTOSH III</td><td>Unidad de arte
1673</td><td>AIA (primer inventor a archivar) Estado
SI</td></tr>
<tr><td colspan="4">- La FECHA DE ENVÌO de esta comunicación aparece en la portada con la dirección de correspondencia--

Si todas las reivindicaciones son permitidas, EL PROCESO SOBRE EL MÉRITO ES (O PERMANECE) CERRADO en esta solicitud. Si no se incluye aquí (o previamente enviado por correo), un Aviso de Concesión (PTOL-85) u otra comunicación apropiada se enviará por correo a su debido tiempo. ESTE AVISO DE CONCESIÓN NO ES UNA CONCESIÓN DE DERECHOS DE PATENTE. Esta solicitud está sujeta a la retirada del expediente por iniciativa de la Oficina a petición del solicitante. Véase 37 CFR 1.313 y MPEP 1308.

1. ☒ Esta comunicación responde a la petición de <u>enmienda presentada el 12/3/2015.</u>
☐ Una(s) declaración(es)/declaración(es) jurada(s) bajo 37 CFR 1.130 (b) fue/fueron presentadas el _____.

2. ☐ El solicitante hizo una elección en respuesta a un requisito de restricción establecido durante la entrevista en _____; el requisito de restricción y la elección se han incorporado en esta acción.

3. ☒ Las reivindicaciones permitidas son <u>1-10, 13, 14, 16, 17, 23-26, 31 y 33</u>. Como resultado de la(s) reivindicación(es) permitida(s), usted puede ser elegible para beneficiarse del programa de Procedimiento Acelerado de Patente en una oficina de propiedad intelectual participante para la solicitud correspondiente. Para obtener más información,</td></tr>
</table>

consulte http: //www.uspto.gov/patents/initevents/pph/indexJspo envíe una consulta a PPHfeedback@uspto.gov.

4. ☐ Se reconoce una reivindicación de prioridad extranjera bajo 35 U.S.C. § 119 (a)-(d) o (f).

Copias certificadas:

A) ☐Todos b) ☐ Algunos * c) ☐ Ninguno de los:

1. ☐ Se han recibido copias certificadas de los documentos de prioridad.
2. ☐ Se han recibido copias certificadas de los documentos de prioridad en la Solicitud No. _____.
3. Se han recibido copias de las copias certificadas de los documentos de prioridad en la presente solicitud en fase nacional de la Oficina Internacional (Regla 17.2(a) del PCT).

* Copias certificadas no recibidas: _____.

El Solicitante tiene TRES MESES DESDE LA "FECHA DE ENVÍO" de esta comunicación para presentar una respuesta que cumpla con los requisitos indicados a continuación. El incumplimiento de cumplir oportunamente resultará en el ABANDONO de esta solicitud. **ESTE PERIODO DE TRES MESES NO ES EXTENDIBLE.**

5. ☐ DIBUJOS CORREGIDOS (como "hojas de reemplazo") deben ser presentados.

☐ incluyendo los cambios requeridos por la Modificación/Comentario del Examinador adjunta o en la Acción Oficial de Documento No./Fecha del Envío_____.

Los signos de identificación tales como el número de solicitud (véase 37 CFR 1.84 {c)) se deben escribir en los dibujos en la parte delantera (no en la parte posterior) de cada hoja. Las hojas de reemplazo deben ser etiquetadas como tales en la cabecera de acuerdo con 37 CFR 1.121 (d).

6. ☐ DEPOSITO DE y/o INFORMACIÓN sobre el depósito de MATERIAL BIOLÓGICO debe ser presentado. Tenga en cuenta el comentario del Examinador adjunto sobre REQUISITO PARA EL DEPÓSITO DE MATERIAL BIOLÓGICO.

Archivos adjuntos 1. ☐ Aviso de Referencias Citado (PT0-892) 2. ☐ Declaraciones de divulgación de información (PTO / SB / 08), No. del documento / Fecha de envío 143753611/22/16 3. ☐ Comentario del examinador sobre el requisito de depósito de material biológico 4. ☐ Resumen de la entrevista (PT0-413), No. del papel / Fecha del correo __. 5. ☐ Modificación/comentario del Examinador 6. ☒ Declaración del examinador de las razones de la concesión 7. ☐ Otros __.

TRAVISS C. MCINTOSH III/ Examinador primario, Unidad de arte 1673	

Solicitud / Número de control: 14 / 615.928

Unidad de arte: 1673

RAZONES PARA LA CONCESIÓN

La presente solicitud, presentada en o después del 16 de marzo de 2013, se está examinando bajo la primera disposición de las disposiciones de la AIA.

La siguiente es una explicación de los motivos de la concesión del examinador: las modificaciones y los argumentos del solicitante han superado los rechazos establecidos en la acción oficial 11/9/2015.

No se ha visto que la técnica anterior enseñe o sugiera razonablemente los compuestos reivindicados en este momento que requieren un grupo 4'-CF_2H y también tiene las bases reivindicadas. Parece que el arte más cercano es 2015/0011497 (de registro) - pero los compuestos allí comprenden ya sea un 4'-CH_2CHF_2 o están delimitados por la condición expuesta en las reivindicaciones de la presente invención.

Los comentarios que considere necesarios el solicitante deberán presentarse a más tardar el pago de la tasa de emisión y, para evitar retrasos en el procesamiento, deberán acompañar preferentemente la comisión de emisión. Tales presentaciones deben estar claramente etiquetadas como "Comentarios sobre la Declaración de Razones para la Concesión".

Cualquier consulta relacionada con esta comunicación o comunicaciones anteriores del examinador debe dirigirse a TRAVISS C. MCINTOSH III cuyo número de teléfono es (571) 272-0657. El examinador puede ser alcanzado normalmente de M-F 9:30-6:00.

Si los intentos de llegar al examinador por teléfono son infructuosos, el supervisor del examinador, Shaojia A. Jiang puede ser alcanzado en 571-272-0627. El número de teléfono de fax de la organización donde se asigna esta solicitud o procedimiento es 571-273-8300.

Solicitud / Número de control: 14 / 615.928

Unidad de arte: 1673


La información sobre el estado de una solicitud puede obtenerse del sistema de Recuperación de Información de Solicitud de Patente (PAIR). La información de estado para las aplicaciones publicadas puede obtenerse de PAIR privado o PAIR público. La información de estado para aplicaciones no publicadas está disponible solo a través de PAIR privado. Para obtener más información sobre el sistema PAIR, consulte http://pair-direct.uspto.gov. Si tiene preguntas sobre el acceso al sistema PAIR privado, comuníquese con el Centro de Negocios Electrónico (EBC) al 866-217-9197 (sin cargo). Si desea recibir asistencia de un Representante de Servicio al Cliente de USPTO o acceder a la información automatizada, Llame al 800-786-9199 (EN LOS EEUU O CANADÁ) o 571-272-1000.

TRAVISS C. MCINTOSH III/

Examinador primario, Unidad de Arte 1673

REIVINDICACIONES

1. Un compuesto de Fórmula I



en donde:

Y es H o P(═X)(R′)(R);
R es O—R^1 o $NHR^{1'}$;
$R^{1'}$ es —$C(R^{2a})(R^{2b})C(═O)OR^3$;

R′ es $N(R^4)C(R^{2a})(R^{2b})C(═O)OR^3$, —OP(═O)(OH)OP(═O)(OH)OH, o —OR^3;
R^1 es H, haloalquilo inferior, o arilo, en donde arilo es fenilo o naftilenilo, opcionalmente sustituido con uno o más alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi inferior, halo, haloalquilo inferior, —$N(R^{1a})_2$, acilamino, —$SO_2N(R^{1a})_2$, —$C(═O)R^{1b}$, —$SO_2(R^{1c})$, —$NHSO_2(R^{1c})$, nitro, ciano, o $R^{1''}$;
cada R^{1a} es independientemente H o alquilo inferior;

cada R^{1b} es independientemente —OR^{1a} o —$N(R^{1a})_2$;

cada R^{1c} es alquilo inferior;

cada R^{2a} y R^{2b} es independientemente H, alquilo inferior, —$(CH_2)_rN(R^{1a})_2$, hidroxialquilo inferior, —CH_2SH, —$(CH_2)S(O)_pMe$, —$(CH_2)_nNHC(═NH)NH_2$ (1H-indol-3il)metilo, (1H-indol-4-il)metilo, —$(CH2)_mC(═O)R^{1b}$, Arilo y arilalquilo inferior, en donde arilo está opcionalmente sustituido con uno o más hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano;

m es 0, 1, o 2;

n es 1, 2, o 3;

p es 1 o 2;

r es 1 o 2;

o R^{2a} es H y R^{2b} y R^4 juntos forman $(CH_2)_n$;

cada R^3 es independientemente H, alquilo inferior, haloalquilo inferior, fenilo o fenil alquilo inferior, en donde fenilo y fenil alquilo inferior están opcionalmente sustituidos con alcoxi inferior;

o R^3 y $R^{1''}$ juntos forman CH_2;

cada R^4 es independientemente H, alquilo inferior;

o R^{2b} y R^4 juntos forman $(CH_2)_3$;

R^w, R^y, y R^z son cada uno independientemente H, OH o F;

R^x es H, OH, o F;

o R^3 y R^x juntos forman un enlace;

o R^1 y R^x Juntos forman un enlace;

X es O o S;

La base es uracilo, citosina, guanina, adenina, timina o heterocicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más grupos hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano;

con la condición de que si R^w es H, R^y es H, y R^z es H, entonces R^x no es H; y

con la condición de que la Fórmula I no es tetrahidrógeno trifosfato de ((2R,3R,4R,5R)-5-(4-amino-2-oxopirimidin-1(2H)-il)-2-(difluorometil)-4-fluoro-3-hidroxitetrahidrofuran-2-il)metilo;

o una sal farmacológicamente aceptable del mismo.

2. El compuesto de la reivindicación 1, en donde R^W es H, R^y es H, R^x es OH, y R^z es OH.

3. El compuesto de la reivindicación 1, en donde R^W es F, R^y es H, R^x es F, y R^z es OH.

4. El compuesto de la reivindicación 1, en donde R^W es OH, R^y es H, R^x es H, y R^z es OH.

5. El compuesto de la reivindicación 1, en donde R^W es F, R^y es H, R^x es H, y R^z es OH.

6. El compuesto de la reivindicación 1, en donde R^W es H, R^y es H, R^x es F, y R^z es OH.

7. El compuesto de la reivindicación 1, en donde R^W es H, R^y es OH, R^x es OH, y R^z es H.

8. El compuesto de la reivindicación 1, en donde R^W es H, R^y es F, R^x es OH, y R^z es F.

9. El compuesto de la reivindicación 1, en donde R^W es H, R^y es F, R^x es OH, y R^z es H.

10. El compuesto de la reivindicación 1, en donde R^W es H, R^y es H, R^x es OH, y R^z es F.

11. El compuesto de la reivindicación 1, en donde X es O.

12. El compuesto de la reivindicación 1, en donde X es S.

13. El compuesto de la reivindicación 1, en donde R es O—R^1, y R^1 es naftilenilo.

14. El compuesto de la reivindicación 1, en donde R′ es $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, R^4 es H, R^{2a} es H, R^{2b} es metilo, y R^3 es isopropilo.

15. Un compuesto seleccionado de la lista que consta de:
4′-Difluorometiluridina;

4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluorouridina;

4′-Difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometil5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluorouridina;

4′-Difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-clorouridina;

4′-Difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-clorouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-clorouridina;

4′-Difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilcitidina;

4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(benciloxicarbonil)etil fosforamidato;

4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

4′-Difluorometilcitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilcitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluorocitidina;

4′-Difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluorocitidina;

4′-Difluorometil-5-fluorcitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-clorocitidina;

4′-Difluorometil-5-clorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil5-clorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-clorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-clorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-clorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometil-5-clorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorocitidina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-clorocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-clorocitidina;

4′-Difluorometil-5-clorocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-clorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometiladenosina;

4′-Difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]adenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]adenosina;

4′-Difluorometiladenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometiladenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-7-adenosina;

4′-Difluorometil-7-adenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-7-adenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-7-adenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-7-adenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-7-adenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-7-adenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometil-7-adenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-7-adenosina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-7-adenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-7-adenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]adenosina;

4′-Difluorometil-7-adenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-7-adenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilguanosina;

4′-Difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]guanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]guanosina;

4′-Difluorometilguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-uridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-clorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-clorouridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometilcitidina;

2′-Desoxi-2′-fluoro-4′-difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

2′-Desoxi-4′-difluorometil-2′-fluorocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-citidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-fluorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-clorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-clorocitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometil-5-clorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]adenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]adenosina;

2′-Desoxi-4′-difluorometil-2′-fluoroadenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroadenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-Difluorometiladenosina;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]guanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]guanosina;

2′-Desoxi-4′-difluorometil-2′-fluoroguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluoromethyarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]arauridina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]arauridina;

2′-Desoxi-4′-difluorometil-2′-fluoroarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-arauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-arauridina;

2′-Desoxi-4′-difluorometil-2′,5-difluoroarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′,5-difluoroarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-arauridina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-arauridina;

4-Cloro-2′-Desoxi-4′-difluorometil-2′-fluoroarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4-Cloro-2′-Desoxi-4′-difluorometil-2′-fluoroarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluoromethlaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]aracitidina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]aracitidina;

2′-Desoxi-4′-difluorometil-2′-fluoroaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-aracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-aracitidina;

2′-Desoxi-4′-difluorometil-2′,5-difluoroaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′,5-difluoroaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4-Cloro-2′-Desoxi-2′fluoro-4′-difluorometilaracitidina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-aracitidina;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-aracitidina;

4-Cloro-2′-Desoxi-4′-difluorometil-2′-fluoroaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4-Cloro-2′-Desoxi-4′-difluorometil-2′-fluoroaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluoromethlaraadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato 2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-araadenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-araadenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]araadenosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]araadenosina;

2′-Desoxi-4′-difluorometil-2′-fluoroaraadenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroaraadenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluoromethlaraguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometilaraguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-araguanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-araguanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]araguanosina;

2′-Desoxi-2′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]araguanosina;

2′-Desoxi-4′-difluorometil-2′-fluoroaraguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-4′-difluorometil-2′-fluoroaraguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-DiDesoxi-2′-difluoro-4′-Difluorometiluridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-DiDesoxi-2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-uridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-clorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-clorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-clorouridina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-clorouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilcytdine-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroucitidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorocitidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5-fluorocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-2′-desoxi-2,2″-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)citidina;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)citidina;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

5-Cloro-2′-desoxi-2′,2′-difluoro-4′-Difluorometilcitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-fluoro-4′-difluorometilcitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′2′-difluoro-4′-difluorometiladenosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]adenosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]adenosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometiladenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometilguanosina-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]guanosina;

2′-Desoxi-2′,2′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]guanosina;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

2′-Desoxi-2′,2′-difluoro-4′-Difluorometilguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilarauridina;

4′-Difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluoromethlarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato};

4′-Difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato};

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]arauridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]arauridina;

4′-Difluorometilarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluoroarauridina;

4′-Difluorometil-5-fluoroarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato

4′-Difluorometil-5-fluoroarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato

4′-Difluorometil-5-fluoroarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato

4′-difluorometil-5-fluoroarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometil-5-fluoroarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroarauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroarauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluoroarauridina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluoroarauridina;

4′-Difluorometil-5-fluoroarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluoroarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

5-Cloro-4′-difluorometilarauridina;

5-Cloro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilarauridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilarauridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilarauridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-4′-difluorometilarauridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

5-Cloro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-arauridina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-arauridina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-arauridina;

5-Cloro-4′-difluorometilarauridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

5-Cloro-4′-difluorometilarauridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilaracitidina;

4′-Difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluoromethlaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]aracitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]aracitidina;

4′-Difluorometilaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluoroaracitidina;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-difluorometil-5-fluoroaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometil-5-fluoroaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroaracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroaracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluoroaracitidina;

2′-Desoxi-2′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluoroaracitidina;

4′-Difluorometil-5-fluoroaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluoroaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

5-Cloro-4′-difluorometilaracitidina;

5-Cloro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilaracitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4-Cloro-2′-Desoxi-2′-fluoro-4′-difluorometilaracitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilaracitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-4′-difluorometilaracitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

5-Cloro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-aracitidina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-aracitidina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-aracitidina;

5-Cloro-4′-difluorometilaracitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

5-Cloro-4′-difluorometilaracitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilaraadenosina;

4′-Difluorometilaraadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluoromethlaraadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaraadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaraadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilaraadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-araadenosina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-araadenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]araadenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]araadensoine;

4′-Difluorometilaraadenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilaraadenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilaraguanosina;

4′-Difluorometilaraguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluoromethlaraadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaraguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilaraguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilaraguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilaraguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-araguanosina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-araguanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]araguanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]araguanosina;

4′-Difluorometilaraguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilaraguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilouridina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilouridina;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilouridina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilouridina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilouridina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilouridina;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

3′-Desoxi-3′5-difluoro-4′-difluorometilxilocitidina;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

3′-Desoxi-3′,5-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

5-Cloro-3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

5-Cloro-3′-Desoxi 3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xiloadenosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xiloadenosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloadenosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloadenosina;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometilxiloguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xiloguanosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xiloguanosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloguanosina;

3′-Desoxi-3′-fluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloguanosina;

4′-Difluorometilxilouridina;

4′-Difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilouridina;

4′-Difluorometilxilouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilxilouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluoroxilouridina;

4′-Difluorometil-5-fluoroxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluororxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometil-5-fluororxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroxilouridina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroxilouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluoroxilouridina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluororxilouridina;

4′-Difluorometil-5-fluoroxilouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluoroxilouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

5-Cloro-4′-difluorometilxilouridina;

5-Cloro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-4′-difluorometilxilouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

5-Cloro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilouridina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilouridina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilouridina;

5-Cloro-4′-difluorometilxilouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

5-Cloro-4′-difluorometilxilouridina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilxilocitidina;

4′-Difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

4′-Difluorometilxilocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilxilocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometil-5-fluoroxilocitidina;

4′-Difluorometil-5-fluoroxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluororxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometil-5-fluoroxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometil-5-fluoroxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometil-5-fluororxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroxilocitidina;

4′-Difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluoroxilocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluoroxilocitidina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluororxilocitidina;

4′-Difluorometil-5-fluoroxilouridina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometil-5-fluoroxilocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

5-Cloro-4′-difluorometilxilocitidina;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-4′-difluorometilxilocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

5-Cloro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-xilocitidina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xilocitidina;

5-Cloro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xilocitidina;

5-Cloro-4′-difluorometilxilocitidina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

5-Cloro-4′-difluorometilxilocitidina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilxiloadenosina;

4′-Difluorometilxiloadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil; fosforamidato;

4′-Difluorometilxiloadenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxiloadenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxiloadenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilxiloadenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloadenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloadenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloadenosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloadenosina;

4′-Difluorometilxiloadenosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilxiloadenosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

4′-Difluorometilxiloguanosina;

4′-Difluorometilxiloguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxiloguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxiloguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

4′-Difluorometilxiloguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

4′-Difluorometilxiloguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

4′-Difluorometilxiloguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloguanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloguanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]xiloguanosina;

4′-Difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]xiloguanosina;

4′-Difluorometilxiloguanosina-3′,5′-éster isopropílico del ácido fosfórico cíclico;

4′-Difluorometilxiloguanosina-3′,5′-éster isopropílico del ácido tiofosfórico cíclico;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluororuridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluororuridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorouridina-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorouridina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluorouridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometiluridina-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]uridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]uridina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-citidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluororcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluororcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5-fluorocitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

3′-Desoxi-3′,3′-difluoro-4′-difluoromethy-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-5-fluorocitidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]-5-fluorocitidina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]-5-fluorocitidina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-uridina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]citidina;

5-Cloro-3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]citidina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilcitidina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometiladenosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-adenosina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]adenosina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]adenosina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-fenil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-1-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil fosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-(O-2-naftil-N—(S)-1-(isopropoxicarbonil)etil tiofosforamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]fosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-Difluorometilguanosina-5′-{N,N′-bis[(S)-1-(isopropoxilcarbonil)etil]tiofosforodiamidato;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-oxido-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-(2-sulfuro-4-H-1,3,2-benzodioxafosforin-2-il)-guanosina;

3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)fosfinil]guanosina; y


3′-Desoxi-3′,3′-difluoro-4′-difluorometil-5′-O-[bis(4-metoxifenoxi)tiofosfinil]guanosina.

16. Un método de tratamiento para la Influenza que comprende administrar a un paciente que lo necesite una cantidad terapéuticamente eficaz del compuesto de la reivindicación 1.

17. Una composición que comprende el compuesto de la reivindicación 1, mezclado con al menos un vehículo, diluyente o excipiente.

18. Una composición que comprende el compuesto de la reivindicación 1 en combinación con uno o más compuestos antivirales.

19. Un método para tratar una infección por Influenza que comprende administrar a un paciente que lo necesite una cantidad terapéuticamente eficaz de un compuesto de Fórmula I



en donde:

Y es H o P(═X)(R′)(R);

R es O—R^1 o NH$R^{1'}$;

$R^{1'}$ es —C(R^{2a})(R^{2b})C(═O)OR^3;

R′ es N(R^4)C(R^{2a})(R^{2b})C(═O)OR^3, —OP(═O)(OH)OP(═O)(OH)OH, o —OR^3;

R^1 es H, haloalquilo inferior o arilo, en donde arilo es fenilo o naftilenilo, opcionalmente sustituido con uno o más alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi inferior, halo, haloalquilo inferior, —N(R^{1a})$_2$, acilamino, —SO_2N(R^{1a})$_2$, —C(═O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, ciano, o $R^{1''}$;

cada R^{1a} es independientemente H o alquilo inferior;

cada R^{1b} es independientemente —OR^{1a} o —$N(R^{1a})_2$;

cada R^{1c} es alquilo inferior;

cada R^{2a} y R^{2b} es independientemente H, alquilo inferior, —$(CH_2)_rN(R^{1a})_2$, hidroxialquilo inferior, —CH_2SH, —$(CH_2)S(O)_pMe$, —$(CH_2)_nNHC(=NH)NH_2$, (1H-indol-3-il)metil, (1H-indol-4-il)metil, —$(CH2)_mC(=O)R^{1b}$, arilo y aril alquilo inferior, en donde arilo está opcionalmente sustituido con uno o más hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano;

m es 0, 1, o 2;

n es 1, 2, o 3;

p es 1 o 2;

r es 1 o 2;

o R^{2a} es H y R^{2b} y R^4 juntos forman $(CH_2)_n$;

cada R^3 es independientemente H, alquilo inferior, haloalquilo inferior, fenilo o fenil alquilo inferior, en donde fenilo y fenil alquilo inferior están opcionalmente sustituidos con alcoxi inferior;

o R^3 y $R^{1''}$ juntos forman CH_2;

cada R^4 es independientemente H, alquilo inferior;

o R^{2b} y R^4 juntos forman $(CH_2)_3$;

R^w, R^y, y R^z son cada uno independientemente H, OH o F;

R^x es H, OH, o F;

o R^3 y R^x juntos forman un enlace;

o R^1 y R^x juntos forman un enlace;

X es O o S; y

La base es uracilo, citosina, guanina, adenina, timina o heterocicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano;

o una sal farmacológicamente aceptable del mismo.

20. Un método para tratar una infección por Influenza que comprende administrar a un paciente que lo necesite una cantidad terapéuticamente eficaz del compuesto de la reivindicación 15.

US009370569B2

(12) **United States Patent**
Smith et al.

(10) **Patent No.: US 9,370,569 B2**
(45) **Date of Patent: Jun. 21, 2016**

(54) **4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION**

(71) Applicant: **Riboscience LLC**, Palo Alto, CA (US)

(72) Inventors: **Mark Smith**, San Francisco, CA (US); **Klaus G. Klumpp**, West Chester, PA (US)

(73) Assignee: **Riboscience LLC**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/615,928**

(22) Filed: **Feb. 6, 2015**

(65) **Prior Publication Data**

US 2015/0225441 A1 Aug. 13, 2015

Related U.S. Application Data

(60) Provisional application No. 61/936,569, filed on Feb. 6, 2014.

(51) **Int. Cl.**

C07H 19/213	(2006.01)
C07H 19/06	(2006.01)
C07H 19/10	(2006.01)
C07H 19/16	(2006.01)
A61K 45/06	(2006.01)
A61K 31/7072	(2006.01)
A61K 31/7068	(2006.01)
A61K 31/7076	(2006.01)
A61K 31/708	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 45/06*** (2013.01); ***A61K 31/708*** (2013.01); ***A61K 31/7068*** (2013.01); ***A61K 31/7072*** (2013.01); ***A61K 31/7076*** (2013.01); ***C07H 19/06*** (2013.01); ***C07H 19/10*** (2013.01); ***C07H 19/16*** (2013.01); ***C07H 19/213*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2015/0011497 A1* 1/2015 Beigelman C07H 19/11 514/47

* cited by examiner


Primary Examiner — Traviss C McIntosh, III

(74) *Attorney, Agent, or Firm* — GrayRobinson, P.A.; Jennifer L. Kisko

(57) **ABSTRACT**

The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.

I



20 Claims, No Drawings

4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION

FIELD OF THE INVENTION

The invention relates to nucleoside derivatives as inhibitors of Influenza RNA replication. In particular, the invention is concerned with the use of purine and pyrimidine nucleoside derivatives as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.

Influenza virus is causing seasonal epidemics of respiratory disease throughout the world. Approved treatment options for Influenza infection fall into two classes, neuraminidase inhibitors (Oseltamivir, Zanamivir) and M2 inhibitors (Amantadine, Rimantadine). However, the yearly influenza epidemics are still associated with a significant number of excess deaths every year. The occurrence of yearly deaths due to influenza and pneumonia correlates with circulating influenza virus and with the relative pathogenicity of the particular circulating influenza strain. In addition, new virus strains for which little or no population resistance exists can emerge through gene reassortment with viruses from a large animal reservoir and cause pandemics, which are a serious global public health issue. The available treatments of influenza virus infection have limited efficacy because of widespread resistance (amantadine, rimantadine) or requirement for early start of treatment (neuraminidase inhibitors). In addition, naturally resistant viruses have emerged that are resistant to both classes of inhibitors.


Many of the drugs approved for the treatment of viral infections are nucleosides or nucleoside analogues and most of these nucleoside analogue drugs inhibit viral replication, following conversion to the corresponding triphosphates, through inhibition of the viral polymerase enzymes. The influenza virus polymerase is essential for viral replication, and its inhibition by nucleoside triphosphate analogs results in the shut-down of virus production. Only very few nucleoside analogs have been previously found that can inhibit the influenza virus polymerase.

Influenza virus belongs to the family of Orthomyxoviridae. It is an RNA virus with a segmented negative sense RNA genome. The synthesis of viral messenger RNA and of viral genomic RNA in infected cells is performed by the trimeric influenza virus polymerase. Three virus encoded polymerase subunits (PA, PB1, PB2) and a virus encoded single stranded RNA binding protein (NP) are necessary and sufficient to perform RNA replication.

SUMMARY OF THE INVENTION

The compounds of Formula I are useful for the treatment of diseases mediated by Influenza and for pharmaceutical compositions comprising such compounds.

The application provides a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NH$R^{1'}$;

$R^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2(1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$ C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate; or a pharmacologically acceptable salt thereof.

The application provides the compounds of Formula I which are useful for the treatment of diseases mediated by Influenza, pharmaceutical compositions comprising such compounds of Formula I, or result in the formation of such compounds of Formula I in vivo during said treatment.

The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I or a compound resulting in the formation of a compound of Formula I in vivo.

The application provides a composition comprising a compound of Formula I and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of Formula I have been shown to be inhibitors of the influenza virus RNA polymerase or result in the

formation of inhibitors of the influenza virus polymerase after metabolic conversion in human cells.

The term "alkyl" as used herein denotes a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms. Preferably, the term "alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms. Most preferred are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert.-butyl or pentyl. The alkyl may be unsubstituted or substituted. The substituents are selected from one or more of cycloalkyl, nitro, amino, alkyl amino, dialkyl amino, alkyl carbonyl and cycloalkyl carbonyl.

The term "cycloalkyl" as used herein denotes an optionally substituted cycloalkyl group containing 3 to 7 carbon atoms, e. g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

The term "alkoxy" as used herein denotes an optionally substituted straight or branched chain alkyl-oxy group wherein the "alkyl" portion is as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, tert.-butyloxy, pentyloxy, hexyloxy, heptyloxy including their isomers.

The term "alkoxyalkyl" as used herein denotes an alkoxy group as defined above which is bonded to an alkyl group as defined above. Examples are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propyloxypropyl, methoxybutyl, ethoxybutyl, propyloxybutyl, butyloxybutyl, tert.-butyloxybutyl, methoxypentyl, ethoxypentyl, propyloxypentyl including their isomers.

The term "alkenyl" as used herein denotes an unsubstituted or substituted hydrocarbon chain radical having from 2 to 7 carbon atoms, preferably from 2 to 4 carbon atoms, and having one or two olefinic double bonds, preferably one olefinic double bond. Examples are vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

The term "alkynyl" as used herein denotes to unsubstituted or substituted hydrocarbon chain radical having from 2 to 7 carbon atoms, preferably 2 to 4 carbon atoms, and having one or where possible two triple bonds, preferably one triple bond. Examples are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

The term "H" as used herein refers to hydrogen, including deuterium.

The term "hydroxyalkyl" as used herein denotes a straight or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a hydroxy group. Examples are hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, hydroxyisopropyl, hydroxybutyl and the like.

The term "haloalkyl" as used herein denotes a straight or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl and the like.

The term "alkylthio" as used herein denotes a straight or branched chain (alkyl)S-group wherein the "alkyl" portion is as defined above. Examples are methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio or tert.-butylthio.

The term "aryl" as used herein denotes an optionally substituted phenyl and naphthyl (also referred to as naphthylenyl) (e. g. 1-naphthyl, 2-naphthyl or 3-naphthyl). Suitable substituents for aryl can be selected from those named for alkyl, in addition however, halogen, hydroxy and optionally substituted alkyl, haloalkyl, alkenyl, alkynyl and aryloxy are substituents which can be added to the selection.

The term "heterocyclyl" or "heterocycloalkyl" or "heterocycle" as used herein denotes an optionally substituted saturated, partially unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic systems which contain one or more hetero atoms selected from nitrogen, oxygen and sulfur which can also be fused to an optionally substituted saturated, partially unsaturated or aromatic monocyclic carbocycle or heterocycle.

Examples of suitable heterocycles are oxazolyl, isoxazolyl, furyl, tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, 2-thienyl, 3-thienyl, pyrazinyl, isothiazolyl, dihydrooxazolyl, pyrimidinyl, tetrazolyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinonyl, (N-oxide)-pyridinyl, 1-pyrrolyl, 2-pyrrolyl, triazolyl e. g. 1,2,3-triazolyl or 1,2,4-triazolyl, 1-pyrazolyl, 2-pyrazolyl, 4-pyrazolyl, piperidinyl, morpholinyl (e. g. 4-morpholinyl), thiomorpholinyl (e. g. 4-thiomorpholinyl), thiazolyl, pyridinyl, dihydrothiazolyl, imidazolidinyl, pyrazolinyl, piperazinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, thiadiazolyl e. g. 1,2,3-thiadiazolyl, 4-methylpiperazinyl, 4-hydroxypiperidin-1-yl.

Suitable substituents for heterocycloalkyls can be selected from those named for alkyl, in addition however, optionally substituted alkyl, alkenyl, alkynyl, an oxo group (=O) or aminosulphonyl are substituents which can be added to the selection.

The term "acyl" ("alkylcarbonyl") as used herein denotes a group of formula C(=O)R wherein R is hydrogen, an unsubstituted or substituted straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms or a phenyl group. Most preferred acyl groups are those wherein R is hydrogen, an unsubstituted straight chain or branched hydrocarbon residue containing 1 to 4 carbon atoms or a phenyl group.

The term "halogen" or "halo" stands for fluorine, chlorine, bromine or iodine, preferable fluorine, chlorine, bromine.

In the pictorial representation of the compounds given throughout this application, a thickened tapered line () indicates a substituent which is above the plane of the ring to which the asymmetric carbon belongs and a dotted line () indicates a substituent which is below the plane of the ring to which the asymmetric carbon belongs.

Compounds of formula I may exhibit stereoisomerism. These compounds can be any isomer of the compound of formula I or mixtures of these isomers. The compounds and intermediates of the present invention having one or more asymmetric carbon atoms may be obtained as racemic mixtures of stereoisomers which can be resolved.


Compounds of formula I may exhibit tautomerism which means that the compounds of this invention can exist as two or more chemical compounds that are capable of facile interconversion. In many cases it merely means the exchange of a hydrogen atom between two other atoms, to either of which it forms a covalent bond. Tautomeric compounds exist in a mobile equilibrium with each other, so that attempts to prepare the separate substances usually result in the formation of a mixture that shows all the chemical and physical properties to be expected on the basis of the structures of the components.

The most common type of tautomerism is that involving carbonyl, or keto, compounds and unsaturated hydroxyl compounds, or enols. The structural change is the shift of a hydrogen atom between atoms of carbon and oxygen, with the rearrangement of bonds. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form is the predominant one; in phenols, the enol form is the major component.

Compounds of formula I which are basic can form pharmaceutically acceptable salts with inorganic acids such as hydrohalic acids (e.g. hydrochloric acid and hydrobromic acid), sulphuric acid, nitric acid and phosphoric acid, and the like, and with organic acids (e.g. with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulphonic acid and p-toluene sulphonic acid, and the like). The formation and isolation of such salts can be carried out according to methods known in the art.

Inhibitors of Influenza

The application provides a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NHR$^{1'}$;

R$^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or R$^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$ C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and R$^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate; or a pharmacologically acceptable salt thereof.

The application provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

The application alternatively provides the above compound of Formula I, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

The application alternatively provides the above compound of Formula I, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

The application alternatively provides the above compound of Formula I, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

The application provides the compound of Formula I, wherein R^z is H.

The application provides the compound of Formula I, wherein R^y is OH.

The application provides the compound of Formula I, wherein R^W is H.

The application provides the compound of Formula I, wherein R^x is OH.

The application provides the compound of Formula I, wherein R' is O—R^3, R^3 is lower alkyl, R is —OR^1, and R^1 and R^x together form a bond.

The application provides the compound of Formula I, wherein R is —OR^1, R^1 is phenyl substituted with R$^{1''}$, R' is —OR^3, and R^3 and R$^{1''}$ together form CH_2.

The application provides the compound of Formula I, wherein X is O.

The application provides the compound of Formula I, wherein X is S.

The application provides the compound of Formula I, wherein R is O—R^1, and R^1 is phenyl optionally substituted with methoxy.

The application provides the compound of Formula I, wherein R is O—R^1, and R^1 is naphthylenyl.

The application provides the compound of Formula I, wherein R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

The application provides the compound of Formula I, wherein R' is —OP(=O)(OH)OP(=O)(OH)OH.

The application provides the compound of Formula I, wherein Base is cytidine optionally substituted with halo.

The application provides the compound of Formula I, wherein Base is uridine optionally substituted with halo.

The application provides the compound of Formula I, wherein Base is guanosine.

The application provides the compound of Formula I, wherein Base is adenosine.

The application provides the compound of Formula I, wherein R^w is F if R^w is not H or OH.

The application provides the compound of Formula I, wherein R^y is F if R^y is not H or OH.

The application provides the compound of Formula I, wherein R^z is F if R^z is not H or OH.

The application provides the compound of Formula I, wherein both R^y and R^z are F if both R^y and R^z are not H or OH.

The application provides the compound of Formula I, wherein R^y is H and R^z is OH if R^y is not OH or F and R^z is not H or F.

The application provides a compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylcytidine;

4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyladenosine;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylguanosine;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadenosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaradenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaradenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2,2"-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylarauridine;

4'-Difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;
4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine;
4'-Difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;
4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine;
4'-Difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadensoine;
4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine;
4'-Difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;
4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;

5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxylouridine;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine-30',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethy-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine; and

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine.

The application provides a composition comprising the compound of Formula I.

The application provides the above composition, admixed with at least one carrier, diluent or excipient.

The application provides a composition comprising the compound of Formula I in combination with one or more antiviral compounds.

The application provides a composition comprising the compound of Formula I in combination with one or more anti-Influenza compounds.


The application provides a composition comprising the compound of Formula I in combination with one or more antiviral compounds, admixed with at least one carrier, diluent or excipient.

The application provides a composition comprising the compound of Formula I in combination with one or more anti-Influenza compounds, admixed with at least one carrier, diluent or excipient.

The application provides a method of preventing or treating a virus comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,

I



wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or $NHR^{1'}$;

$R^{1'}$ is —$C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —$N(R^{1a})_2$, acylamino, —$SO_2N(R^{1a})_2$, —$C(=O)R^{1b}$, —$SO_2(R^{1c})$, —$NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —$N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —$(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, —CH_2SH, —$(CH_2)S(O)_pMe$, —$(CH_2)_nNHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$ $C(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;


Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano; and

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H;

or a pharmacologically acceptable salt thereof.

The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,

I



wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or $NHR^{1'}$;

$R^{1'}$ is —$C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —$N(R^{1a})_2$, acylamino, —$SO_2N(R^{1a})_2$, —$C(=O)R^{1b}$, —$SO_2(R^{1c})$, —$NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —$N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —$(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, —CH_2SH, —$(CH_2)S(O)_pMe$, —$(CH_2)_nNHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$ $C(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;
or R^{2b} and R^4 together form $(CH_2)_3$;
R^w, R^y, and R^z are each independently H, OH or F;
R^x is H, OH, or F;
or R^3 and R^x together form a bond;
or R^1 and R^x together form a bond;
X is O or S; and
Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
or a pharmacologically acceptable salt thereof

The application provides a method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I or a compound resulting in the formation of a compound of Formula I in vivo.

The application provides the use of a compound of Formula I in the preparation of a medicament for the treatment of a viral infection.

The application provides the use of the compound of Formula I in the preparation of a medicament for the treatment of an Influenza infection.

The application provides any compound, composition, method, or use as described herein.

The application provides the above method, further comprising administering an immune system modulator or one or more antiviral agents that inhibits replication of Influenza, or a combination thereof.

The application provides the above method for inhibiting replication of Influenza in a cell comprising administering a compound of Formula I.

Examples of representative compounds encompassed by the present invention and within the scope of the invention are provided in the following Tables. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

In general, the nomenclature used in this application is based on standard nucleic acid nomenclature common to one of ordinary skill in the art. If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

TABLE 1

Examples of compounds of generic Formula I.




Compound Number	Structure	Name
I-1		4'-Difluoromethyluridine
I-2		4'-Difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-3		4'-Difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-4		4'-Difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-5		4'-Difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-6		4'-Difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-7		4'-Difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-8		4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-9		4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-10		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-11		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-12		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-13		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine
I-14		4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester
I-15		4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-16		4'-Difluoromethyl-5-fluorouridine
I-17		4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-18		4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-19		4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-20		4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-21		4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-22		4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-23		4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-24		4'-Difluoromethyl5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-25		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-26		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-27		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-28		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluorouridine
I-29		4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-30		4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-31		4'-Difluoromethyl-5-chlorouridine
I-32		4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-33		4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-34		4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-35		4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-36		4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-37		4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-38		4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-39		4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-40		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-41		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-42		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-43		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-chlorouridine
I-44		4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-45		4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-46		4'-Difluoromethylcytidine
I-47		4'-Difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-48		4'-Difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-49		4'-Difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-50		4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-51		4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-52		4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-53		4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-54		4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-55		4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-56		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-57		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-58		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-59		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine
I-60		4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-61		4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-62		4'-Difluoromethyl-5-fluorocytidine
I-63		4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-64		4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-65		4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-656		4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-67		4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-68		4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-69		4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-70		4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-71		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-72		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-73		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) phosphinyl]-5-fluorocytidine
I-74		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluorocytidine
I-75		4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-76		4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-77		4'-Difluoromethyl-5-chlorocytidine
I-78		4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-79		4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-80		4'-Difluoromethyl5-chlorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-81		4'-Difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-82		4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-83		4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-84		4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-85		4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}
I-86		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-87		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-88		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine
I-89		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-chlorocytidine
I-90		4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-91		4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-92		4'-Difluoromethyladenosine
I-93		4'-Difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-94		4'-Difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-95		4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-96		4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-97		4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-98		4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-99		4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-100		4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-101		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-102		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-103		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] adenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-104		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] adenosine
I-105		4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-106		4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-107		4'-Difluoromethyl-7-adenosine
I-108		4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-109		4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-110		4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-111		4'-Difluoromethyl-7-adenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-112		4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-113		4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-114		4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-115		4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-116		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine
I-117		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine
I-118		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-119		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] adenosine
I-120		4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-121		4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-122		4'-Difluoromethylguanosine
I-123		4'-Difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-124		4'-Difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-125		4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-126		4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-127		4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-128		4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-129		4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-130		4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-131		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-132		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-133		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-134		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] guanosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-135		4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-136		4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-137		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine
I-138		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-139		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-140		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-141		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-142		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-143		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-144		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-145		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-146		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-147		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-148		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-149		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-150		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester
I-151		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-152		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine
I-153		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-154		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-155		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-156		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-157		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-158		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-159		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-160		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-161		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-162		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-163		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine
I-164		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-uridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-165		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-166		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-167		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine
I-168		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(isopropoxycarbonyl)ethyl phosphoramidate
I-169		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-170		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-171		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-172		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-173		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-174		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-175		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-176		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-177		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-178		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine
I-179		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-chlorouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-180		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-181		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-182		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine
I-183		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-184		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-185		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-186		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-187		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-188		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-189		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-190		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-191		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2 benzodioxaphosphorin-2-yl)-cytidine
I-192		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-193		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-194		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-195		2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-196		2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-197		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine
I-198		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-199		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-200		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-201		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-202		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-203		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-204		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-205		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-206		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-207		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-208		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-209		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-210		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-211		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-212		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine
I-213		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-214		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-215		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-216		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-217		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-218		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-219		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-220		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-221		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-222		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-223		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine
I-224		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-chlorocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-225		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-226		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-227		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine
I-228		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-229		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-230		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-231		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-232		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-233		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-234		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-235		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-236		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-237		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-238		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-239		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] adenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-240		2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-241		2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-242		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine
I-243		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-244		2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-245		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-246		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-247		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-248		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-249		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-250		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-251		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-252		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-253		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-254		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] guanosine
I-255		2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-256		2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-257		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine
I-258		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-259		2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-260		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-261		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-262		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-263		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-264		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-265		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-266		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-267		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-268		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] arauridine
I-269		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] arauridine
I-270		2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-271		2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-272		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine
I-273		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-274		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-275		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-276		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-277		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-278		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-279		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-280		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-281		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-282		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-283		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine
I-284		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-arauridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-285		2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-286		2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-287		4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylarauridine
I-28		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-289		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-290		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-291		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-292		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-293		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-294		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-295		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-296		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-297		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-298		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine
I-299		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-arauridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-300		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-301		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-302		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine
I-303		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-304		2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-305		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-306		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-307		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-308		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-309		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-310		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-311		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-312		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-313		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] aracytidine
I-314		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] aracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-315		2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-316		2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-317		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine
I-318		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-319		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-320		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-321		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-322		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-323		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-324		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-325		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-326		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-327		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-328		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-329		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-aracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-330		2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-331		2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-332		4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine
I-333		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-334		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-335		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-336		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-337		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-338		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-339		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-340		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-341		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-342		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-343		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-344		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-aracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-345		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-346		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-347		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine
I-348		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-349		2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-350		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-351		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-352		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-353		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-354		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-355		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-356		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-357		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-358		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] araadenosine
I-359		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] araadenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-360		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-361		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-362		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine
I-363		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-364		2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-365		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-366		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-367		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-368		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-369		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-370		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-371		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-372		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-373		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] araguanosine
I-374		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] araguanosine
I-375		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-376		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-377		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine
I-378		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-379		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-380		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-381		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-382		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-383		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-384		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-385		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-386		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-387		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-388		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-389		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine
I-390		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-391		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-392		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine
I-393		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-394		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-395		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-396		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-397		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-398		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-399		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-400		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-401		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-402		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-403		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine
I-404		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-uridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-405		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-406		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-407		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine
I-408		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-409		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-410		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-411		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-412		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-413		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-414		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-415		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-416		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-417		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-418		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine
I-419		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-chlorouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-420		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-421		2'-Deoxy-2',2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-422		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine
I-423		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-424		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-425		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-426		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-427		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-428		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-429		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-430		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-431		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-432		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-433		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-434		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-435		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester
I-436		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-437		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine
I-438		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-439		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-440		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-441		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-442		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-443		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-444		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-445		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-446		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine
I-447		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-448		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-449		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-450		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-451		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-452		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine
I-453		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-454		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-455		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-456		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-457		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-458		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-459		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-460		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-461		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine
I-462		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine
I-463		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-464		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-465		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-466		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-467		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine
I-468		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-469		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-470		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-471		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-472		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-473		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-474		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-475		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-476		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-477		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-478		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-479		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] adenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-480		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-481		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-482		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine
I-483		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-484		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-485		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-486		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-487		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-488		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-489		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-490		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-491		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-492		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-493		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-494		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] guanosine
I-495		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-496		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-497		4'-Difluoromethylarauridine
I-498		4'-Difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-499		4'-Difluoromethlarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-500		4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-501		4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-502		4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-503		4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-504		4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate}
I-505		4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate}

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-506		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-507		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-508		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] arauridine
I-509		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] arauridine
I-510		4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-511		4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-512		4'-Difluoromethyl-5-fluoroarauridine
I-513		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-514		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-515		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-516		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-517		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-518		4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-519		4'-difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-520		4'-Difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-521		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine
I-522		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine
I-523		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine
I-524		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluoroarauridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-525		4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-526		4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-527		5-Chloro-4'-difluoromethylarauridine
I-528		5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-529		5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-530		5-Chloro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-531		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-532		5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-533		5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-534		5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-535		5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-536		5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-537		5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-538		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine
I-539		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-arauridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-540		5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-541		5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-542		4'-Difluoromethylaracytidine
I-543		4'-Difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-544		4'-Difluoromethlaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-545		4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-546		4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-547		4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-548		4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-549		4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-550		4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-551		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2 benzodioxaphosphorin-2-yl)-aracytidine
I-552		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-553		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] aracytidine
I-554		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] aracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-555		4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-556		4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-557		4'-Difluoromethyl-5-fluoroaracytidine
I-558		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-559		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-560		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-561		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-562		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-563		4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-564		4'-difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-565		4'-Difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-566		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine
I-567		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine
I-568		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine
I-569		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluoroaracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-570		4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-571		4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-572		5-Chloro-4'-difluoromethylaracytidine
I-574		5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-575		5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-576		5-Chloro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-577		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-578		5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-579		5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-580		5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-581		5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-582		5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-583		5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-584		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-585		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-aracytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-586		5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-587		5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-588		4'-Difluoromethylaraadenosine
I-589		4'-Difluoromethylaraadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-590		4'-Difluoromethlaraadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-591		4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-592		4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-593		4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-594		4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-595		4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-596		4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-597		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-598		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-599		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] araadenosine
I-600		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] araadensoine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-601		4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-602		4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-603		4'-Difluoromethylaraguanosine
I-604		4'-Difluoromethylaraguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-605		4'-Difluoromethlaraadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-606		4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-607		4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-608		4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-609		4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-610		4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-611		4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-612		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-613		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-614		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] araguanosine
I-615		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] araguanosine
I-616		4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-617		4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-618		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine
I-619		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-620		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-621		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-622		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-623		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-624		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-625		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-626		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-627		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-628		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-629		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-630		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine
I-631		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-632		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-633		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-634		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-635		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-636		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-637		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-638		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxycarbonyl)ethyl] phosphorodiamidate
I-639		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-640		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-641		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-642		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-643		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine
I-644		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine
I-645		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-646		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-647		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-648		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-649		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-650		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-651		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-652		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-653		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-654		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-655		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-656		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylouridine
I-657		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine
I-658		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-659		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-660		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-661		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-662		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-663		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-664		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-665		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-666		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-667		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-668		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-669		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylouridine
I-670		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine
I-671		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-672		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-673		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-674		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-675		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-676		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-677		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-678		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-679		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-680		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-681		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-682		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-683		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine
I-684		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-685		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-686		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-687		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-688		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-689		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-690		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-691		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-692		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-693		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-694		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-695		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine
I-696		3'-Deoxy-3'5-fluoro-4'-difluoromethylxylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-697		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-698		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-699		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-700		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-701		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-702		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-703		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-704		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-705		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-706		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-707		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-708		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine
I-709		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine
I-710		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-711		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-712		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-713		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-714		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-715		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-716		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-717		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-718		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-719		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-720		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-721		5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine
I-722		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine
I-723		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-724		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-725		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-726		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-727		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-728		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-729		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-730		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-731		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine
I-732		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine
I-733		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-734		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloadenosine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-735		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine
I-736		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-737		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-738		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-739		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-740		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-741		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-742		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-743		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-744		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-745		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine
I-746		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine
I-747		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloguanosine
I-748		4'-Difluoromethylxylouridine
I-749		4'-Difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-750		4'-Difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-751		4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-752		4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-753		4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-754		4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-755		4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-756		4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-757		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-758		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-759		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-760		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylouridine
I-761		4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-762		4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-763		4'-Difluoromethyl-5-fluoroxylouridine
I-764		4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-765		4'-Difluoromethyl-5-fluororxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-766		4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-767		4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-768		4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-769		4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-770		4'-Difluoromethyl-5-fluoroxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-771		4'-Difluoromethyl-5-fluororxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-772		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine
I-773		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-774		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine
I-775		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluororxylouridine
I-776		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-777		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-778		5-Chloro-4'-difluoromethylxylouridine
I-779		5-Chloro-4'-difluoromethylxylouridine-5'(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-780		5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-781		5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-782		5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-783		5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-784		5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-785		5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-786		5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-787		5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-788		5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-789		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-790		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylouridine
I-791		5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-792		5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-793		4'-Difluoromethylxylocytidine
I-794		4'-Difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-795		4'-Difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-796		4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-797		4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-798		4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-799		4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-800		4'-Difluoromethylxylocytidine-5-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-801		4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-802		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-603		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-804		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-805		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine
I-806		4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-807		4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-808		4'-Difluoromethyl-5-fluoroxylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-809		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-810		4'-Difluoromethyl-5-fluororxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-811		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-812		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-813		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-814		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-815		4'-Difluoromethyl-5-fluoroxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-816		4'-Difluoromethyl-5-fluororxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-817		4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-818		4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine
I-819		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine
I-820		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluororxylocytidine
I-821		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-822		4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-823		5-Chloro-4'-difluoromethylxylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-824		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-825		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-826		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-827		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-828		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-829		5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-830		5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-831		5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-832		5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-833		5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-834		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-835		5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xylocytidine
I-836		5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-837		5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-838		4'-Difluoromethylxyloadenosine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-839		4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-840		4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-841		4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-842		4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-843		4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-844		4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-845		4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-846		4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-847		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-848		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloadenosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-849		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-850		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloadenosine
I-851		4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-852		4'-Difluoromethylxyloadenosme-3',5'-cyclic thiophosphoric acid isopropyl ester
I-853		4'-Difluoromethylxyloguanosine
I-854		4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-855		4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-856		4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-857		4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-858		4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-859		4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-860		4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-861		4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-862		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine
I-863		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloguanosine
I-864		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine

TABLE 1-continued

Examples of compounds of generic Formula I.







Compound Number	Structure	Name
I-865		4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] xyloguanosine
I-866		4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-867		4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-868		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine
I-869		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-870		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-871		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-872		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-873		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-874		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-875		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-876		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-877		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-878		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-879		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-880		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine
I-881		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine
I-882		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-883		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-884		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-885		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-886		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-887		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-888		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-889		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-890		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-891		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-892		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine
I-893		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluorouridine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-894		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine
I-895		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-896		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-897		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-898		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-899		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-900		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-901		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-902		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-903		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-904		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-905		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-906		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] uridine
I-907		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-908		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-909		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-910		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-911		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-912		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-913		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-914		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-915		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-916		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-917		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-918		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-919		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine
I-920		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine
I-921		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-922		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-923		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-924		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-925		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-926		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-927		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-928		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-929		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-930		3'-Deoxy-3',3'-difluoro-4'-difluoromethy-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-931		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-932		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl]-5-fluorocytidine
I-933		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine
I-934		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-935		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-936		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-937		5-Chloro-3'-deoxy-3',3'-difluoro-4'-dffluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-938		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-939		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-940		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-941		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-942		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-943		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-944		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] cytidine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-945		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] cytidine
I-946		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine
I-947		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-948		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-949		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-950		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-951		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-952		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-953		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-954		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-955		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-956		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-957		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-958		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] adenosine

TABLE 1-continued

Examples of compounds of generic Formula I.






Compound Number	Structure	Name
I-959		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine
I-960		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-961		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-962		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-963		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

TABLE 1-continued

Examples of compounds of generic Formula I.









Compound Number	Structure	Name
I-964		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-965		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-966		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate
I-967		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate
I-968		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine

TABLE 1-continued

Examples of compounds of generic Formula I.

Compound Number	Structure	Name
I-969		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-970		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-971		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy) thiophosphinyl] guanosine

EXAMPLES

Abbreviations used in this application include: acetyl (Ac), acetic acid (HOAc), azo-bis-isobutyrylnitrile (AIBN), 1-N-hydroxybenzotriazole (HOBt), atmospheres (Atm), high pressure liquid chromatography (HPLC), 9-borabicyclo [3.3.1]nonane (9-BBN or BBN), methyl (Me), tert-butoxycarbonyl (Boc), acetonitrile (MeCN), di-tert-butyl pyrocarbonate or boc anhydride (BOC_2O), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), benzoyl (Bz), benzyl (Bn), m-chloroperbenzoic acid (MCPBA), butyl (Bu), methanol (MeOH), benzyloxycarbonyl (cbz or Z), melting point (mp), carbonyl diimidazole (CDI), $MeSO_2$-(mesyl or Ms), 1,4-diazabicyclo[2.2.2]octane (DABCO), mass spectrum (ms) diethylaminosulfur trifluoride (DAST), methyl t-butyl ether (MTBE), dibenzylideneacetone (Dba), N-carboxyanhydride (NCA), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), N-bromosuccinimide (NBS), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), 1,2-dichloroethane (DCE), pyridinium chlorochromate (PCC), N,N'-dicyclohexylcarbodiimide (DCC), pyridinium dichromate (PDC), dichloromethane (DCM), propyl (Pr), diethyl azodicarboxylate (DEAD), phenyl (Ph), di-iso-propylazodicarboxylate, DIAD, pounds per square inch (psi), di-iso-propylethylamine (DIPEA), pyridine (pyr), di-iso-butylaluminumhydride, DIBAL-H, room temperature, rt or RT, N,N-dimethyl acetamide (DMA), tert-butyldimethylsilyl or t-$BuMe_2Si$, (TBDMS), 4-N,N-dimethylaminopyridine (DMAP), triethylamine (Et_3N or TEA), N,N-dimethylformamide (DMF), triflate or CF_3SO_2-(Tf), dimethyl sulfoxide (DMSO), trifluoroacetic acid (TFA), 1,1'-bis-(diphenylphosphino)ethane (dppe), 2,2,6,6-tetramethylheptane-2,6-dione (TMHD), 1,1'-bis-(diphenylphosphino)ferrocene (dppf), thin layer chromatography (TLC), ethyl acetate (EtOAc), tetrahydrofuran (THF), diethyl ether (Et_2O), trimethylsilyl or Me_3Si (TMS), ethyl (Et), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), lithium hexamethyl disilazane (LiHMDS), 4-Me-$C_6H_4SO_2$— or tosyl (Ts), iso-propyl (i-Pr), N-urethane-N-carboxyanhydride (UNCA), ethanol (EtOH). Conventional nomenclature including the prefixes normal (n), iso (i-), secondary (sec-), tertiary (tert-) and neo have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, *Nomenclature in Organic Chemistry*, IUPAC 1979 Pergamon Press, Oxford.).

General Conditions

Compounds of the invention can be made by a variety of methods depicted in the illustrative synthetic reactions described below in the Examples section.

The starting materials and reagents used in preparing these compounds generally are either available from commercial

suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's *Reagents for Organic Synthesis*; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's *Chemistry of Carbon Compounds*, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplementals; and *Organic Reactions*, Wiley & Sons: New York, 1991, Volumes 1-40. It should be appreciated that the synthetic reaction schemes shown in the Examples section are merely illustrative of some methods by which the compounds of the invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this application.


The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein are typically conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about −78° C. to about 150° C., often from about 0° C. to about 125° C., and more often and conveniently at about room (or ambient) temperature, e.g., about 20° C.

Various substituents on the compounds of the invention can be present in the starting compounds, added to any one of the intermediates or added after formation of the final products by known methods of substitution or conversion reactions. If the substituents themselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups are known in the art, and can be employed. Examples of many of the possible groups can be found in "*Protective Groups in Organic Synthesis*" by Green et al., John Wiley and Sons, 1999. For example, nitro groups can be added by nitration and the nitro group can be converted to other groups, such as amino by reduction, and halogen by diazotization of the amino group and replacement of the diazo group with halogen. Acyl groups can be added by Friedel-Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product, including isolated products.

The starting material 1 can be purchased through numerous vendors (CAS: 63593-03-3). Selective benzyl protection followed by oxidation, under Swern conditions, provided aldehyde intermediate 3. Fluorination with DAST, followed by treatment with acetic anhydride under acidic conditions provided the diacetate intermediate 5. Vorbrüggen reaction followed by deprotection, under standard conditions, provided 4'-difluoromethyluridine 7 (Scheme 1).


Scheme 1



i) NaH, BnBr, DMF; ii) DMSO, $(ClCO_2)$, -78° C., iii) DAST, CH_2Cl_2; iv) Ac_2O, cat. H_2SO_4, AcOH; v) Uridine, BSA, $SnCl_4$, MeCN; vi) $NH_3 \cdot H_2O$, MeCN; vii) $Pd(OH)_2/C$, cat. HCl.

Compound 8 can be prepared, from the uridine analogue 7, by those skilled in the art of organic synthesis following the synthetic sequence outlined below (Scheme 2).


Scheme 2



i) Ac_2O, AcOH; ii) 4-Cl—CPhOP(O)Cl_2, 1-H-tetrazole, pyriidine; iii) $NH_3 \cdot H_2O$; iv) NH_3, MeOH


Phosphoramidate compounds of the present invention can be prepared by condensation of nucleoside 7, 8 or 9 with a suitably substituted phosphochloridate, or its sulfur analogue, of type 10 in the presence of a strong base (Scheme 3). The coupled product 11 of formula I is obtained as a mixture of two diastereomers initially under the coupling reaction and can be separated into their corresponding chiral enantiomers by chiral column, chiral HPLC, or chiral SFC chromatography.

Scheme 3




Phosphorodiamidate compounds of formula I in the present invention can be prepared by condensation of nucleoside 7, 8 or 9 with a suitably substituted phosphorodiamidic chloride, or phosphorodiamidothioic chloride, of type 12 in the presence of a strong base (Scheme 4).

Scheme 4




Cyclic phosphates of the present invention can be prepared by condensation of nucleoside 4 or 5 with isopropyl N,N,N,N-tetraisopropylphosphorodiamidite 14 (Scheme 5). Conversion to the thio derivative can be performed by heating the crude reaction mixture with bis(3-triethoxylsilyl)propyl-tetrasulfide (TEST).

Scheme 5



-continued




15

X = O or S


An alternative cyclic phosphate can be furnished from the reaction of the nucleoside 7, 8 or 9 with the appropriate chlorophosphite 16 in the presence of a base and Oxone (Scheme 6).

Scheme 6




7, 8 or 9

R^1 = H, OH or F



16


i) DIPEA, Oxone, MeCN



17

Phosphate prodrugs of type 19 are readily prepared from the reaction of compounds 7, 8 or 9 with chlorophosphates of type 18 (Scheme 7).


Scheme 7



7, 8 or 9


R^1 = H, OH or F

-continued



18


i) NMI




19

The synthesis of 4'-difluoromethylguanidine is outlined in Scheme 8. Herein, the ribose intermediate 5 undergoes a Vorbrüggen reaction with 20 to give the guanidine 23 derivative, following deprotection.

Scheme 8




5




20

i)


-continued



21



22




23


i) BSA, TMSOTf, MeCN; vi) NH_3•H_2O, MeCN; vii) $HCOONH_4$, MeOH

The synthesis of 4'-difluoromethyladenosine is outlined in Scheme 9. Herein, the ribose intermediate 5 undergoes a Vorbrüggen reaction with 24 to give the adenosine derivative 27, following deprotection.


Scheme 9



5




24




25

-continued



26




27


i) BSA, $SnCl_4$MeCN; vi) NH_3•H_2O, MeCN; vii) $Pd(OH)_2$/C, MeOH

Synthesis of 4'-difluoromethyl-5-chlorocytidine is outlined in Scheme 10. Herein, the ribose intermediate 5 undergoes a Vorbrüggen reaction with 28 to give the cytidine derivative 31, following deprotection.


Scheme 10




5




28



29



30




31


i) BSA, $SnCl_4$MeCN; ii) NH_3, MeOH; iii) BCl_3, CH_2Cl_2, -78° C.

4'-Difluoromethylaracytidine synthesis is outlined in Scheme 11. Herein, the uridine intermediate 6 is reacted with diphenyl carbonate to provide the anhydro compound 33. Hydrolysis and deprotection yield the arabinocytidine 38, following deprotection.

Scheme 11




-continued



i) $NH_3 \cdot H_2O$, dioxane; ii) $(Ph_2O)CO$, $NaHCO_3$, DMF; iii) NaOH, EtOH; iv) Ac_2O, Pyridine; v) 1H-tetrazole, pyridine, $POCl_3$, $NH_3 \cdot H_2O$, dioxane; vi) $NH_3 \cdot H_2O$, dioxane, 60° C.; vii) BCl_3, CH_2Cl_2, -78° C.

The arabinouridine intermediate 34 was converted to its 2'-deoxy-2'-fluoro derivative 39 through a reaction with DAST. Subsequent base conversion and deprotection provides the 2'-deoxy-2'-fluorocytidine 41 (Scheme 12).


Scheme 12



i) DAST, THF, 25-60° C.; $NH_3 \cdot H_2O$, dioxane; iii) 1H-tetrazole, 4-Cl—$PhOP(O)Cl_2$, pyridine; iii) $NH_3 \cdot H_2O$, dioxane; iv) $Pd(OH)_2/C$, MeOH, H_2.

The phosphoramidate compound 47 was synthesized following standard coupling methods as shown in Scheme 13. The neopently ester derivative was synthesized in a similar manner and outlined in Scheme 14.


Scheme 13.




-continued

i) BnOH, $SOCl_2$; ii) $PhOP(O)Cl_2$, Et_3N, CH_2Cl_2; iii) 1,1-dimethoxycyclopentane, 4-$MePhSO_3H$, DCE, 65° C.; iv) 44, t-BuMgCl, THF; v) HCO_2H (80%)

Scheme 14.



-continued




50

i) 48, t-BuMgCl, THF; ii) HCO_2H (80%).

General Preparations

Synthesis of compound ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol (2)


2



To a solution of compound 1 (0.5 g, 1.61 mmol) in dry DMF (20 mL), was added NaH (77.6 mg, 1.94 mmol). After the mixture stirred at room temperature for 0.5 h, BnBr (355 mg, 2.09 mmol) was added drop-wise. The mixture was allowed to stir at r.t. for 4 hrs. TLC (Petroleum ether:Ethyl acetate; 1:3) showed the reaction was complete. The reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried over Na_2SO_4 and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [ethyl acetate:petroleum ether (1:10 to 1:3)] provided the product 2 (0.42 g, 65%) as a colorless oil. LC-MS $(M+H)^+$=401.0

Synthesis of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde (3)


3



DMSO (1.65 mL, 23.6 mmol) was added drop-wise to a cold (−78° C.) solution of oxalyl chloride (1.05 mL, 12.0 mmol) in dichloromethane (50 mL). After stirring for 30 min, a solution of compound 2 (3 g, 7.5 mmol) in dichloromethane (25 mL) was added to the reaction. The stirring was continued for 45 min at −78° C., and triethylamine (3.5 mL, 25.0 mmol) was added to the reaction. The reaction was stirred at −78° C. for 15 min, after which the ice-bath was removed and the reaction was allowed to gradually warm over 45 min. The reaction was diluted with dichloromethane and the organic phase was sequentially washed with 5% aqueous HCl solution, saturated aqueous $NaHCO_3$ solution, brine, dried (Na_2SO_4) and concentrated under reduced pressure to provide 3 (2.2 g, crude), which was used without any further purification. LC-MS $(M+H)^+$=399.1

Synthesis of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole (4)


4



To a solution of compound 3 (2.2 g, 5.5 mmol) in dichloromethane (20 mL) was added DAST (4.45 g, 27.6 mmol). The mixture was stirred at room temperature for 14 hrs and then quenched by the addition of saturated $NaHCO_3$, extracted with EtOAc, dried (Na_2SO_4) and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] to afford 4 (1.0 g, 43%) as an oil. LC-MS $(M+H)^+$=421.1

Synthesis of (3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-2,3-diyl diacetate (5)


5



To a solution of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole (1.0 g, 6.3 mmol) in Ac2O (2.5 mL) and AcOH (10 mL) was added H2SO4 (3 drops). The mixture was stirred at room temperature for 3 hrs. TLC showed the reaction was complete. The mixture was poured to water, extracted with EtOAc, dried (Na2SO4) and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:3)] to afford compound 5 (1.0 g, crude) as a light-color oil. LC-MS (M+H)+=465.1

Synthesis of compound (2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl acetate (6)


6



The mixture of uracil (482 mg, 4.32 mmol) and BSA (1.75 g, 8.64 mmol) in MeCN (20 ml) was stirred at room temperature for 3 hrs. Compound 5 (1.0 g, 2.16 mmol) and $SnCl_4$ (2.4 g, 9.3 mmol) was added respective, then stirred at 65° C. for 12 hrs. The mixture was quenched with saturated $NaHCO_3$ solution, extracted with EtOAc (200 mL×3), dried over Na_2SO_4 and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] to afford the product (450 mg, 40%) as a yellow solid. LC-MS $(M+H)^+$=517.1

Synthesis of compound 1-(2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7)

7




The mixture of compound 1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (450 mg 0.87 mmol) in CH_3CN (10 mL) was added $NH_3.H_2O$ (10 mL) stirred at room temperature overnight. The mixture was concentrated and concentrated and dissolved in methanol (30 mL). To this was added $Pd(OH)_2/C$ (1.0 g). The reaction mixture was stirred under an atmosphere of hydrogen and at room temperature overnight, the mixture was concentrated and purified by Prep-HPLC to afford 7 (100 mg, 40%) as white solid. LC-MS $(M+H)^+$=295.0

^1H NMR (300 MHz, DMSO-d6): δ11.42 (s, 1H), 7.89-7.86 (d, 1H, J=8.1 Hz), 6.30-5.94 (m, 2H), 5.78-5.64 (m, 2H), 5.56-5.51 (m, 2H), 4.31-4.25 (m, 1H), 4.21-4.18 (m, 1H), 3.75-3.71 (m, 1H), 3.62-3.57 (m, 1H).

Synthesis of compound 4-amino-1-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (8)

8




To a solution of 7 (0.1 g, 0.34 mmol) in dry pyridine (15 mL) was added Ac_2O (5 mL). The mixture was stirred at room temperature overnight and then evaporated to dyness under reduced pressure. The residue was treated with saturated aqueous $NaHCO_3$ solution extracted with ethyl acetate. The organic phase was separated, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] gave the acetylated intermediate (0.12 g, 84%) as a white solid. MS $[M+H]^+$=420.1. The acetylated intermediate (0.12 g, 0.286 mmol) and 1H-tetrazole (0.02 g, 0.429 mmol) were azeotroped with pyridine and then dissolved in anhydrous pyridine (20 mL). The solution was cooled by an ice-water bath, and 4-chlorophenylphosphorodichloridate (84 mg, 0.343 mmol) was added. The reaction mixture was stirred at 0-5° C. for 5 min and then allowed to warm to room temperature. After 5 h, the reaction mixture was evaporated to dryness under reduced pressure and the residue was partitioned between CH_2Cl_2 and saturated aqueous $NaHCO_3$ solution. The organic phase was separated, dried (Na_2SO_4), and evaporated to dryness under reduced pressure. The crude product was treated with $NH_3.H_2O$ (10 mL) in 1,4-dioxane (20 mL) for 16 h at room temperature and then evaporated to dryness under reduced pressure. The crude material was dissolved in NH_3 in MeOH (7N, 30 mL) and the mixture was stirred for 18 h at room temperature and then evaporated to dryness under reduced pressure. Purification by preparative HPLC column purification gave 8 (51 mg, 61%) as a white solid. MS $[M+H]^+$=294.0

^1H NMR (300 MHz, DMSO-d6) δ 7.80-7.78 (d, J=7.8 Hz, 1H), 7.28-7.24 (brs, 2H), 6.28-5.92 (m, 2H), 5.81-5.78 (d, J=7.5 Hz, 1H), 5.53-5.38 (m, 3H), 4.30-4.19 (m, 2H), 3.68-3.60 (m, 2H).

Synthesis of compound (2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydropurin-9-yl)-tetrahydrofuran-3-yl acetate (21)


21



To a solution of compound N-(6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide (0.57 g, 2.58 mmol) in anhydrous CH_3CN (50 mL) was added BSA (1.26 mL, 5.17 mmol) portion-wise while maintaining the reaction temperature at 25° C. Then the reaction was stirred at 40° C. for 1 h until a clear solution persisted. Compound 5 (0.6 g, 1.29 mmol) in CH_3CN (5 mL) was added into the mixture at 0° C. followed by TMSOTf (0.94 mL, 5.17 mmol). The mixture was stirred at 40° C. for 2 h and then poured into saturated $NaHCO_3$ solution (10 mL) at 0° C., extracted with ethyl acetate, washed with water, brine solution, dried over Na_2SO_4 and evaporated to dryness under reduced pressure. The crude compound was purified by silica gel chromatography [petroleum ether:ethyl acetate (5:1 to 1:1)] to provide the product 21 as a white foam (0.5 g, 60%). LC-MS: $(M+H)^+$=626

Synthesis of compound 2-amino-9-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one (22)


22



A mixture of compound 21 (0.5 g, crude) in NH_3.MeOH (7 N, 40 mL) was stirred at 35° C. for 16 h and then evaporated to dryness. Purification by silica gel chromatography [dichloromethane:methanol (100:1 to 20:1)] to give the product 22 as a white foam (0.22 g, 53%). LC-MS $(M+H)^+$=514

Synthesis of compound 2-amino-9-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one (23)

23




To a solution of compound 22 (0.22 g, 0.42 mmol) in methanol (30 mL) was added HCO_2NH_4 (600 mg, 9.52 mmol), followed by $Pd(OH)_2/C$ (500 mg). The reaction mixture was stirred at 80° C. for 15 h, then cooled to 25° C., filtered and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (20:1 to 5:1)] and prep-HPLC provided the product 23 (0.046 g, 33%) as a white solid. LC-MS $(M+H)^+$=334.1

^1H NMR (300 MHz, d_6-DMSO) δ 10.64 (s, 1H), 7.93 (s, 1H), 6.50 (s, 2H), 6.28-5.92 (dd, J=52.8, 56.4 Hz, 1H), 5.87-5.83 (d, J=14.7 Hz, 1H), 5.62-5.45 (m, 3H), 4.73-4.67 (m, 1H), 4.27-4.24 (m, 1H), 3.72-3.58 (m, 2H).

Synthesis of (2R,3R,4S,5R)-2-(6-benzamido-9H-purin-9-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (25)


25



To a solution of compound 5 (1.44 g, 6.02 mmol) in anhydrous CH_3CN (15 mL) was added BSA (7.2 mL, 30.1 mmol) portion-wise while maintaining the reaction temperature at 25° C. After the reaction mixture became clear, compound 1 (0.4 g, 0.86 mmol) in CH_3CN (5 mL) and $SnCl_4$ (0.42 mL, 3.5 mmol) was added into the mixture. The mixture was stirred at 85° C. for 20 h, then it was poured into saturated $NaHCO_3$ (10 mL) at 0° C., extracted with ethyl acetate, the combined organic layer was washed with H_2O (100 mL), brine solution (100 mL), dried over Na_2SO_4 and evaporated to dryness. Purification by silica gel chromatography column [dichloromethane:methanol; (30:1)] to give product 25 as an colorless oil (0.225 g, 25%). LC-MS: $(M+H)^+$=393

Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-4-(benzyloxy)-5-(benzyloxy methyl)-5-(difluoromethyl)-tetrahydrofuran-3-ol (26)

26




A mixture of compound 25 (0.225 g, 0.35 mmol) in NH_3.MeOH (40 mL) was stirred in a sealed tube at 65° C. for 16 hrs, warmed to 25° C. and stirred for 3 hrs. TLC showed the reaction was completed, the reaction solution was concentrated and the crude compound was purified by silica gel chromatography column [dichloromethan:methanol (30:1)] to give product 26 as an colorless oil (0.16 g, 92%).

LC-MS $(M+H)^+$=469

Synthesis of (2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(difluoromethyl)-2-(hydroxylmethyl)-tetrahydrofuran-3,4-diol (27)

27




Concentrated HCl (37%) 1 drop was added into the mixture of compound 3 (0.048 g, 0.1 mmol) and $Pd(OH)_2/C$ (0.8 g) in MeOH (5 mL), after addition, the whole mixture was stirred at 25° C. under hydrogen atmosphere. After 2 h, the reaction mixture was filtered and evaporated to dryness under reduced pressure. Purification by prep-HPLC afforded 27 (0.024 g, 85%) as a white solid. L-MS $(M+H)^+$=318.

^1H NMR (300 MHz, d_6-DMSO) δ 8.52 (s, 1H), 8.24 (s, 1H), 6.94 (br s, 2H), 6.47-6.11 (m, 1H), 5.99 (d, J=7.8 Hz, 1H), 5.81-5.79 (m, 2H), 5.59 (br s, 1H), 4.46 (br s, 1H), 4.32 (br s, 1H), 3.74 (br s, 1H), and 3.65 (br s, 1H).

Synthesis of (2R,3R,4S,5R)-2-(4-amino-5-chloro-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (29)


29



To a solution of 4-amino-5-chloropyrimidin-2(1H)-one 28 (0.336 g, 2.33 mmol) in anhydrous CH_3CN (10 mL) was added BSA (0.945 g, 4.64 mmol) portion-wise while maintaining the reaction temperature at 25° C. After the reaction mixture became clear, compound 5 (0.54 g, 1.16 mmol) in CH_3CN (2 mL) and $SnCl_4$ (1.2 g, 4.64 mmol) was added into the mixture. The mixture was stirred at 65° C. for 1 h, then cooled and poured into saturated $NaHCO_3$ solution (20 mL). The organic phase was extracted with ethyl acetate, washed with water, brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by flash silica gel chromatography [dichloromethane:methanol (40:1)] gave 29 as a white solid (0.24 g, 31%). LC-MS: $(M+H)^+$=550.1

Synthesis of 4-amino-1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)-5-chloropyrimidin-2(1H)-one (30)


30



A mixture of compound 29 (0.235 g, 0.43 mmol) in NH_3.MeOH (10 mL) was stirred at r.t for 3 h and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography column [dichloromethane:methanol (40:1)] gave 30 as a white solid (0.135 g, 62%). LC-MS: $(M+H)^+$=508.1

Synthesis of 4-amino-5-chloro-1-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (31)

31




BCl_3 (2.46 mL, 2.46 mmol) was added to a cooled (−78° C.) solution of compound 30 (0.125 g, 0.246 mmol) in dry dichloromethane (10 mL). The mixture was cooled to 0° C. and pyridine (0.5 mL) and MeOH (2 mL) were added. The reaction mixture was evaporated to dryness under reduced pressure. Purification by prep-HPLC provided 31 (0.035 g, 44%) as a white solid. LC-MS $(M+H)^+$=328.1

^1H NMR (300 MHz, DMSO-d_6) δ 8.12 (s, 1H), 7.99 (s, 1H), 7.35 (s, 1H), 6.27-5.91 (m, 2H), 5.57 (m, 2H), 5.44-5.42 (d, J=6.3 Hz, 1H), 4.25-4.16 (m, 2H), 3.62 (m, 2H).

Synthesis of 1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (32)

32




A solution of compound 6 (0.52 g, 1 mmol) in NH_3.MeOH/dioxane (6 mL/6 mL) was stirred at 20° C. After 18 h the reaction mixture was evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1 to 1.5:1)] provided 32 (0.314 g, 61%) as a white solid.

LC-MS: $(M+H)^+$=475.1

Synthesis of 2,2'-anhydro-4'-difluoromethyl-1-(β-arabinofuranosyl)uracil (33)


33



Diphenyl carbonate (0.258 g, 1.2 mmol) and sodium hydrogen carbonate (0.184 g, 2.2 mmol) were added to a solution of 32 (0.52 g, 1.1 mmol) in dry DMF (10 mL). The reaction mixture was stirred at 110° C. for 2 h, then cooled and evaporated to dryness under reduced pressure. The residue was dissolved with dichloromethane and washed with water, brine, dried (Na_2SO_4) and then evaporated to dryness under reduced pressure to give the crude product 33 (0.45 g) as a white solid, which was used directly without further purification. LC-MS: $(M+H)^+$=457.2

Synthesis of 1-((2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (34)


34



A solution of aqueous NaOH (1N, 5 mL) was added to a solution of compound 33 (0.45 g) in ethanol (10 mL). After stirring at 20° C. for 3 h, the reaction mixture was adjusted to pH=7 by strong-acid cation-exchange resin, filtered and evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichlormethane:methanol (40:1)] provided 34 (0.12 g, 25%) as a white solid. LC-MS: $(M+H)^+$=475.2

Synthesis of (2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl acetate (35)


35



Ac_2O (0.5 mL) was added into a solution of compound 34 (0.114 g, 0.24 mmol) in dry pyridine (4 mL). The reaction mixture was stirred at 20° C. for 3 h and then quenched by saturated aqueous $NaHCO_3$ solution (2 mL). The organic phase was extracted with dichloromethane and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1)] afforded 35 (0.12 g, 88%) as a white solid. LC-MS: $(M+H)^+$=517.2

Synthesis of (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (36)


26



4-Chlorophenylphosphonic dichloride (0.4 g, 0.81 mmol) was added to a cooled (0° C.) solution of 1-H-tetrazole (0.056 g, 0.81 mmol) and 35 (0.113 g, 0.22 mmol) in dry pyridine (5 mL). The reaction mixture was left to stir under a nitrogen atmosphere at 20° C. for 3 h and then evaporated to dryness under reduced pressure. The residue was dissolved in dioxane and $NH_3.H_2O$ (5 mL) was added. After stirring for 5 h at 20° C., the reaction mixture was evaporated to dryness under reduced pressure to afford 36 (0.2 g, crude).

Synthesis of 4-amino-1-((2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (37)


37



A solution of compound 36 (0.112 g, 0.21 mmol) in NH_3.MeOH (4 mL) was stirred at 60° C. for 12 h and then cooled and evaporated to dryness under reduced pressure to give 37 as a white solid. LC-MS: $(M+H)^+$=474.2

Synthesis of 4-amino-1-((2R,3S,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (38)

38




BCl_3 (3.7 mL, 3.7 mmol) was added to a solution of compound 37 (0.175 g, 0.37 mmol) in dichloromethane (10 mL) cooled to −78° C. The reaction was stirred at −78° C. for 3 h, then warmed to 25° C. and stirred for a further 12 h. The reaction mixture was cooled to 0° C. and then pyridine was added into the mixture, followed by methanol. The reaction mixture was evaporated to dryness under reduced pressure. Purification by prep-HPLC afforded the product 38 (0.052 g, 41%) as a white solid. LC-MS $(M+H)^+$=294.1

^1H NMR (300 MHz, DMSO-d_6) δ 7.59-7.56 (d, J=7.5 Hz, 1H), 7.13-7.06 (d, J=21.3 Hz, 2H), 6.24-6.23 (d, J=5.7 Hz, 1H), 6.07 (s, 1H), 5.92-5.90 (d, J=5.1 Hz, 1H), 5.67-5.62 (m, 2H), 5.41-5.38 (m, 1H), 4.30-4.28 (m, 1H), 4.15-4.14 (m, 1H), 3.64-3.59 (m, 2H).


Synthesis of compound 1-((2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (39)

39




Diethylaminosulfur trifluoride (7.6 g, 47.4 mmol) was added to a suspension of compound 34 (1.5 g, 3.16 mmol) in dry THF (150 mL). The mixture was stirred at 60° C. for 16 h and then cooled to room temperature. The mixture was quenched by the addition of saturated aqueous $NaHCO_3$ solution and then extracted with ethyl acetate. The organic phase was washed with brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1)] afforded 39 as a brown solid (700 mg, 46%). LC-MS $(M+H)^+$=477.4

Synthesis of compound 4-amino-1-((2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (40)



4-Chlorophenyl phosphorodichloridate (0.68 g, 2.77 mmol) was added to a solution of compound 39 (0.22 g, 0.462 mmol) and 1-H-tetrazole (0.485 g, 6.93 mmol) in dry pyridine (100 mL) at 0° C. After stirring at room temperature for 3 h, the reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane and washed with saturated aqueous $NaHCO_3$ solution, brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by silica gel chromatography (petroleum ether:ethyl acetate (4:1)] provided the intermediate as an red oil. The intermediate was dissolved in dioxane (40 mL) and $NH_3.H_2O$ (2 mL) was added. After stirring for 30 min, the reaction mixture was evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (10:1)] provided 40 as a brown solid (180 mg, 81%). LC-MS $(M+H)^+$=476.1

Synthesis of compound 4-amino-1-((2R,3R,4R,5R)-5-(difluoromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (41)




A mixture of compound 40 (160 mg, 0.34 mmol), $Pd(OH)_2/C$ (0.8 g) and concentrated aqueous HCl (2 drops, 37%) in methanol (10 mL) was stirred under an atmosphere of hydrogen for 10 min, filtered and evaporated to dryness under reduced pressure. Purification by preparative HPLC afforded 41 as a white solid (26 mg, 25%). LC-MS $(M+H)^+$=296.1

^1H NMR (300 MHz, d_6-DMSO) δ 7.79 (d, J=7.2 Hz, 1H), 7.33 (d, J=10.4 Hz, 2H), 6.26-5.99 (m, 3H), 5.77 (d, J=7.6 Hz, 1H), 5.44 (t, J=5.2 Hz, 1H), 5.15 (dt, J_1=53.6 Hz, J_2=5.2 Hz, 1H), 4.58-4.53 (m, 1H), 3.70-3.58 (m, 2H).

Synthesis of (S)-1-(benzyloxy)-1-oxopropan-2-aminium chloride (43)


43



Thionyl chloride (27 mL) was added drop-wise to a solution L-alanine (42) (6.83 g, 76.6 mmol) in benzyl alcohol (120 mL). After stirring at 0° C. for 2 h, the reaction mixture was warmed to room temperature and stirred for a further 24 h and then evaporated to dryness under reduced pressure. Trituration with diethyl ether, followed by filtration and evaporation under reduced pressure, provided the crude product 43 (3.5 g), which was used directly without further purification. LC-MS $(M-Cl)^+$=180

Synthesis of (25)-benzyl 2-(chloro(phenoxy)phosphorylamino) propanoate (44)


44



Phenyl phosphorodichloridate (1.17 g, 2 N) was added to a solution of 43 (1 g, 5.58 mmol) in dichloromethane at −78° C. Triethylamine (1.13 g, 11.173 mmol) was then added drop-wise. Once complete, the reaction mixture was allowed to warm to room temperature and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (3:1)] provided 44 as an colorless oil (1.2 g, 60%). LC-MS $(M+H)^+$=354

Synthesis of Compound (45)


45



To a mixture of compound 8 (0.11 g, 0.375 mmol) and compound 1,1-dimethoxycyclopentane (0.495 g, 3.8 mmol) in dichloromethane was added PTSA (0.01 g). The resulting mixture was stirred at 65° C. for 1 h and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (10:1)] afforded 45 as a white solid (0.17 g, 90%). LC-MS $(M+H)^+$=360.2

Synthesis of Compound (46)


46



To a suspension of compound 45 (0.08 g, 0.223 mmol) in dry THF was added t-BuMgBr (1.3 mL, 1.34 mmol) at 0° C. under nitrogen atmosphere, then warmed to 25° C. and stirred for 30 min. The reaction mixture was then cooled to 0° C. and then (2S)-Benzyl 2-(chloro(phenoxy)phosphorylamino)propanoate (0.236 g, 0.668 mmol) was added drop-wise. The reaction mixture was stirred at room temperature for 2 h and then quenched by the addition of methanol (1 mL). The mixture was then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane: methanol (10:1)] afforded 46 as a white solid (0.19 g). LC-MS $(M+H)^+$=677.1

Synthesis of compound (S)-benzyl 2-((((2R,3S,4R, 5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (47)

47




A solution of compound 46 (0.18 g, 0.26 mmol) in formic acid (80%, v/v) was stirred at 25° C. for 18 h and then evaporated to dryness under reduced pressure. Purification by prep-HPLC provided 47 as a white solid (12.8 mg, 5%). LC-MS $(M+H)^+$=611.1

^{1}H NMR (300 MHz, DMSO-d_6) δ 7.55-7.16 (m, 13H), 6.33-5.97 (m, 3H), 5.78-5.77 (m, 2H), 5.47-5.46 (m, 1H), 5.15-5.06 (m, 2H), 4.23-3.95 (m, 5H), 1.28-1.23 (t, J=7.5 Hz, 3H).

Synthesis of Compound (49)


49



To a suspension of compound 45 (0.2 g, 0.5 mmol) in dry THF was added t-BuMgBr (3 mL, 3 mmol) at 0° C. under nitrogen atmosphere, then warmed to 25° C. and stirred for 30 min, compound (2S)-neopentyl 2-(chloro(phenoxy)phosphorylamino)propanoate (0.5 g, 1.5 mmol) was added drop wise at 0° C. over 10 min, after addition, the whole mixture was stirred at 25° C. After 2 hrs, the reaction mixture was quenched with 1 mL MeOH and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (20:1 to 15:1)], provided 49 as a white solid (0.3 g, crude). LC-MS $(M+H)^+$=657

Synthesis of compound (S)-neopentyl 2-((((2R,3S, 4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (50)

50



A solution of compound 49 (0.3 g, crude) in HCOOH (80%, v/v, 30 mL) was stirred at room temperature. After 12 h the reaction mixture was cooled to 0° C. and neutralized with 1M aqueous NaHCO3 solution. The organic phase was extracted with ethyl acetate, washed with water, brine solution, dried (Na2SO4) and evaporated to dryness under reduced pressure. Purification by prep-HPLC provided 50 (17 mg, 9.8%) as a white solid. LC-MS $(M+H)^+$=590.9

^{1}H NMR (300 MHz, DMSO-d_6) δ 7.54-7.18 (m, 8H), 6.32-6.06 (m, 3H), 5.81-5.65 (m, 2H), 5.48-5.46 (m, 1H), 4.24-4.12 (m, 4H), 3.95-3.89 (dd, 1H), 3.79-3.69 (m, 2H), 1.29-1.24 (m, 3H), 0.88 (s, 9H).

Biological Examples

Influenza Assay

This assay measures the ability of the active compounds derived from the compounds of formula I to inhibit the essential influenza RNA polymerase. The influenza polymerase was obtained from purified influenza virus particles and the

rate of nucleotide incorporation was measured from the quantitation of a radiolabeled nucleotide tracer during the polymerase reaction.

Metabolism Assay

This assay measures the ability of human cells to generate the active compounds from the compounds of formula I. The active compounds are the triphosphate (TP) derivatives of the nucleoside analogs. The assay is determining the concentration of specific nucleoside triphosphates formed in human cells exposed to compounds of formula I after methanol extraction of cells and analysis of soluble nucleoside triphosphate using LC-MS.

TABLE 2

Activity of nucleotide triphosphates in influenza polymerase assay.











Compound Number	Structure	Activity IC_{50} μM
TPP-1		B
TPP-2		B
TPP-3		B
TPP-4		A
TPP-5		B
TPP-6		A
TPP-7		C

TABLE 2-continued

Activity of nucleotide triphosphates in influenza polymerase assay.

Compound Number	Structure	Activity IC_{50} μM
TPP-8		A
TPP-9		A
TPP-10		A

Activity in influenza polymerase assay is as follows: A = IC_{50} < 10 μM; B = IC_{50} 10-100 μM; C = IC_{50} > 100 μM

Dosage and Administration

As shown in above Table the compounds of formula I have the potential to be efficacious as antiviral drugs for the treatment of influenza infections in humans, or are metabolized to a compound that exhibit such activity.

In another embodiment of the invention, the active compound or its prodrug derivative or salt can be administered in combination with another antiviral agent, such as an anti-influenza agent or an immunomodulatory compound, including those of formula I. When the active compound or its derivative or salt are administered in combination with another antiviral or immunomodulatory agent the activity may be increased over the parent compound. This can easily be assessed by preparing the derivative and testing its anti-influenza activity according to the method described herein.

Administration of the active compound may range from continuous (intravenous drip) to several or single administrations per day (for example, Q.I.D) or less frequent administrations and may include oral, topical parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration.

The 4'-difluoromethyl substituted nucleoside derivatives as well as their pharmaceutically useable salts, can be used as medicaments in the form of any pharmaceutical formulation. The pharmaceutical formulation can be administered enterally, either orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions, syrups, or suspensions, or rectally, e.g. in the form of suppositories. They can also be administered parenterally (intramuscularly, intravenously, subcutaneously or intrasternal injection or infusion techniques), e.g. in the form of injection solutions, nasally, e.g. in the form of nasal sprays, or inhalation spray, topically and so forth.

For the manufacture of pharmaceutical preparations, the 4'-substituted nucleoside derivatives, as well as their pharmaceutically useable salts, can be formulated with a therapeutically inert, inorganic or organic excipient for the production of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.

The compounds of formula I can be formulated in admixture with a pharmaceutically acceptable carrier. For example, the compounds of the present invention can be administered orally as pharmacologically acceptable salts. Because the compounds of the present invention are mostly water soluble, they can be administered intravenously in physiological saline solution (e.g., buffered to a pH of about 7.2 to 7.5). Conventional buffers such as phosphates, bicarbonates or citrates can be used for this purpose. Of course, one of ordinary skill in the art may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity. In particular, the modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.) which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, though other ingredients including those which aid dispersion may be included. Of course, where sterile water is to be used and maintained as sterile, the compositions and carriers must

also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.

Suitable excipients for tablets, coated tablets, dragées, and hard gelatin capsules are, for example, lactose, corn starch and derivatives thereof, talc, and stearic acid or its salts.

If desired, the tablets or capsules may be enteric-coated or sustained release by standard techniques.

Suitable excipients for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols.

Suitable excipients for injection solutions are, for example, water, saline, alcohols, polyols, glycerin or vegetable oils.

Suitable excipients for suppositories are, for example, natural and hardened oils, waxes, fats, semi-liquid or liquid polyols.

Suitable excipients for solutions and syrups for enteral use are, for example, water, polyols, saccharose, invert sugar and glucose.

The pharmaceutical preparations of the present invention may also be provided as sustained release formulations or other appropriate formulations.

The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavourants, salts for adjustment of the osmotic pressure, buffers, masking agents or antioxidants.

The pharmaceutical preparations may also contain other therapeutically active agents known in the art.

The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case. For oral administration, a daily dosage of between about 0.01 and about 100 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 100 mg/kg body weight per day. A typical preparation will contain from about 5% to about 95% active compound (w/w). The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day.

In certain pharmaceutical dosage forms, the pro-drug form of the compounds, especially including acylated (acetylated or other) derivatives, pyridine esters and various salt forms of the present compounds are preferred. One of ordinary skill in the art will recognize how to readily modify the present compounds to pro-drug forms to facilitate delivery of active compounds to a target site within the host organism or patient. One of ordinary skill in the art will also take advantage of favorable pharmacokinetic parameters of the pro-drug forms, where applicable, in delivering the present compounds to targeted site within the host organism or patient to maximize the intended effect of the compound.

Indications and Method of Treatment

The application provides a method for treating a Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I.

The application provides the above method, further comprising administering an immune system modulator or one or more antiviral agents that inhibits replication of Influenza, or a combination thereof.

The application provides the above method for inhibiting replication of Influenza in a cell comprising administering a compound of Formula I.

Combination Therapy

The compounds of the invention and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing influenza infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the influenza life-cycle. Classes of compounds useful in the invention include, without limitation, all classes of influenza antivirals.

The present invention is not limited to the aforementioned classes or compounds and contemplates known and new compounds and combinations of biologically active agents. It is intended that combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the anti-viral activity of the compound of this inventive group or the anti-viral activity of the pharmaceutical composition itself.

Combination therapy can be sequential, that is treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be treatment with both agents at the same time (concurrently). Sequential therapy can include a reasonable time after the completion of the first therapy before beginning the second therapy. Treatment with both agents at the same time can be in the same daily dose or in separate doses. Combination therapy need not be limited to two agents and may include three or more agents. The dosages for both concurrent and sequential combination therapy will depend on absorption, distribution, metabolism and excretion rates of the components of the combination therapy as well as other factors known to one of skill in the art. Dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules may be adjusted over time according to the individual's need and the judgment of the one skilled in the art administering or supervising the administration of the combination therapy.

It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions, and that the treatment of animals includes the treatment of humans as well as other mammals. Furthermore, treatment of an Influenza infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by Influenza infection, or the clinical symptoms thereof.

The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.


The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

All patents, patent applications and publications cited in this application are hereby incorporated by reference in their

entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

We claim:

1. A compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NHR$^{1'}$;

$R^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2 (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

2. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

3. The compound of claim **1**, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

4. The compound of claim **1**, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

5. The compound of claim **1**, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

6. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

7. The compound of claim **1**, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

8. The compound of claim **1**, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

9. The compound of claim **1**, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

10. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

11. The compound of claim **1**, wherein X is O.

12. The compound of claim **1**, wherein X is S.

13. The compound of claim **1**, wherein R is O—R^1, and R^1 is naphthylenyl.

14. The compound of claim **1**, wherein R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

15. A compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;
4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorouridine;
4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylcytidine;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyladenosine;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylguanosine;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadenosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2,2"-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylarauridine;
4'-Difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;
4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine;
4'-Difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;
4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine;
4'-Difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadensoine;
4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine;
4'-Difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;
4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxylouridine;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine; and


3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine.

16. A method of treating Influenza comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim **1**.

17. A composition comprising the compound of claim **1**, admixed with at least one carrier, diluent or excipient.

18. A composition comprising the compound of claim **1** in combination with one or more antiviral compounds.

19. A method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NH$R^{1'}$;

$R^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S; and

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

or a pharmacologically acceptable salt thereof.

20. A method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim **15**.

* * * * *

Industria y Comercio SUPERINTENDENCIA	Espacio reservado para el adhesivo de radicación

DIRECCIÓN DE NUEVAS CREACIONES
Procedimiento acelerado de exámenes de patente (PPH)

1	**NÚMERO DE SOLICITUD ANTE LA SIC**	NC2016/0001536	
2	**OFICINA DE PRIMERA PRESENTACIÓN (OPP)** ☒	**USPTO** ☒	**OEPM** ☐
3	**OFICINA DE EXAMEN ANTERIOR (OEA)** ☐	**JAPON** ☐	**KR Sur** ☐
4	**PPH – PCT** ☐	**JAPON** ☐	**KR Sur** ☐
5	**NÚMERO DE SOLICITUD O PUBLICACIÓN DE LA SOLICITUD (OPP)** ☒ **NÚMERO DE SOLICITUD EN OFICINA DE EXAMEN ANTERIOR (OEA):** ☐ **NÚMERO DE SOLICITUD PCT:** ☐	1. US 14/615,928	
6	☒ **REPRESENTANTE LEGAL** ☒ **APODERADO**		

APELLIDOS	NOMBRES	IDENTIFICACIÓN
LLOREDA RICAURTE	**ALICIA**	C.C . **39.690.713** T.P . **53.215**

DIRECCIÓN	Calle 72 N°5-83 Piso 5to	No. TELÉFONO	3264270
CIUDAD	Bogotá	CORREO ELECTRÓNICO	notificacionespatentes@lloredacamacho.com
PAÍS	Colombia	No. RADICACIÓN O PROTOCOLO DE PODER GENERAL	

7 CONDICIONES PARA ACCEDER A ESTE PROCESO:

7.1. DATOS DE PRIORIDAD ☒ SI ☐ NO

(33) PAÍS DE ORIGEN	CÓDIGO PAÍS	(31) NÚMERO	(32) FECHA (AAAA/MM/DD)
1. Estados Unidos de América	US	61/936,569	2014/02/06

7.2. DATOS SOLICITUD INTERNACIONAL PCT ☐ SI ☐ NO

Solicitud Internacional No.	PCT/US2015/014762	**Fecha**	2015/02/06
Publicación Internacional No.	WO 2015/120237 A3	**Fecha**	2015/08/13

*El solicitante presenta una copia de la(s) reivindicación(es) patentable(s) u otorgable(s) de la solicitud de la Oficina de Primera Presentación que profirió el examen de patentabilidad, junto con una traducción al castellano. ☒ SI ☐ NO

*El solicitante presenta los resultados de búsqueda de la Oficina de Examen Anterior, junto con una traducción al castellano ☒ SI ☐ NO

REQUISITOS PARA EL RECONOCIMIENTO DE LOS RESULTADOS DE EXÁMENES DE PATENTABILIDAD EFECTUADOS A SOLICITUDES EXTRANJERAS

Para que la Superintendencia de Industria y Comercio pueda reconocer los resultados de exámenes de patentabilidad producidos por otras Oficinas de Propiedad Industrial se debe cumplir con las siguientes condiciones:

(a) Al momento de solicitar el examen de patentabilidad, si el solicitante pide que se reconozcan exámenes de patentabilidad de otras oficinas extranjeras, deberá aportar junto con el pago de la tasa correspondiente, los siguientes anexos:

(i) Copia de las resoluciones, fallos o decisiones que han sido relevantes para la determinación de la patentabilidad de la(s) solicitud(es) en la Oficina que haya proferido el examen de patentabilidad que contienen reivindicaciones patentables u otorgables que son la base de la petición, y si es del caso, su traducción al castellano. ☒ SI ☐ NO

(ii) Copia de todas las reivindicaciones determinadas como patentables u otorgables en la Oficina que profirió el examen de patentabilidad y, si es del caso, su traducción al castellano. ☒ SI ☐ NO


(iii) Copia de los antecedentes, información o documentos citados por el examinador de la Oficina de Primera Presentación del examen de patentabilidad, en las resoluciones, fallos o decisiones correspondientes, incluyendo la literatura no patente. Los documentos de patente deberán presentarse siempre y cuando no estén disponibles para la Superintendencia de Industria y Comercio mediante el simple acceso a bases de datos gratuitas. ☐ SI ☒ NO

(iv) Una tabla de correspondencias de las reivindicaciones que han sido determinadas como patentables u otorgables en la solicitud de la Oficina que haya proferido el examen de patentabilidad. . ☒ SI ☐ NO

FIRMA DEL SOLICITANTE, DEL APODERADO O DEL REPRESENTANTE LEGAL

Junto a cada firma, indicar el nombre del firmante y su calidad (si tal calidad no es obvia al leer el petitorio)


ALICIA LLOREDA RICAURTE

Reivindicaciones de la presente solicitud	Reivindicaciones patente US 14/615,928	Correspondencia de las reivindicaciones
1	1	Ambas reivindicaciones se refieren al compuesto de fórmula I  , el cual corresponde al objeto de la presente solicitud. La definición de las restricciones son las mismas. Los sustituyentes definidos en la presente solicitud son más claros y concisos.
2	2	Las reivindicaciones son idénticas.
3	3	Las reivindicaciones son idénticas.
4	4	Las reivindicaciones son idénticas.
5	5	Las reivindicaciones son idénticas.
6	6	Las reivindicaciones son idénticas.
7	7	Las reivindicaciones son idénticas.
8	8	Las reivindicaciones son idénticas.
9	9	Las reivindicaciones son idénticas.
10	10	Las reivindicaciones son idénticas.
11	11	Las reivindicaciones son idénticas.
12	12	Las reivindicaciones son idénticas.
13	13	Las reivindicaciones son idénticas.
14	14	Las reivindicaciones son idénticas.
15	15	Las reivindicaciones son idénticas.
16	17	Las reivindicaciones son idénticas.
17	18	Las reivindicaciones son idénticas.
--	16, 19 y 20	Dichas reivindicaciones de la patente **US 14/615,928** no tiene equivalente en el pliego reivindicatorio de la presente solicitud, puesto que la materia definida en las mismas se refiere a métodos de tratamiento, lo cual se considera como materia no patentable, según la legislación colombiana.

entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

We claim:

1. A compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NHR$^{1'}$;

$R^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2 (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

2. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

3. The compound of claim **1**, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

4. The compound of claim **1**, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

5. The compound of claim **1**, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

6. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

7. The compound of claim **1**, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

8. The compound of claim **1**, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

9. The compound of claim **1**, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

10. The compound of claim **1**, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

11. The compound of claim **1**, wherein X is O.

12. The compound of claim **1**, wherein X is S.

13. The compound of claim **1**, wherein R is O—R^1, and R^1 is naphthylenyl.

14. The compound of claim **1**, wherein R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

15. A compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;
4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorouridine;
4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylcytidine;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;
4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyladenosine;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-7-adenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylguanosine;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadenosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2,2"-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylarauridine;
4'-Difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine;
4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
4'-Difluoromethyl-5-fluoroarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
4'-difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylarauridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine;
4'-Difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine;
4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluoroaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylaracytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine;
4'-Difluoromethylaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadensoine;
4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine;
4'-Difluoromethylaraguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaraadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaraguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine;
4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxylouridine;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluoroxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-5-fluororxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine;
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloadenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloadenosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine;
4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xyloguanosine;
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloguanosine;
4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl phosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl) ethyl thiophosphoramidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] phosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl] thiophosphorodiamidate;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-1-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-2-naphthyl-N—(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{N,N'-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine; and


3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]guanosine.

16. A method of treating Influenza comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim **1**.

17. A composition comprising the compound of claim **1**, admixed with at least one carrier, diluent or excipient.

18. A composition comprising the compound of claim **1** in combination with one or more antiviral compounds.

19. A method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O—R^1 or NHR$^{1'}$;

$R^{1'}$ is —C(R^{2a})(R^{2b})C(=O)OR^3;

R' is N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3, —OP(=O)(OH)OP(=O)(OH)OH, or —OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R^{1a})$_2$, acylamino, —SO_2N(R^{1a})$_2$, —C(=O)R^{1b}, —SO_2(R^{1c}), —NHSO_2(R^{1c}), nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently —OR^{1a} or —N(R^{1a})$_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, —(CH_2)$_r$N(R^{1a})$_2$, lower hydroxyalkyl, —CH_2SH, —(CH_2)S(O)$_p$Me, —(CH_2)$_n$NHC(=NH)NH_2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)$_m$C(=O)R^{1b}, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form (CH_2)$_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form (CH_2)$_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S; and

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

or a pharmacologically acceptable salt thereof.

20. A method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim **15**.

* * * * *

Señor
SUPERINTENDENTE DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES
E. S. D.

Re: PI.-**RIBOSCIENCE LLC.**-Solicitud de Patente de Invención en Fase Nacional PCT para **"DERIVADOS DE NUCLEÓSIDO SUSTITUIDOS CON 4'-DIFLUOROMETILO COMO INHIBIDORES DE LA REPLICACIÓN DE ARN DE LA INFLUENZA"**.-Clase **A61K 31/7052**.-Expediente número **NC2016/0001536**.-


1. Me refiero a mi memorial de Respuesta al Oficio No. 13450 del pasado 26 de enero de 2017 y a mi memorial de modificación voluntaria al capítulo reivindicatorio presentado hoy 3 de agosto de 2017.

2. Dicho lo anterior y de conformidad con lo dispuesto en el Artículo 1 de la Resolución N° 54093 de 18 de septiembre de 2012, y en virtud del Acuerdo para el Procedimiento Acelerado de Estudio de Solicitudes de Patente (PPH) suscrito entre la Superintendencia de Industria y Comercio (SIC) y la Oficina de Patentes y Marcas de los Estados Unidos de América (USPTO) solicito a su Despacho hacer estudio de patentabilidad de la presente solicitud de conformidad con la guía de procedimiento para este tipo de trámite.

Para la solicitud de referencia específicamente, **solicito se tenga en cuenta el resultado del examen de patentabilidad realizado por la Oficina de Marcas y Patentes de Estados Unidos de América (USPTO),** aquí presentada bajo la notificación de admisibilidad expedida por esta entidad en relación con la patente identificada bajo la Solicitud No. 14/615,928; la presente solicitud es equivalente a la patente antes mencionada que fue aceptada por la **USPTO** como **primera oficina de presentación**, tal y como se podrá evidenciar más adelante.

3. La equivalencia entre la materia concedida en la patente No. **US 14/615,928** y la materia reclamada en la presente solicitud, de acuerdo con el capítulo reivindicatorio que comprende **17 reivindicaciones, de conformidad con la modificación voluntaria presentada en conjunto con esta solicitud**, es explicada tal como se muestra a continuación:

Tabla de equivalencias:

Reivindicaciones de la presente solicitud	**Reivindicaciones patente US 14/615,928**	**Correspondencia de las reivindicaciones**
1	1	Ambas reivindicaciones se refieren al compuesto de fórmula I  , el cual corresponde al objeto de la presente solicitud. La definición de las restricciones son las mismas. Los sustituyentes definidos en la presente solicitud son más claros y concisos.
2	2	Las reivindicaciones son idénticas.
3	3	Las reivindicaciones son idénticas.
4	4	Las reivindicaciones son idénticas.
5	5	Las reivindicaciones son idénticas.
6	6	Las reivindicaciones son idénticas.
7	7	Las reivindicaciones son idénticas.
8	8	Las reivindicaciones son idénticas.
9	9	Las reivindicaciones son idénticas.
10	10	Las reivindicaciones son idénticas.
11	11	Las reivindicaciones son idénticas.
12	12	Las reivindicaciones son idénticas.
13	13	Las reivindicaciones son idénticas.
14	14	Las reivindicaciones son idénticas.
15	15	Las reivindicaciones son idénticas.
16	17	Las reivindicaciones son idénticas.
17	18	Las reivindicaciones son idénticas.
--	16, 19 y 20	Dichas reivindicaciones de la patente **US 14/615,928** no tiene equivalente en el pliego reivindicatorio de la presente solicitud, puesto que la materia definida en las mismas se refiere a métodos de tratamiento, lo cual se considera como materia no patentable, según la legislación colombiana.

Teniendo en cuenta la tabla de equivalencias aquí presentadas, considero viable la utilización del examen realizado por la Oficina de Patentes y Marcas de los Estados Unidos de América como guía para el estudio de patentabilidad de la solicitud en trámite.

4. De igual forma me permito llamar su atención en cuanto a que la presente solicitud cumple con los requisitos para el reconocimiento de los resultados de exámenes de patentabilidad efectuados a solicitudes extranjeras, establecidos en la Resolución N° 54093 de 2012, de acuerdo con las siguientes condiciones:

a. Se está solicitando el reconocimiento del examen de patentabilidad realizado por la USPTO, como oficina de propiedad industrial reconocida por el Tratado de Cooperación en materia de Patentes (PCT) que actúa como autoridad reconocida de búsqueda y examen. Además, se realiza esta solicitud junto con la petición del examen de patentabilidad.

b. La presente solicitud se encuentra en fase nacional en virtud del PCT y reivindica prioridad de acuerdo con el artículo 9 de la Decisión 486 (US 61/936,569) del 6 de Febrero de 2014).

c. La patente Estadounidense No. 14/615,928 tiene correspondencia con la presente solicitud, tal como se evidencia de los capítulos reivindicatorios arriba comparados, la descripción de las solicitudes y los datos bibliográficos.

d. La decisión de concesión por parte de la USPTO, hace mención a que las reivindicaciones concedidas corresponden a las reivindicaciones 1-10, 13,14,16,17,23-26,31 y 33. (ver Notice of Allowance and Fee(s) Due). Existiendo así reivindicaciones ya aceptadas para patentabilidad.

e. Así mismo me permito señalar que el documento más relevantes del arte previo citado por el examinador de la Oficina de Marcas y Patentes de Estados Unidos, responden a US 20150011497 A1, tal como se evidencia en la página 2 del NOTICE OF ALLOWANCE. Me permito resaltar que debido a que dicho documento corresponde a un documento accesible mediante bases de datos gratuitas, no se adjunta copia del mismo.

5. Por favor encuentre a continuación los datos bibliográficos de la solicitud tal y como se presentó en Estados Unidos.

N° de la solicitud	14/615,928
Fecha de presentación	02/06/2015
Solicitante	Riboscience LLC,

Inventores	Mark Smith Klaus G. Klumpp
Título de la invención	4´-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

6. Finalmente y en cumplimiento de los requisitos para la tramitación del Procedimiento Acelerado de Estudio de Solicitudes de Patente**, me permito anexar los siguientes documentos:**

a) Formato único de procedimiento acelerado de exámenes de patentes;

b) Copia de la decisión de concesión por parte de la USPTO, donde se detalla el número de la solicitud 14/615,928 otorgada el 18 de febrero de 2016 (ver página 1 del Notice of Allowance).

c) Traducción de la decisión de concesión por parte de la USPTO.

d) Copia de las reivindicaciones que han sido determinadas como patentables en la USPTO (reivindicaciones 1-10, 13, 14, 16, 17,23-26,31 y 33).

e) Traducción de las reivindicaciones que han sido determinadas como patentables en la USPTO (reivindicaciones 1-10, 13, 14, 16, 17,23-26,31 y 33).

7. De igual forma manifiesto que se ha presentado de manera independiente una modificación voluntaria al capítulo reivindicatorio actualmente presentado en Colombia con el fin de ajustar dicho capitulo al concedido en Estados Unidos, el pago por dicha modificación se ha realizado el día de hoy mediante la plataforma virtual SIPI.

8. Ruego a usted tomar atenta nota de lo anterior y proceder de conformidad.

Señor Superintendente,

ALICIA LLOREDA RICAURTE

T.P. 53.215

Direcciones para Notificación: **notificacionesip@lloredacamacho.com**
notificacionespatentes@lloredacamacho.com

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	06/21/2016	9370569	596000-00410	4203

115777 7590 06/01/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Mark Smith, San Francisco, CA;
Riboscience LLC, Palo Alto, CA;
Klaus G. Klumpp, West Chester, PA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

115777 7590 02/18/2016
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TITLE OF INVENTION: 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	05/18/2016

EXAMINER	ART UNIT	CLASS-SUBCLASS
MCINTOSH III, TRAVISS C	1673	514-047000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 GrayRobinson, P.A.
2 Jennifer L. Kisko
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: Riboscience LLC

(B) RESIDENCE: (CITY and STATE OR COUNTRY): Palo Alto, California

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:
☒ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 501678 (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
☐ Applicant certifying micro entity status. See 37 CFR 1.29
NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
☐ Applicant asserting small entity status. See 37 CFR 1.27
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
☐ Applicant changing to regular undiscounted fee status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Jennifer L. Kisko/ Date May 16, 2016
Typed or printed name Jennifer L. Kisko Registration No. 56907

PTOL-85 Part B (10-13) Approved for use through 10/31/2013. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Electronic Patent Application Fee Transmittal

Application Number:	14615928
Filing Date:	06-Feb-2015
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Filer:	Jennifer Kisko/Lynnette Dewitz
Attorney Docket Number:	596000-00410

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl Issue Fee	1501	1	960	960

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**960**

Electronic Acknowledgement Receipt

EFS ID:	25783202
Application Number:	14615928
International Application Number:	
Confirmation Number:	4203
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Customer Number:	115777
Filer:	Jennifer Kisko/Lynnette Dewitz
Filer Authorized By:	Jennifer Kisko
Attorney Docket Number:	596000-00410
Receipt Date:	16-MAY-2016
Filing Date:	06-FEB-2015
Time Stamp:	11:46:38
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$960
RAM confirmation Number	9431
Deposit Account	501678
Authorized User	KISKO, JENNIFER L.
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	Issue_Fee.pdf	151333 2a701048b7bafacecf5561d3d939bda800ad075c	no	1
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	30590 9af55df6532ea8018ec590f45d42af495faffc3e	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	181923		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

115777 7590 02/18/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

EXAMINER
MCINTOSH III, TRAVISS C

ART UNIT	PAPER NUMBER
1673	

DATE MAILED: 02/18/2016

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TITLE OF INVENTION: 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	05/18/2016

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

115777 7590 02/18/2016
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TITLE OF INVENTION: 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	05/18/2016

EXAMINER	ART UNIT	CLASS-SUBCLASS
MCINTOSH III, TRAVISS C	1673	514-047000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.
1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:
❑ Issue Fee
❑ Publication Fee (No small entity discount permitted)
❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
❑ A check is enclosed.
❑ Payment by credit card. Form PTO-2038 is attached.
❑ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
❑ Applicant certifying micro entity status. See 37 CFR 1.29
NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
❑ Applicant asserting small entity status. See 37 CFR 1.27
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
❑ Applicant changing to regular undiscounted fee status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

PTOL-85 Part B (10-13) Approved for use through 10/31/2013. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

115777 7590 02/18/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

EXAMINER	
MCINTOSH III, TRAVISS C	

ART UNIT	PAPER NUMBER
1673	

DATE MAILED: 02/18/2016

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 14/615,928	Applicant(s) SMITH ET AL.	
	Examiner TRAVISS C. MCINTOSH III	Art Unit 1673	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *amendment filed 12/3/2015*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *1-10,13,14,16,17,23-26,31 and 33*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov .
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
5. ☐ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/TRAVISS C MCINTOSH III/
Primary Examiner, Art Unit 1673

REASONS FOR ALLOWANCE

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

The following is an examiner's statement of reasons for allowance: applicant's amendments and arguments have overcome the rejections set forth in the 11/9/2015 office action. The prior art is not seen to teach or fairly suggest the instantly claimed compounds which require a 4'-CF_2H group and also has the claimed bases. The closest art is seen to be 2015/0011497 (of record) – but the compounds therein comprise either a 4'-CH_2CHF_2 or are delimited by the proviso set forth in the instant claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/TRAVISS C MCINTOSH III/
Primary Examiner, Art Unit 1673

```
Connecting via Winsock to STN at pto-stn on port 23



Welcome to STN International!  Enter x:X

LOGINID:ssspta1600txm

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:12:04 ON 03 NOV 2015
FILE 'CAPLUS' ENTERED AT 11:12:04 ON 03 NOV 2015
COPYRIGHT (C) 2015 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     103.72     335.38

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     103.72     335.38

FILE 'REGISTRY' ENTERED AT 11:12:15 ON 03 NOV 2015
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2015 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 NOV 2015  HIGHEST RN 1817756-00-5
DICTIONARY FILE UPDATES:   2 NOV 2015  HIGHEST RN 1817756-00-5

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy

TSCA INFORMATION NOW CURRENT THROUGH JULY 10, 2015

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/training/stn/database-specific

=>
Uploading C:\Users\tmcintosh\Documents\STN Express 8.4\Queries\14615928.str

L6      STRUCTURE UPLOADED
```

```
=> d l6
L6 HAS NO ANSWERS
L6              STR
```




```
Structure attributes must be viewed using the Structure Drawing program.


=> s l6 sam
SAMPLE SEARCH INITIATED 11:12:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      315 TO ITERATE

100.0% PROCESSED      315 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         5236 TO     7364
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 11:12:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     6233 TO ITERATE

100.0% PROCESSED     6233 ITERATIONS                              7 ANSWERS
SEARCH TIME: 00.00.01

L8            7 SEA SSS FUL L6

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               231.41     566.79

FILE 'CAPLUS' ENTERED AT 11:12:39 ON 03 NOV 2015
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2015 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Nov 2015 VOL 163 ISS 20
FILE LAST UPDATED: 2 Nov 2015 (20151102/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2015
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Sep 2014

CAplus includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2015.

CAplus now includes the comprehensive Cooperative Patent Classification
(CPC). See HELP CPC for details.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l8
L9 3 L8

=> d bib hitstr 1-3


L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2010:844748 CAPLUS
DN 153:145774
TI Preparation and enzymic resistance of bis-modified bicyclic nucleic acid analogs
IN Seth, Punit P.; Swayze, Eric E.
PA Isis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 138pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010077578	A1	20100708	WO 2009-US66863	20091204

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,


ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20090156792 A1 20090618 US 2008-331226 20081209
US 7666854 B2 20100223
EP 2376516 A1 20111019 EP 2009-775431 20091204
EP 2376516 B1 20130417
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR
AU 2012201664 A1 20120412 AU 2012-201664 20120321
AU 2013203064 A1 20130502 AU 2013-203064 20130409
PRAI US 2008-331226 A 20081209
US 2006-60747059 P 20060511
AU 2007-211080 A3 20070127
AU 2007-258117 A3 20070507
US 2007-747057 A2 20070510
WO 2009-US66863 W 20091204
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 153:145774; MARPAT 153:145774
IT 1160288-53-8P 1160288-54-9P 1160288-55-0P
1160288-56-1P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enzymic resistance of bis-modified bicyclic nucleic acid analogs)
RN 1160288-53-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1160288-54-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1160288-55-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1160288-56-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2009:743100 CAPLUS
DN 151:57092
TI Preparation and enzymic resistance of bis-modified bicyclic nucleic acid analogs
IN Seth, Punit P.; Swayze, Eric E.
PA Isis Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 747,057.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090156792	A1	20090618	US 2008-331226	20081209
	US 7666854	B2	20100223		
	US 20070287831	A1	20071213	US 2007-747057	20070510
	US 7547684	B2	20090616		
	US 20090192302	A1	20090730	US 2009-407643	20090319
	US 7750131	B2	20100706		
	WO 2010077578	A1	20100708	WO 2009-US66863	20091204
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 2376516	A1	20111019	EP 2009-775431	20091204
	EP 2376516	B1	20130417		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR				
	US 20100121045	A1	20100513	US 2010-687429	20100114
	US 8088746	B2	20120103		
	US 20100184966	A1	20100722	US 2010-751706	20100331
	US 8030467	B2	20111004		
	US 20120010393	A1	20120112	US 2011-13243321	20110923
	US 8268980	B2	20120918		
	AU 2012201664	A1	20120412	AU 2012-201664	20120321
	AU 2013203064	A1	20130502	AU 2013-203064	20130409
PRAI	US 2006-60747059	P	20060511		
	US 2007-747057	A2	20070510		
	AU 2007-211080	A3	20070127		
	AU 2007-258117	A3	20070507		
	US 2008-331226	A	20081209		
	US 2009-407643	A1	20090319		


WO 2009-US66863 W 20091204
US 2010-751706 A1 20100331
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 151:57092; MARPAT 151:57092
IT 1160288-53-8P 1160288-54-9P 1160288-55-0P
1160288-56-1P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enzymic resistance of bis-modified bicyclic nucleic acid analogs)
RN 1160288-53-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1160288-54-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1160288-55-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1160288-56-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2007:1336679 CAPLUS
DN 147:542075
TI Preparation of 5'-Modified bicyclic nucleic acid analogs useful for enhancing nuclease resistance
IN Seth, Punit P.; Swayze, Eric E.
PA Isis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007134181	A2	20071122	WO 2007-US68690	20070510
	WO 2007134181	A3	20080110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU	2007249349	A1	20071122	AU 2007-249349	20070510
AU	2007249349	B2	20120308		
CA	2651453	A1	20071122	CA 2007-2651453	20070510
CA	2651453	C	20141014		
EP	2066684	A2	20090610	EP 2007-797414	20070510
EP	2066684	B1	20120718		

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

CN	101490074	A	20090722	CN 2007-80026285	20070510
CN	101490074	B	20130626		
JP	2009536955	T	20091022	JP 2009-510176	20070510
JP	5441688	B2	20140312		
ES	2389737	T3	20121031	ES 2007-797414	20070510
IN	2008CN06802	A	20090327	IN 2008-CN6802	20081211
US	20100184966	A1	20100722	US 2010-751706	20100331
US	8030467	B2	20111004		
US	20120010393	A1	20120112	US 2011-13243321	20110923
US	8268980	B2	20120918		
AU	2012201664	A1	20120412	AU 2012-201664	20120321
AU	2013203064	A1	20130502	AU 2013-203064	20130409
PRAI US	2006-60747059	P	20060511		
AU	2007-211080	A3	20070127		
AU	2007-258117	A3	20070507		
US	2007-747057	A1	20070510		
WO	2007-US68690	W	20070510		
US	2009-407643	A1	20090319		
US	2010-751706	A1	20100331		

OS CASREACT 147:542075; MARPAT 147:542075

IT 1057385-69-9 1057386-32-9 1070907-84-4


RL: PRPH (Prophetic)

(Preparation of 5'-Modified bicyclic nucleic acid analogs useful for enhancing nuclease resistance)

RN 1057385-69-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1057386-32-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1070907-84-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14615928	SMITH ET AL.
	Examiner	Art Unit
	TRAVISS C MCINTOSH III	1673

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
palm - inventor	11/3/15	tcm
google/pubmed	11/3/15	tcm
east	11/3/15	tcm
stn	11/3/15	tcm
palm - inventor	2/8/16	tcm
reviewed stn	2/8/16	tcm
google/pubmed	2/8/16	tcm

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
C07H	19/16, 19/213, 19/06, 19/10	2/8/16	tcm

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 4203

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
14/615,928	02/06/2015	514	1673	596000-00410

APPLICANTS

Riboscience LLC, Palo Alto, CA;

INVENTORS

Mark Smith, San Francisco, CA;
Klaus G. Klumpp, West Chester, PA;

**** CONTINUING DATA ***************************

This appln claims benefit of 61/936,569 02/06/2014

**** FOREIGN APPLICATIONS ***************************

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ****

02/23/2015

Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged / / Examiner's Signature	☐ Met after Allowance Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
		CA	0	20	3

ADDRESS

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801
UNITED STATES

TITLE

4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

FILING FEE RECEIVED		
3200	FEES: Authority has been given in Paper No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

EAST Search History (Prior Art)

		<This search history is empty>			

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2140	C07H19/16.cpc.	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L2	58	C07H19/213.cpc.	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L3	2372	C07H19/06.cpc.	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L4	2234	C07H19/10.cpc.	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L5	4724	1 2 3 4	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L6	216	5 and difluoromethyl	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09
L7	1	5 and 4'-difluoromethyl	US-PGPUB; USPAT	OR	ON	2016/02/08 13:09

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14615928	SMITH ET AL.
	Examiner	**Art Unit**
	TRAVISS C MCINTOSH III	1673

CPC						
Symbol					**Type**	**Version**
A61K		45	/	06	F	2013-01-01
C07H		19	/	06	I	2013-01-01
A61K		31	/	7072	I	2013-01-01
C07H		19	/	10	I	2013-01-01
A61K		31	/	7068	I	2013-01-01
C07H		19	/	16	I	2013-01-01
A61K		31	/	7076	I	2013-01-01
A61K		31	/	708	I	2013-01-01
C07H		19	/	213	I	2013-01-01
			/			
			/			
			/			
			/			
			/			
			/			

CPC Combination Sets								
Symbol					**Type**	**Set**	**Ranking**	**Version**
A61K		31	/	7072	I	1	1	2013-01-01
A61K		2300	/	00	A	1	2	2013-01-01
A61K		31	/	7076	I	2	1	2013-01-01
A61K		2300	/	00	A	2	2	2013-01-01
A61K		31	/	708	I	3	1	2013-01-01
A61K		2300	/	00	A	3	2	2013-01-01
A61K		31	/	7068	I	4	1	2013-01-01
A61K		2300	/	00	A	4	2	2013-01-01

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	20	
/TRAVISS C MCINTOSH III/ Primary Examiner.Art Unit 1673	2/8/16	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	none

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14615928	SMITH ET AL.
	Examiner	**Art Unit**
	TRAVISS C MCINTOSH III	1673

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**
514	47

CROSS REFERENCE(S)					
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**				
514	46	49	50	51	
536	26.8	27.81	28.5	28.52	27.6
536	28.53	28.55			

INTERNATIONAL CLASSIFICATION					
CLAIMED					**NON-CLAIMED**
C	0	7	H	19 / 213 (2006.01.01)	
C	0	7	H	19 / 06 (2006.01.01)	
C	0	7	H	19 / 10 (2006.01.01)	
C	0	7	H	19 / 16 (2006.01.01)	

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 20	
/TRAVISS C MCINTOSH III/ Primary Examiner.Art Unit 1673 (Primary Examiner)	2/8/16 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure none

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14615928	SMITH ET AL.
	Examiner	**Art Unit**
	TRAVISS C MCINTOSH III	1673

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	1	14	17	20	33										
2	2	-	18												
3	3	-	19												
4	4	-	20												
5	5	-	21												
6	6	-	22												
7	7	15	23												
8	8	16	24												
9	9	17	25												
10	10	18	26												
-	11	-	27												
-	12	-	28												
11	13	-	29												
12	14	-	30												
-	15	19	31												
13	16	-	32												

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 20	
/TRAVISS C MCINTOSH III/ Primary Examiner.Art Unit 1673 (Primary Examiner)	2/8/16 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure none

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Mark Smith, et al.	Examiner: **Traviss C. McIntosh III**
Serial No. **14/615,928**	Art Unit: **1673**
Filing Date: **February 6,2015**	Conf. No. **4203**
For: **4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication**	Attorney Docket No. **596000-00410**

VIA EFS WEB

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Responsive to the Examiner's Office Action of November 9, 2015, please enter the amendments and remarks set forth below. The Commissioner is authorized to charge or credit any discrepancies in fee amounts to Deposit Account No. 501678.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Mark Smith, et al.	Examiner: **Traviss C. McIntosh III**
Serial No. **14/615,928**	Art Unit: **1673**
Filing Date: **February 6,2015**	Conf. No. **4203**
For: **4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication**	Attorney Docket No. **596000-00410**

VIA EFS WEB


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Responsive to the Examiner's Office Action of November 9, 2015, please enter the amendments and remarks set forth below. The Commissioner is authorized to charge or credit any discrepancies in fee amounts to Deposit Account No. 501678.

In the Claims:

1. (Currently amended) A compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

3. (Original) The compound of claim 1, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

4. (Original) The compound of claim 1, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

5. (Original) The compound of claim 1, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

6. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

7. (Original) The compound of claim 1, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

8. (Original) The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

9. (Original) The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

10. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

11-12. (Cancelled)

13. (Original) The compound of claim 1, wherein X is O.

14. (Original) The compound of claim 1, wherein X is S.

15. (Cancelled)

16. (Original) The compound of claim 1, wherein R is O-R^1, and R^1 is naphthylenyl.

17. (Original) The compound of claim 1, wherein R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

18-22. (Cancelled)

23. (Original) A compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylcytidine;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorocytidine;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorocytidine;

4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorocytidine;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-chlorocytidine;

4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyladenosine;

4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-7-adenosine;

4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylguanosine;

4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2,2''-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylarauridine;

4'-Difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroarauridine;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4'-difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;

4'-Difluoromethyl—5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine;

4'-Difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;

4'-Difluoromethyl—5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine;

4'-Difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadensoine;

4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraguanosine;

4'-Difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxylouridine;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylouridine;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylouridine;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxylocytidine;

4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxyloadenosine;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxyloguanosine;

4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;

3'-Deoxy-3'.3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy -5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine; and

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine.


24. (Currently amended) A method of ~~preventing or~~ treating Influenza comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

25. (Original) A composition comprising the compound of claim 1, admixed with at least one carrier, diluent or excipient.

26. (Original) A composition comprising the compound of claim 1 in combination with one or more antiviral compounds.

27-30. (Cancelled)

31. (Currently amended) A method for ~~preventing or~~ treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I~~, or a compound resulting in the formation of a compound of Formula I in vivo,~~



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S; and

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

or a pharmacologically acceptable salt thereof.

32. (Cancelled)

33. (Currently amended) A method for ~~preventing or~~ treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 23

Remarks

Applicant and the undersigned would like to thank the Examiner for his efforts in the examination of this application. Reconsideration is respectfully requested. Claims 1-10, 13-14, 16-17, 23-26, 31, and 33 are currently pending. Claims 11-12, 15, 18-22, 27-30, and 32 have previously been cancelled. Claims 1, 24, 31, and 33 are herein amended.

No new matter has been added.

Amendments

Claim 1 has been amended to include the structure of Formula I. The amendment finds support in paragraph [0006] on page 2 and paragraph [0032] on page 7 of the application as originally filed.

Claims 24, 31, and 33 have been amended herein to remove recitation of "*preventing or*" in order to overcome the rejection of claims 24, 31, and 33 under AIA 35 U.S.C. 112(a) for lack of enablement.

Claim 31 has been amended herein to remove the functional language "*or a compound resulting in the formation of a compound of Formula I in vivo*," in order to overcome the rejection under AIA 35 U.S.C. §112(b) for being indefinite.

Rejections

Rejections under AIA 35 U.S.C. §112(b)

According to the Office Action of November 9, 2015, claims 1-10, 13-14, 16-17, 24-26, and 31 were rejected under AIA 35 U.S.C. §112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.

In particular, on page 2 of the Office Action of November 9, 2015, claim 1 was rejected under AIA 35 U.S.C. §112(b) for lacking the structure of formula I in the claim. As claim 1 has herein been amended to include the structure of Formula I, the rejection under AIA 35 U.S.C. §112(b) is now moot. Accordingly, Applicant respectfully requests that the Examiner withdraw the rejection of claim 1 under AIA 35 U.S.C. §112(b) for lacking the structure of formula I.

Claims 2-10, 13-14, 16-17, 24-26 were likewise rejected under AIA 35 U.S.C. §112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention because they are all dependent on claim 1. As the rejection under AIA 35 U.S.C. §112(b) is now moot due to the amendment herein of claim 1, the rejection of dependent claims 2-10, 13-14, 16-17, 24-26 should likewise be rendered moot.

Accordingly, Applicant respectfully requests that the Examiner withdraw the rejection of claims 2-10, 13-14, 16-17, 24-26 under AIA 35 U.S.C. §112(b) for indefiniteness.

On pages 2-3 of the Office Action of November 9, 2015, claim 31 was rejected under AIA 35 U.S.C. §112(b) for being indefinite due to inclusion of functional language in the claim:

> "*Claim 31 is indefinite wherein the claim is drawn to methods of treatment by administering a therapeutically effective amount of the compound of formula I or "a compound resulting in the formation of a compound of Formula I in vivo". The use of this functional language to define the active agent intended to be administered is seen to be indefinite as it does not allow a skilled artisan to know the metes and bounds of the claim. For example, if another artisan were to administer a structurally related compound not embraced by that of formula I, they would not necessarily know whether they were infringing on the instant claims or not, as the compound may or may not be known to be one which when administered would result in a compound of formula I. Per the MPEP*:
>
> > The second paragraph of 35 U.S.C. 112 is directed to requirements for the claims: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. There are two separate requirements set forth in this paragraph:
> > (A) the claims must set forth the subject matter that applicants regard as their invention; and
> > (B) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant.
>
> *Although an essential purpose of the examination process is to determine whether or not the claims define an invention that is both novel and nonobvious over the prior art, another essential purpose of patent examination is to determine whether or not the claims are precise, clear, correct, and unambiguous. The uncertainties of claim scope should be removed, as much as possible, during the examination process. The inquiry during examination is patentability of the invention as applicant regards it. If the claims do not particularly point out and distinctly claim that which applicants regard as their invention, the appropriate action by the examiner is to reject the claims under 35 U.S.C. 112, second paragraph. In re Zletz, 893 F.2d 319, 13 USPQ2d 1320 (Fed. Cir. 1989).*
>
> *The use of the functional language to define the scope of compounds which applicants are administering is not seen to clearly allow a skilled artisan to know the metes and bounds of the claimed subject matter, as it is not known what*

every compound, once administered, are converted to and whether they would be converted to a compound of formula I."

Claim 31 has therefore been amended herein to remove the functional language "*or a compound resulting in the formation of a compound of Formula I in vivo*," in order to facilitate prosecution and allowance of the instant application. Thus, the rejection of claim 31 under AIA 35 U.S.C. §112(b) for being indefinite due to inclusion of functional language in the claim has been rendered moot. Applicant therefore respectfully requests that the Examiner withdraw the rejection of claim 31 under AIA 35 U.S.C. §112(b).

Rejection under AIA 35 U.S.C. §112(a)


On page 4 of the Office Action of November 9, 2015, claims 24, 31, and 33 have been rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, for lack of enablement "because the specification, while being enabling for treating Influenza, does not reasonably provide enablement for preventing an Influenza infection." In order to facilitate prosecution and allowance of the instant application, claims 24, 31, and 33 have therefore been amended herein to remove recitation of "*preventing or*." Thus, the rejection of claims 24, 31, and 33 under AIA 35 U.S.C. 112(a) is believed to be moot.

Accordingly, Applicant respectfully requests that the Examiner withdraw the rejection of claims 24, 31, and 33 under AIA 35 U.S.C. §112(a) for lack of enablement.

Rejection under AIA 35 U.S.C. §102(a)(2)

On page 9 of the Office Action of November 9, 2015, claims 1, 10, 13, 25, and 26 were rejected under AIA 35 U.S.C. §102(a)(2) as being anticipated by US2015/0011497. According to the Examiner:

"The '497 document discloses the compound:



on the bottom of page 49. This compound anticipates the instant compounds wherein the instant variables are seen to be: R^{te} and RY are H; R' is OH; R^z is F; Base is uracil; and Y is triphosphate."

However, Applicant respectfully points out that the cited compound does not anticipate claim 1 as there is an extra CH_2 group at the 4'-position between the ring and the CHF_2 moiety. The compound of formula 1 is directed strictly to compounds with 4'- CHF_2 substitution, NOT 4'-CH_2CHF_2 substitution.

Applicant would additionally like to point out that there is one compound in US2015/0011497 (on page 50) which does have 4'- CHF_2 substitution, ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate. However, this compound has been eliminated from the scope of claim 1 by proviso in the application as originally filed.

Accordingly, Applicant respectfully requests that the Examiner withdraw the rejection of claim 1 under AIA 35 U.S.C. §102(a)(2) for anticipation by US2015/0011497.

Conclusions

Applicant respectfully submits that the above amendments place this application in a condition for allowance, and passage to issue is respectfully solicited. The Applicant and the undersigned would like to again thank the Examiner for his efforts in the examination of this application and for reconsideration of the claims as amended in light of the arguments presented. If the further prosecution of the application can be facilitated through telephone interview between the Examiner and the undersigned, the Examiner is requested to telephone the undersigned at the Examiner's convenience.

Respectfully submitted,

/Jennifer L. Kisko J.D., Ph.D./
Jennifer L. Kisko J.D., Ph.D.
Reg. No. 56907
GrayRobinson, P.A.
P.O. Box 3068
Orlando, FL 32802-3068
Telephone: (407) 244-5681
Email: Jennifer.Kisko@gray-robinson.com

Electronic Acknowledgement Receipt

EFS ID:	24252687
Application Number:	14615928
International Application Number:	
Confirmation Number:	4203
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Customer Number:	115777
Filer:	Jennifer Kisko/Lynnette Dewitz
Filer Authorized By:	Jennifer Kisko
Attorney Docket Number:	596000-00410
Receipt Date:	03-DEC-2015
Filing Date:	06-FEB-2015
Time Stamp:	13:44:24
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		ROA.pdf	287301 ccdc8152f4d594ce6b01465f24d09a77e40b0c86	yes	73

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	67
	Applicant Arguments/Remarks Made in an Amendment	68	73
Warnings:			
Information:			
	Total Files Size (in bytes):	287301	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
14/615,928	02/06/2015	

ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **12/03/2015**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 20	Minus	** 20	=	X $ =	
Independent (37 CFR 1.16(h))	* 3	Minus	***3	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/PEGGY S. YARBOROUGH/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

115777 7590 11/09/2015

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

EXAMINER	
MCINTOSH III, TRAVISS C	

ART UNIT	PAPER NUMBER
1673	

NOTIFICATION DATE	DELIVERY MODE
11/09/2015	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ipteam@gray-robinson.com
jennifer.kisko@gray-robinson.com
lynnette.dewitz@gray-robinson.com

Office Action Summary	Application No. 14/615,928	Applicant(s) SMITH ET AL.	
	Examiner TRAVISS C. MCINTOSH III	Art Unit 1673	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *4/24/2015*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-10,13,14,16,17,23-26,31 and 33* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☒ Claim(s) *23* is/are allowed.

7)☒ Claim(s) *1-10,13,14,16,17,24-26,31 and 33* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

DETAILED ACTION

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Claim Rejections - 35 USC § 112

The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-10, 13-14, 16-17, 24-26, and 31 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.

Claim 1 is drawn to a compound of formula I, but fails to set forth the actual structure of the compound of formula I. It is noted that applicants should include the structure of formula I in the independent claim. The examiner is interpreting the compound of formula I of claim 1 to be the same as that of formula I in claim 31 wherein claim 1 comprises the different definitions for the various R-groups compared to the definitions of claim 31.

Claim 31 is indefinite wherein the claim is drawn to methods of treatment by administering a therapeutically effective amount of the compound of formula I or "a compound resulting in the formation of a compound of Formula I in vivo". The use of this functional language to define the active agent intended to be administered is seen to be indefinite as it does

not allow a skilled artisan to know the metes and bounds of the claim. For example, if another artisan were to administer a structurally related compound not embraced by that of formula I, they would not necessarily know whether they were infringing on the instant claims or not, as the compound may or may not be known to be one which when administered would result in a compound of formula I. Per the MPEP:

> The second paragraph of 35 U.S.C. 112 is directed to requirements for the claims: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. There are two separate requirements set forth in this paragraph:
> (A) the claims must set forth the subject matter that applicants regard as their invention; and
> (B) **the claims must particularly point out and distinctly define the metes and bounds of the subject matter** that will be protected by the patent grant.
>
> Although an essential purpose of the examination process is to determine whether or not the claims define an invention that is both novel and nonobvious over the prior art, **another essential purpose of patent examination is to determine whether or not the claims are precise, clear, correct, and unambiguous**. The **uncertainties of claim scope should be removed**, as much as possible, during the examination process.
> The inquiry during examination is patentability of the invention as applicant regards it. If the claims do not particularly point out and distinctly claim that which applicants regard as their invention, the appropriate action by the examiner is to reject the claims under 35 U.S.C. 112, second paragraph. In re Zletz, 893 F.2d 319, 13 USPQ2d 1320 (Fed. Cir. 1989).

The use of the functional language to define the scope of compounds which applicants are administering is not seen to clearly allow a skilled artisan to know the metes and bounds of the claimed subject matter, as it is not known what every compound, once administered, are converted to and whether they would be converted to a compound of formula I.

All claims which depend from an indefinite claim are also indefinite. ***Ex parte Cordova, 10 U.S.P.Q. 2d 1949, 1952 (P.T.O. Bd. App. 1989).***

The following is a quotation of the first paragraph of 35 U.S.C. 112(a):

> (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.

The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 24, 31, and 33 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, because the specification, while being enabling for treating Influenza, does not reasonably provide enablement for preventing an Influenza infection. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

Undue experimentation is a conclusion reached by weighing the noted factual considerations set forth below as seen in ***In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)***. A conclusion of lack of enablement means that, based on the evidence regarding a fair evaluation of an appropriate combination of the factors below, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

These factors include:

(A) The breadth of the claims;
(B) The nature of the invention;
(C) The state of the prior art;
(D) The level of one of ordinary skill;
(E) The level of predictability in the art;
(F) The amount of direction provided by the inventor;
(G) The existence of working examples; and
(H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

The breadth of the claims/Nature of the Invention:

The claims are drawn to methods of treating or preventing an Influenza infection using the compounds of formula I. In the absence of an explicit definition in Applicant's specification, "Prevention" as recited in the instant claims, is interpreted to mean the complete and total blocking of all symptoms of a disorder for an indefinite period of time. Any therapy which merely reduces the number or severity of symptoms, or which is effective for a period shorter than the subject's remaining lifespan, is considered to be ineffective at preventing a disorder.

The state of the prior art:

Generic prevention of an Influenza infection in the sense being used herein is not a recognized clinical outcome in the art.

The level of predictability in the art:

Regarding prevention, prevention of a disease is not the same as treatment of said disease. In order to prevent a disease, as opposed to merely delaying or reducing its symptoms, a dosing must either render the subject completely resistant to said disease after a single treatment or a limited number of treatments, or else, when continued indefinitely, continue to completely suppress the occurrence of said disease. In order to practice a preventative method, one of skill in the art must know the answer to several questions in addition to the effectiveness of the therapy

in short-term relief of symptoms, including: 1) What is the duration of a single course of therapy? How often must the therapy be administered to completely suppress the disease? 2) Does the subject develop tolerance to the therapy over time? Does the disease eventually progress to a point where the therapy is unable to completely suppress all symptoms? For example, will a metastatic cancer eventually adapt to overcome treatments directed to preventing it from metastasizing into the bone? Or will a case of osteoporosis or rheumatoid arthritis ultimately progress to a point where symptoms develop regardless of which therapy is administered. 3) What are the long-term effects of the therapy? Does it cause progressive damage to the kidneys, liver, or other organs? Does the active agent accumulate in the subject's tissues? Is the minimum dose necessary to completely prevent the disease safe for long-term administration? Are there any steps that can be taken to reduce side effects? Additionally, because various physiological systems are interdependent and affect one another, any hypothetical preventative treatment would have to be broad-based and treat all of the various causes of a disorder. For example, because osteoporosis is, in the majority of cases, caused at least in part by a reduction in estrogen levels, a true preventative treatment for osteoporosis must be capable of preventing or reversing menopause in a subject. For this reason, many therapies which are suitable for short-term relief of symptoms are not suitable for lifelong prevention of disease. For example, antibiotics, chemotherapeutics, and antiviral drugs are not normally administered to healthy subjects in order to prevent the development of infection or cancer. Furthermore, a tissue can degenerate for a variety of reasons, including but not limited to, exposure to toxins, chronic viral infection, autoimmune attack, and deposition of amyloid

protein. To be fully successful, a preventative method would have to guard against all of these possible insults.

The amount of direction provided by the inventor:

Applicant's specification discloses assays by which the RNAa polymerase inhibitory activity of various compounds can be determined. However, this assay shows which compounds would be beneficial in treating an Influenza virus infection since RNA polymerase is known to be part of the viral replication, however, this would not be sufficient to show action on actually preventing an infection.

The existence of working examples:

No working examples are given for the prevention of any disease. Note that lack of working examples is a critical factor to be considered, especially in a case involving an unpredictable and undeveloped art such as the treatment of broad categories of disease with a single agent. See MPEP 2164.

The quantity of experimentation needed to make or use the invention based on the content of the disclosure:

As mentioned above, the short-term usefulness of a therapy for relief of symptoms is no guarantee of its long-term usefulness for prevention of disease. Because no guidance is given for the use of the claimed therapeutic method for the long-term prevention of disease, one skilled in the art wishing to practice the invention would be unable to do so without first gathering information as to the long-term effectiveness of the therapy. In particular, one skilled in the art, in order to practice the invention for prevention of disease, would need to know whether the preventative effect remains potent over the long term. In order to answer these questions in the absence of any existing data, one skilled in the art, in order to practice the invention, would

undertake long-term animal tests, preferably over a period of years, preferably involving a relatively long-lived experimental animal such as dogs or monkeys, or a human clinical trial. Animal experiments include, along with induction of the disease state, administration of the potential pharmaceutical compound and collection and analysis of data, additional burdens associated with compliance with animal welfare regulations, care, feeding, and other maintenance of the animals, dissection of dead animals to collect data, and disposal of dead animals after the protocol is finished. Administering the claimed compounds for a period of years to a suitable subject population is an undue amount of experimentation needed in order to practice the full range of the claimed invention. As prevention in the full sense is an extremely high bar for any clinical outcome, there is no reason to believe that the therapy would be successful, and any actual success would be a surprising and unpredictable result.

Claim Rejections - 35 USC § 102

In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless –

(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent

or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.

Claims 1, 10, 13, 25, and 26 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by US2015/0011497.

The '497 document discloses the compound:



on the bottom of page 49. This compound anticipates the instant compounds wherein the instant variables are seen to be: R^W and R^y are H; R^x is OH; R^z is F; Base is uracil; and Y is triphosphate. The compound is also taught to be used in pharmaceutical compositions and also comprise additional antiviral agents (see 0219]).

Conclusion

Claim 23 is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/TRAVISS C MCINTOSH III/
Primary Examiner, Art Unit 1673

Notice of References Cited	Application/Control No. 14/615,928	Applicant(s)/Patent Under Reexamination SMITH ET AL.	
	Examiner TRAVISS C. MCINTOSH III	Art Unit 1673	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-2015/0011497 A1	01-2015	Beigelman; Leonid	C07H19/11	514/47
	B	US-				
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 4203

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
14/615,928	02/06/2015	514	1673	596000-00410

APPLICANTS

Riboscience LLC, Palo Alto, CA;

INVENTORS

Mark Smith, San Francisco, CA;
Klaus G. Klumpp, West Chester, PA;

**** CONTINUING DATA ***************************

This appln claims benefit of 61/936,569 02/06/2014

**** FOREIGN APPLICATIONS ***************************

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ****

02/23/2015

Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged / / Examiner's Signature	☐ Met after Allowance Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
		CA	0	20	3

ADDRESS

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801
UNITED STATES

TITLE

4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

FILING FEE RECEIVED		
3200	FEES: Authority has been given in Paper No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"20150225441"	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 11:16
L2	16	"2013138236" "20130243725" "2014209979" "2015054465"	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 11:28
L3	3	"20150011497"	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 11:31
L4	0	3 and triphosphate.clm.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:30
L5	1	1 and triphosphate.clm.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:30
L6	0	3 and influenza	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:32
L7	1	3 and combination	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:35
L8	106	4'-difluoromethyl	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:41

EAST Search History (Prior Art)

L9	13	8 and influenza	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:41
L10	0	8 and "536".ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:42
L11	3	8 and 536/$.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2015/11/03 12:42

EAST Search History (Interference)

		<This search history is empty>				

Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:ssspta1600txm

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:17:16 ON 03 NOV 2015
FILE 'CAPLUS' ENTERED AT 11:17:16 ON 03 NOV 2015
COPYRIGHT (C) 2015 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.16	582.95

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.16	582.95

FILE 'REGISTRY' ENTERED AT 11:17:29 ON 03 NOV 2015
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2015 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 NOV 2015 HIGHEST RN 1817756-00-5
DICTIONARY FILE UPDATES: 2 NOV 2015 HIGHEST RN 1817756-00-5

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy

TSCA INFORMATION NOW CURRENT THROUGH JULY 10, 2015

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/training/stn/database-specific

=>
Uploading C:\Users\tmcintosh\Documents\STN Express 8.4\Queries\14615928a.str

L10   STRUCTURE UPLOADED

```
=> d l10
L10 HAS NO ANSWERS
L10             STR
```




```
Structure attributes must be viewed using the Structure Drawing program.


=> s l10
SAMPLE SEARCH INITIATED 11:18:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      369 TO ITERATE

100.0% PROCESSED      369 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         6228 TO     8532
PROJECTED ANSWERS:             640 TO     1520

L11          50 SEA SSS SAM L10

=> s l10 full
FULL SEARCH INITIATED 11:18:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     7571 TO ITERATE

100.0% PROCESSED     7571 ITERATIONS                             918 ANSWERS
SEARCH TIME: 00.00.01

L12         918 SEA SSS FUL L10

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               231.41     814.36

FILE 'CAPLUS' ENTERED AT 11:18:07 ON 03 NOV 2015
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2015 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Nov 2015 VOL 163 ISS 20
FILE LAST UPDATED: 2 Nov 2015 (20151102/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2015
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Sep 2014

CAplus includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2015.

CAplus now includes the comprehensive Cooperative Patent Classification (CPC). See HELP CPC for details.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L13 7 L12

=> d bib 1-7

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2015:1320099 CAPLUS
DN 163:319921
TI Preparation of 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
IN Smith, Mark; Klumpp, Klaus G.
PA Riboscience LLC, USA
SO PCT Int. Appl., 357pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2015120237	A2	20150813	WO 2015-US14762	20150206

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,

SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM

US 20150225441 A1 20150813 US 2015-14615928 20150206

PRAI US 2014-61936569 P 20140206

OS MARPAT 163:319921

L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN

AN 2015:656201 CAPLUS

DN 162:550756

TI prepn of substituted nucleosides, nucleotides and analogs thereof as antiviral agents

IN Beigelman, Leonid; Wang, Guangyi; Smith, David Bernard; Prhavc, Marija; Jekle, Christian Andreas; Deval, Jerome

PA Alios Biopharma, Inc., USA

SO PCT Int. Appl., 854pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2015054465	A1	20150416	WO 2014-US59849	20141009

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM

US 20150105341 A1 20150416 US 2014-14510451 20141009

PRAI US 2013-61890136 P 20131011

US 2014-62016288 P 20140624

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 162:550756

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN

AN 2015:259020 CAPLUS

DN 162:320182

TI Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection

AU Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo

CS Alios BioPharma, Inc., South San Francisco, CA, 94080, USA

SO Journal of Medicinal Chemistry (2015), 58(4), 1862-1878
CODEN: JMCMAR; ISSN: 0022-2623
DOI 10.1021/jm5017279
PB American Chemical Society
DT Journal; (online computer file)
LA English
OS CASREACT 162:320182
OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2014:2181636 CAPLUS
DN 162:161199
TI Preparation of substituted nucleosides, nucleotides and analogs thereof as antiviral agents
IN Beigelman, Leonid; Deval, Jerome; Jin, Zhinan
PA Alios Biopharma, Inc., USA
SO PCT Int. Appl., 582pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2014209979	A1	20141231	WO 2014-US43836	20140624
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 20150011497	A1	20150108	US 2014-14313043	20140624
PRAI US 2013-61839711	P	20130626		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 162:161199
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2013:1470317 CAPLUS
DN 159:526750
TI 2'-Substituted carbanucleoside analogs for antiviral treatment
IN Clarke, Michael O' Neil Hanrahan
PA Gilead Sciences , Inc., USA
SO PCT Int. Appl., 94pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2013138236	A1	20130919	WO 2013-US30196	20130311
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
	CA 2866381	A1	20130919	CA 2013-2866381	20130311
	US 20130243725	A1	20130919	US 2013-13793557	20130311
	AU 2013232378	A1	20140925	AU 2013-232378	20130311
	IL 234586	A	20141030	IL 2013-234586	20130311
	KR 2014135820	A	20141126	KR 2014-7028523	20130311
	CN 104185638	A	20141203	CN 2013-80014318	20130311
	EP 2834258	A1	20150211	EP 2013-712043	20130311
	R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BA, ME				
	MD 20140112	A2	20150228	MD 2014-112	20130311
	JP 2015509983	T	20150402	JP 2015-500493	20130311
	MX 2014011009	A	20141013	MX 2014-11009	20140912
	IN 2014DN08505	A	20150515	IN 2014-DN8505	20141010
PRAI	US 2012-61610411	P	20120313		
	WO 2013-US30196	W	20130311		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 159:526750; MARPAT 159:526750
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 1997:192727 CAPLUS
DN 126:293562
OREF 126:56857a,56860a
TI Through-space 7JHF and 6JCF spin-spin couplings in 2',3'-dideoxy-4'-fluoroalkylnucleosides. The role of sugar ring conformation and solvent effect
AU Mele, Andrea; Salani, Giuliana; Viani, Fiorenza; Bravo, Pierfrancesco
CS Dip. Chimica Politecnico, Milan, I-20131, Italy
SO Magnetic Resonance in Chemistry (1997), 35(3), 168-174
CODEN: MRCHEG; ISSN: 0749-1581
DOI 10.1002/(SICI)1097-458X(199703)35:3<168::AID-OMR58>3.0.CO;2-2
PB Wiley
DT Journal
LA English
OSC.G 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)

L13 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 1995:755465 CAPLUS
DN 124:30216
OREF 124:5807a,5810a
TI Synthesis of 4'-fluoroalkyl nucleoside analog
AU Bravo, Pierfrancesco; Mele, Andrea; Salani, Giuliana; Viani, Fiorenza; La Colla, Paolo
CS Dip. Chim., Politecnico Milano, Milan, I-20131, Italy
SO Gazzetta Chimica Italiana (1995), 125(7), 295-303
CODEN: GCITA9; ISSN: 0016-5603
PB Societa Chimica Italiana
DT Journal
LA English
OS CASREACT 124:30216
OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

=> d bib hitstr 1-6

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2015:1320099 CAPLUS
DN 163:319921
TI Preparation of 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
IN Smith, Mark; Klumpp, Klaus G.
PA Riboscience LLC, USA
SO PCT Int. Appl., 357pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2015120237	A2	20150813	WO 2015-US14762	20150206
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 20150225441	A1	20150813	US 2015-14615928	20150206
PRAI US 2014-61936569	P	20140206		

OS MARPAT 163:319921
IT 1702842-46-3P, 4-Amino-1-[(2R,3R,4R,5R)-5-(difluoromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 1803126-04-6P, 4-Amino-1-[(2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 1803126-09-1P, 2-Amino-9-[(2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydro 1803126-10-4P,

(2R,3R,4S,5R)-2-(6-Benzamido-9H-purin-9-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)tetrahydrofuran-3-yl acetate 1803126-12-6P, (2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(difluoromethyl)-2-(hydroxymethyl)tetrahydrofuran-3,4-diol 1803126-15-9P, 4-Amino-5-chloro-1-[(2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5- (hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 1803126-22-8P, 4-Amino-1-[(2R,3S,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 1803126-27-3P, (S)-Benzyl-2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy](phenoxy)phosphorylamino]propanoate 1803126-29-5P, (S)-Neopentyl-2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy](phenoxy)phosphorylamino]propanoate 1803126-30-8P 1803126-31-9P 1803126-32-0P 1803126-33-1P 1803126-34-2P 1803126-35-3P 1803126-36-4P 1803126-37-5P 1803126-38-6P 1803126-39-7P 1803126-40-0P, 4'-Difluoromethyluridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-41-1P, 4'-Difluoromethyluridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-42-2P, 4'-Difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-43-3P 1803126-44-4P, 4'-Difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-45-5P, 4'-Difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-46-6P, 4'-Difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803126-47-7P, 4'-Difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803126-48-8P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803126-49-9P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803126-50-2P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803126-51-3P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine 1803126-54-6P, 4'-Difluoromethyl-5-fluorouridine 1803126-55-7P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-56-8P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-57-9P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-58-0P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-59-1P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-60-4P, 4'-Difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-62-6P 1803126-63-7P 1803126-64-8P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine 1803126-65-9P, 4'-Difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-

fluorouridine 1803126-66-0P,
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine
1803126-67-1P, 4'-Difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl]-5-fluorouridine 1803126-70-6P,
4'-Difluoromethyl-5-chlorouridine 1803126-71-7P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] phosphoramidate] 1803126-72-8P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] thiophosphoramidate] 1803126-73-9P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] phosphoramidate] 1803126-74-0P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-75-1P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-76-2P,
4'-Difluoromethyl-5-chlorouridine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-77-3P,
4'-Difluoromethyl-5-chlorouridine-5'-[N,N-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803126-78-4P,
4'-Difluoromethyl-5-chlorouridine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl] thiophosphorodiamidate 1803126-79-5P
, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-
chlorouridine 1803126-80-8P,
4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-
chlorouridine; 1803126-81-9P,
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine
1803126-82-0P, 4'-Difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl]-5-chlorouridine 1803126-85-3P
1803126-86-4P, 4'-Difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-87-5P,
4'-Difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-88-6P,
4'-Difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803126-89-7P,
4'-Difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl] phosphoramidate 1803126-90-0P,
4'-Difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803126-91-1P,
4'-Difluoromethylcytidine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803126-92-2P,
4'-Difluoromethylcytidine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803126-93-3P
, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-
yl)cytidine 1803126-94-4P,
4'-Difluoromethyl-5'-O-(2-sulflde-4H-1,3,2-benzodioxaphosphorin-2-
yl)cytidine 1803126-95-5P,
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine
1803126-96-6P, 4'-Difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl]cytidine 1803126-99-9P,
4'-Difluoromethyl-5-fluorocytidine 1803127-00-5P,
4'-Difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803127-01-6P,
4'-Difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-02-7P,
4'-Difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803127-03-8P,

4'-Difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-04-9P, 4'-Difluoromethyl-5-fluorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-05-0P, 4'-Difluoromethyl-5-fluorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-06-1P, 4'-Difluoromethyl-5-fluorocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-08-3P, 4'-Difluoromethyl-5-fluorocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-09-4P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803127-10-7P, 4'-Difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803127-11-8P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine 1803127-12-9P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine 1803127-16-3P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-17-4P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-18-5P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-19-6P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-20-9P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-21-0P, 4'-Difluoromethyl-5-chlorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-22-1P, 4'-Difluoromethyl-5-chlorocytidine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-23-2P, 4'-Difluoromethyl-5-chlorocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-24-3P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine 1803127-25-4P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine 1803127-26-5P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine 1803127-27-6P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine 1803127-30-1P 1803127-31-2P, 4'-Difluoromethyladenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-32-3P, 4'-Difluoromethyladenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-33-4P, 4'-Difluoromethyladenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-34-5P, 4'-Difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-35-6P, 4'-Difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-36-7P, 4'-Difluoromethyladenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-37-8P, 4'-Difluoromethyladenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-38-9P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)adenosine 1803127-39-0P,

4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)adenosine 1803127-40-3P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine 1803127-41-4P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine 1803127-44-7P, 4'-Difluoromethyl-7-adenosine 1803127-45-8P, 4'-Difluoromethyl-7-adenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-46-9P, 4'-Difluoromethyl-7-adenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-47-0P, 4'-Difluoromethyladenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-48-1P, 4'-Difluoromethyl-7-adenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-49-2P, 4'-Difluoromethyl-7-adenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-50-5P, 4'-Difluoromethyl-7-adenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-51-6P, 4'-Difluoromethyl-7-adenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-52-7P, 4'-Difluoromethyl-7-adenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-53-8P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine 1803127-54-9P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine 1803127-55-0P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine 1803127-56-1P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine 1803127-59-4P 1803127-60-7P, 4'-Difluoromethylguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-61-8P, 4'-Difluoromethylguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-62-9P, 4'-Difluoromethyl guanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-63-0P, 4'-Difluoromethylguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-64-1P, 4'-Difluoromethyl guanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-65-2P, 4'-Difluoromethyl guanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-66-3P, 4'-Difluoromethyl guanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-67-4P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803127-68-5P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803127-69-6P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine 1803127-70-9P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine 1803127-73-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine 1803127-74-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-O-(phenyl N-(S)-1-(isopropoxycarbonyl)ethyl) phosphoramidate 1803127-75-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-O-(phenyl N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate 1803127-76-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[O-1-

naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-77-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-78-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-79-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-80-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-81-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-82-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803127-83-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803127-84-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803127-85-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine 1803127-88-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine 1803127-89-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-90-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-91-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-92-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-93-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803127-94-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803127-95-8P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803127-96-9P, [2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-[N,N'-bis(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803127-97-0P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine 1803127-99-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine 1803128-00-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine 1803128-01-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine 1803128-04-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine 1803128-05-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-06-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-07-5P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-08-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-09-7P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-2-naphthyl-N-


(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-10-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-11-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-12-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-[N,N'-bis[(S)-[(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-13-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine 1803128-14-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine 1803128-15-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine 1803128-16-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine 1803128-19-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-20-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-21-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-22-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-23-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-24-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-25-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-26-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-27-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803128-28-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803128-29-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]cytidine 1803128-30-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine 1803128-33-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine 1803128-34-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-35-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-36-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-37-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate 1803128-38-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-39-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-40-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-41-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-bis[(S)-1-

(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-42-8P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803128-43-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803128-44-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine 1803128-45-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine 1803128-48-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine 1803128-49-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-50-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-51-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-52-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-53-1P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-54-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-55-3P , [2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[N,N'-bis(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-56-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-58-6P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine 1803128-59-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine 1803128-60-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine 1803128-61-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine 1803128-64-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine 1803128-65-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl adenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-66-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl adenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-67-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl adenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-68-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl adenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-69-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-70-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-71-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-72-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-73-5P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-

benzodioxaphosphorin-2-yl)adenosine 1803128-74-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)adenosine 1803128-75-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]adenosine 1803128-76-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine 1803128-79-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine 1803128-80-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl guanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-81-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-82-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl guanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-83-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl guanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-84-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-85-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of difluoromethyl substituted nucleoside derivs. as inhibitors of influenza RNA replication)


RN 1702842-46-3 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-04-6 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-09-1 CAPLUS
CN Guanosine, 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-10-4 CAPLUS
CN Adenosine, N-benzoyl-4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)-, 2'-acetate (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-12-6 CAPLUS
CN Adenosine, 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-15-9 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-22-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-27-3 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-29-5 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-cytidylyl]-, 2,2-dimethylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-30-8 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-31-9 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 5-chloro-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-32-0 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-33-1 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-34-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803126-35-3 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-36-4 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 2-amino-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-37-5 CAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-38-6 CAPLUS
CN 7H-Purin-6-amine, 7-[4-C-(difluoromethyl)-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-39-7 CAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-40-0 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-41-1 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-42-2 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-43-3 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-44-4 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-45-5 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-46-6 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-47-7 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-48-8 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-49-9 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-50-2 CAPLUS
CN 5'-Uridylic acid, 4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-51-3 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-54-6 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-55-7 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-56-8 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-57-9 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-58-0 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-59-1 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-60-4 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-62-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803126-63-7 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5-fluoro-P-thio-5'-


uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-64-8 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-65-9 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-66-0 CAPLUS


CN 5'-Uridylic acid, 4'-C-(difluoromethyl)-5-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-67-1 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-5-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-70-6 CAPLUS
CN Uridine, 5-chloro-4'-C-(difluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-71-7 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P-phenyl-5'-uridylyl]-,


1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-72-8 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-73-9 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-74-0 CAPLUS


CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-75-1 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-76-2 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-77-3 CAPLUS
CN L-Alanine, N,N'-[5-chloro-4'-C-(difluoromethyl)-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-78-4 CAPLUS
CN L-Alanine, N,N'-[5-chloro-4'-C-(difluoromethyl)-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-79-5 CAPLUS
CN Uridine, 5-chloro-4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-80-8 CAPLUS
CN Uridine, 5-chloro-4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-81-9 CAPLUS
CN 5'-Uridylic acid, 5-chloro-4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-82-0 CAPLUS
CN Uridine, 5-chloro-4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl)


phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-85-3 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-86-4 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-87-5 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-88-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803126-89-7 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-90-0 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-91-1 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-92-2 CAPLUS


CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-93-3 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-94-4 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-95-5 CAPLUS
CN 5'-Cytidylic acid, 4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-96-6 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-99-9 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-00-5 CAPLUS


CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-01-6 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-02-7 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-03-8 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-04-9 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-05-0 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-5-fluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-06-1 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5-fluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-08-3 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5-fluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-09-4 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-10-7 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-11-8 CAPLUS
CN 5'-Cytidylic acid, 4'-C-(difluoromethyl)-5-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-12-9 CAPLUS
CN Cytidine, 4'-C-(difluoromethyl)-5-fluoro-, 5'-[O,O-bis(4-methoxyphenyl)


phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-16-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803127-17-4 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-18-5 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-19-6 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-20-9 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-21-0 CAPLUS
CN L-Alanine, N-[5-chloro-4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-22-1 CAPLUS
CN L-Alanine, N,N'-[5-chloro-4'-C-(difluoromethyl)-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-23-2 CAPLUS


CN L-Alanine, N,N'-[5-chloro-4'-C-(difluoromethyl)-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-24-3 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-25-4 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-26-5 CAPLUS
CN 5'-Cytidylic acid, 5-chloro-4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-27-6 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-30-1 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-31-2 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-phenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-32-3 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-33-4 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-1-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-34-5 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-35-6 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-36-7 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-37-8 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-P-thio-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-38-9 CAPLUS
CN L-Alanine, 4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-39-0 CAPLUS
CN L-Alanine, 4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-40-3 CAPLUS
CN 5'-Adenylic acid, 4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-41-4 CAPLUS
CN Adenosine, 4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-44-7 CAPLUS
CN 7H-Purin-6-amine, 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-45-8 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-46-9 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-47-0 CAPLUS
RN 1803127-48-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-49-2 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-50-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-51-6 CAPLUS


CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 7-[4-C-(difluoromethyl)-β-D-ribofuranosyl]-7H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-52-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803127-53-8 CAPLUS
CN 7H-Purin-6-amine, 7-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-54-9 CAPLUS
CN 7H-Purin-6-amine, 7-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-55-0 CAPLUS
CN 7H-Purin-6-amine, 7-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-56-1 CAPLUS
CN 7H-Purin-6-amine, 7-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-59-4 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-60-7 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-phenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-61-8 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-1-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-62-9 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-1-naphthalenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-63-0 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P-2-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-64-1 CAPLUS
CN L-Alanine, N-[4'-C-(difluoromethyl)-P(O)-2-naphthalenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-65-2 CAPLUS


CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-66-3 CAPLUS
CN L-Alanine, N,N'-[4'-C-(difluoromethyl)-P-thio-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-67-4 CAPLUS
CN Guanosine, 4'-C-(difluoromethyl)-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-68-5 CAPLUS


CN Guanosine, 4'-C-(difluoromethyl)-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-69-6 CAPLUS
CN 5'-Guanylic acid, 4'-C-(difluoromethyl)-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803127-70-9 CAPLUS
CN Guanosine, 4'-C-(difluoromethyl)-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)


Absolute stereochemistry.



RN 1803127-73-2 CAPLUS


CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-74-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-75-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-76-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-77-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-78-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-79-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-80-1 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-81-2 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-82-3 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-83-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803127-84-5 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-85-6 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-88-9 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-89-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-90-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-91-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-92-5 CAPLUS
RN 1803127-93-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-94-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-95-8 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-96-9 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-97-0 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803127-99-2 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-00-8 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-01-9 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-04-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803128-05-3 CAPLUS


CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-06-4 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-07-5 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-08-6 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-09-7 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-10-0 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-11-1 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-12-2 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-13-3 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-14-4 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-15-5 CAPLUS
CN 5'-Uridylic acid, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-16-6 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-,


5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-19-9 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-20-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-21-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-22-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-23-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-24-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-25-7 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-26-8 CAPLUS


CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-27-9 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-28-0 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-29-1 CAPLUS
CN 5'-Cytidylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-30-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803128-33-7 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-34-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-phenyl-5'-


cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-35-9 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-36-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-37-1 CAPLUS


RN 1803128-38-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-39-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-40-6 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-41-7 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-42-8 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-43-9 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-44-0 CAPLUS
CN 5'-Cytidylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-45-1 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',5-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-48-4 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-49-5 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-50-8 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-51-9 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-52-0 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-53-1 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-54-2 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-55-3 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-56-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803128-58-6 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-59-7 CAPLUS
CN Cytidine, 5'-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-60-0 CAPLUS
CN 5'-Cytidylic acid, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-61-1 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-64-4 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-65-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-66-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-


5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-67-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-68-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-69-9 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-70-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-71-3 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-72-4 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-thio-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-73-5 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-74-6 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-75-7 CAPLUS


CN 5'-Adenylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-76-8 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-79-1 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-80-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-phenyl-5'-


guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-81-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-phenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-82-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-1-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-83-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803128-84-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-2-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-85-9 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1803128-86-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803128-87-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803128-88-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803128-89-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803128-90-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl] guanosine 1803128-91-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine 1803128-94-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine 1803128-95-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl arauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803128-96-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-97-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803128-98-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803128-99-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-00-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-01-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-02-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiam 1803129-03-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-04-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-05-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine 1803129-06-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine 1803129-09-0P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine 1803129-10-3P , 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-11-4P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-12-5P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803129-13-6P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-14-7P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-15-8P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-16-9P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-17-0P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-18-1P , 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-19-2P,

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-20-5P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine 1803129-21-6P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]arauridine 1803129-24-9P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine 1803129-25-0P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-26-1P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-27-2P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803129-28-3P , 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-29-4P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-30-7P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-[O-2-naphthyl-A1-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-31-8P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-32-9P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-O-[bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-33-0P , 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-34-1P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)arauridine 1803129-35-2P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]arauridine 1803129-38-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine 1803129-39-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-40-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-41-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803129-42-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-43-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803129-44-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-45-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-46-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-47-6P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803129-48-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803129-49-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine 1803129-50-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-

methoxyphenoxy)thiophosphinyl]aracytidine 1803129-53-4P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine 1803129-54-5P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-55-6P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoram 1803129-56-7P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-57-8P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-58-9P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphora 1803129-59-0P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-60-3P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-Ay V'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-61-4P, 2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-62-5P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803129-63-6P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803129-64-7P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine 1803129-67-0P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine 1803129-68-1P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-69-2P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-70-5P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-71-6P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-72-7P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803129-73-8P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-74-9P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-75-0P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-76-1P 1803129-77-2P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803129-78-3P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine 1803129-79-4P, 5-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine 1803129-82-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine 1803129-84-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-85-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-86-3P,

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803129-87-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-88-5P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803129-90-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803129-92-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803129-94-3P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803129-95-4P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)araadenosine 1803129-97-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulflde-4H-1,3,2-benzodioxaphosphorin-2-yl)araadenosine 1803129-99-8P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine 1803130-02-0P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araaden 1803130-08-6P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine 1803130-10-0P , 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-12-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-14-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-17-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-19-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-22-4P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-25-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803130-29-1P, 2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803130-32-6P , 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)araguanosine 1803130-35-9P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)araguanosine 1803130-38-2P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]araguanosine 1803130-41-7P, 2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine 1803130-51-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine 1803130-54-2P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[[-3-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-57-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[[-3-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-61-1P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-64-4P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-68-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803130-71-3P,


2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803130-76-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803130-79-1P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(A)AR-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803130-81-5P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803130-84-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803130-87-1P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803130-91-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine 1803130-99-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine 1803131-02-3P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-06-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-09-0P , 2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-12-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-1-Iiaphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-15-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-18-1P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-21-6P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803131-24-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-V, N '-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803131-27-2P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine 1803131-30-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine 1803131-32-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine 1803131-34-1P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine 1803131-41-0P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine 1803131-43-2P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-45-4P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-47-6P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-50-1P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-52-3P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-54-5P , 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[O-2-

naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-56-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803131-58-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803131-60-3P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine 1803131-62-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine 1803131-64-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine 1803131-65-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine 1803131-71-6P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine 1803131-72-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-74-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-77-2P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-79-4P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-83-0P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803131-86-3P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803131-88-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803131-90-9P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803131-92-1P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803131-94-3P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803131-96-5P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine 1803131-98-7P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine 1803132-04-8P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine 1803132-06-0P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803132-08-2P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803132-10-6P, 2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803132-12-8P 1803132-14-0P 1803132-16-2P 1803132-18-4P 1803132-20-8P 1803132-22-0P 1803132-24-2P 1803132-26-4P 1803132-29-7P 1803132-35-5P 1803132-37-7P 1803132-39-9P 1803132-41-3P 1803132-43-5P 1803132-46-8P 1803132-48-0P 1803132-50-4P 1803132-52-6P 1803132-54-8P 1803132-56-0P 1803132-58-2P 1803132-60-6P 1803132-65-1P 1803132-67-3P 1803132-69-5P 1803132-71-9P 1803132-73-1P

1803132-75-3P 1803132-77-5P 1803132-79-7P
1803132-81-1P 1803132-83-3P 1803132-84-4P
1803132-86-6P 1803132-88-8P 1803132-94-6P
1803132-96-8P 1803132-98-0P 1803133-00-7P
1803133-03-0P 1803133-05-2P 1803133-07-4P
1803133-09-6P 1803133-11-0P 1803133-12-1P
1803133-13-2P 1803133-15-4P 1803133-16-5P
1803133-22-3P 1803133-24-5P 1803133-26-7P
1803133-28-9P 1803133-30-3P 1803133-32-5P
1803133-33-6P 1803133-35-8P 1803133-37-0P
1803133-39-2P 1803133-40-5P 1803133-41-6P
1803133-42-7P 1803133-45-0P 1803133-46-1P
1803133-47-2P 1803133-48-3P 1803133-49-4P
1803133-50-7P 1803133-51-8P 1803133-52-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of difluoromethyl substituted nucleoside derivs. as inhibitors of influenza RNA replication)


RN 1803128-86-0 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-87-1 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-P-thio-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-88-2 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-89-3 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-90-6 CAPLUS
CN 5'-Guanylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-91-7 CAPLUS


CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-94-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803128-95-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 1803128-96-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-


arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-97-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-98-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803128-99-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-00-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-01-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-02-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803129-03-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-


(CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-04-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-05-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-06-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-09-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-10-3 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-11-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-12-5 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-13-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-14-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-15-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-16-9 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-17-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803129-18-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-


fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-19-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-20-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-21-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-24-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-25-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-26-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-27-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-28-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-29-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-30-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-31-8 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-32-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803129-33-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-


arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-34-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-35-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-38-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-39-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-40-9 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)


Absolute stereochemistry.



RN 1803129-41-0 CAPLUS


CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-42-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-43-2 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-44-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-45-4 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-46-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803129-47-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-48-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-49-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-50-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-53-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-54-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-55-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-56-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-57-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-58-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-59-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-60-3 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-61-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803129-62-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-63-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-64-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-67-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-68-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-69-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-70-5 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-71-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-72-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-73-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-74-9 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-75-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803129-76-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-


arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-77-2 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-78-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-79-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-82-9 CAPLUS
CN 9H-Purin-6-amine, 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-84-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-85-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-86-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-87-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-88-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.



RN 1803129-90-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)


Absolute stereochemistry.



RN 1803129-92-1 CAPLUS


CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-94-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803129-95-4 CAPLUS
CN 9H-Purin-6-amine, 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-97-6 CAPLUS
CN 9H-Purin-6-amine, 9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803129-99-8 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-02-0 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-08-6 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-10-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-12-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-14-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-17-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-19-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-22-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-25-7 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-29-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803130-32-6 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803130-35-9 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803130-38-2 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro- (CA


INDEX NAME)

Absolute stereochemistry.




RN 1803130-41-7 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-51-9 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-54-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-57-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-61-1 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-64-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-68-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-71-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-76-8 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-79-1 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-81-5 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-84-8 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-87-1 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-91-7 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803130-99-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803131-02-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-06-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-09-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-12-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-15-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-18-1 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-21-6 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-24-9 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-27-2 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-30-7 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-32-9 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-34-1 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-41-0 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-43-2 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-45-4 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-47-6 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-50-1 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-52-3 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-54-5 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-56-7 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-58-9 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-60-3 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-62-5 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-64-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803131-65-8 CAPLUS
CN Uridine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-71-6 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803131-72-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803131-74-9 CAPLUS


CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-77-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-79-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-83-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-86-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-88-5 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-90-9 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-92-1 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-94-3 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-96-5 CAPLUS
CN 5'-Cytidylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803131-98-7 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-04-8 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-06-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-08-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-10-6 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-12-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-14-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-16-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-18-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803132-20-8 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803132-22-0 CAPLUS


CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-24-2 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-26-4 CAPLUS
CN 5'-Cytidylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-29-7 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2',2',5-trifluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-35-5 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-37-7 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-39-9 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-41-3 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-43-5 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-46-8 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-48-0 CAPLUS
CN L-Alanine, N-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-50-4 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-52-6 CAPLUS
CN L-Alanine, N,N'-[5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-54-8 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-56-0 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-58-2 CAPLUS
CN 5'-Cytidylic acid, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-60-6 CAPLUS
CN Cytidine, 5-chloro-2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-65-1 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-67-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-69-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-71-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803132-73-1 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-75-3 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803132-77-5 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-adenylyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803132-79-7 CAPLUS


CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-81-1 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-adenylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-83-3 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-84-4 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-86-6 CAPLUS
CN 5'-Adenylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-88-8 CAPLUS
CN Adenosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-94-6 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-96-8 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-phenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803132-98-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-phenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-00-7 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-1-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-03-0 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-05-2 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-2-naphthalenyl-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-07-4 CAPLUS
CN L-Alanine, N-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-guanylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-09-6 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-11-0 CAPLUS
CN L-Alanine, N,N'-[2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-P-thio-5'-guanylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-12-1 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-13-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803133-15-4 CAPLUS
CN 5'-Guanylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803133-16-5 CAPLUS
CN Guanosine, 2'-deoxy-4'-C-(difluoromethyl)-2',2'-difluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)


Absolute stereochemistry.



RN 1803133-22-3 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-24-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803133-26-7 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 1803133-28-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-


2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-30-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-32-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-33-6 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-35-8 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-37-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803133-39-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-40-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-41-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-42-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-45-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-46-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-47-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-48-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-49-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-50-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-51-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803133-52-9 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



IT 1803133-53-0P 1803133-54-1P 1803133-55-2P
1803133-56-3P 1803133-57-4P 1803133-60-9P
1803133-61-0P 1803133-62-1P 1803133-63-2P
1803133-64-3P 1803133-65-4P 1803133-66-5P
1803133-67-6P 1803133-68-7P 1803133-69-8P
1803133-70-1P 1803133-71-2P 1803133-72-3P
1803133-75-6P, 4'-Difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-76-7P, 4'-Difluoromethylaracyti dine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-77-8P, 4'-Difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-78-9P, 4'-Difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-79-0P, 4'-Difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-80-3P, 4'-Difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-81-4P, 4'-Difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803133-82-5P, 4'-Difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803133-83-6P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803133-84-7P, 4'-Difluoromethyl-5'-O-(2-sulflde-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803133-85-8P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine 1803133-86-9P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine 1803133-89-2P, 4'-Difluoromethyl-5-fluoroaracytidine 1803133-90-5P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-91-6P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-92-7P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-93-8P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-94-9P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803133-95-0P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803133-96-1P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803133-97-2P, 4'-Difluoromethyl-5-fluoroaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803133-98-3P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine 1803133-99-4P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;-2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine 1803134-00-0P, 2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine 1803134-03-3P, 5-Chloro-4'-difluoromethylaracytidine 1803134-04-4P, 5-Chloro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-05-5P

, 5-Chloro-4'-difluoromethylaracytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-06-6P, 5-Chloro-4'-difluoromethylaracytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-07-7P, 4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate 1803134-08-8P, 5-Chloro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-09-9P, 5-Chloro-4'-difluoromethylaracytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-10-2P, 5-Chloro-4'-difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-11-3P, 5-Chloro-4'-difluoromethylaracytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-12-4P, 5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803134-13-5P, 5-Chloro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)aracytidine 1803134-14-6P, 5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]aracytidine 1803134-15-7P, 5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]aracytidine 1803134-18-0P, 4'-Difluoromethylaraadenosine 1803134-19-1P, 4'-Difluoromethylaraadenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-20-4P, 4'-Difluoromethylaraadcnosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-21-5P, 4'-Difluoromethylaraadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-22-6P, 4'-Difluoromethylaraadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-23-7P, 4'-Difluoromethylaraadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-24-8P, 4'-Difluoromethylaraadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-25-9P, 4'-Difluoromethylaraadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-26-0P, 4'-Difluoromethylaraadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-27-1P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)araadenosine 1803134-28-2P, 4'-Difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)araadenosine 1803134-29-3P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araadenosine 1803134-30-6P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araadensoine 1803134-33-9P, 4'-Difluoromethylaraguanosine 1803134-34-0P, 4'-Difluoromethylaraguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-35-1P, 4'-Difluoromethylaraguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-36-2P, 4'-Difluoromethylaraguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-37-3P, 4'-Difluoromethylaraguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-38-4P, 4'-Difluoromethylaraguanosine-5'-[O-2-naphthyl-N-(S)-1-

(isopropoxycarbonyl)ethyl] phosphoramidate 1803134-39-5P, 4'-Difluoromethylaraguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-40-8P, 4'-Difluoromethylaraguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-41-9P, 4'-Difluoromethylaraguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-42-0P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)araguanosine 1803134-43-1P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)araguanosine 1803134-44-2P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]araguanosine 1803134-45-3P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]araguanosine 1803134-48-6P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine 1803134-49-7P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[[-3-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-50-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[[-3-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-51-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-52-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-53-3P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-54-4P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-55-5P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-[(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-56-6P, 3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-57-7P , 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803134-58-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803134-59-9P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803134-60-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine 1803134-61-3P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine 1803134-62-4P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-63-5P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-64-6P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-65-7P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-66-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-67-9P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-68-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-69-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-70-4P

, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803134-71-5P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803134-72-6P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine 1803134-73-7P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine 1803134-74-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine 1803134-75-9P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-76-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-77-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-78-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-79-3P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-80-6P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-81-7P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803134-82-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-83-9P , 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803134-84-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803134-85-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine 1803134-86-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine 1803134-87-3P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine 1803134-88-4P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803134-89-5P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-90-8P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-91-9P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-92-0P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803134-93-1P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803134-94-2P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl] phosphorodiamidate 1803134-95-3P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803134-96-4P, 3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803134-97-5P, 3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803134-98-6P, 3-Deoxy-3',5'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine 1803134-99-7P,

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'O-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine 1803135-00-3P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine 1803135-01-4P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-02-5P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803135-03-6P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] phosphoramidate 1803135-04-7P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl] thiophosphoramidate 1803135-05-8P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803135-06-9P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-07-0P, [5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(N,N'-bis(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-08-1P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-09-2P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803135-10-5P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803135-11-6P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]xylouridine 1803135-12-7P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine 1803135-13-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine 1803135-14-9P , 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-15-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-16-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-17-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-18-3P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-19-4P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-20-7P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-21-8P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-22-9P , 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-23-0P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-24-1P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine 1803135-25-2P, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine 1803135-26-3P,


3'-Deoxy-3',5-difhroro-4'-difluoromethylxylocytidine 1803135-27-4P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-28-5P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-29-6P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-30-9P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-31-0P , 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-32-1P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-33-2P , 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-34-3P, 3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-35-4P , 3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-36-5P, 3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-37-6P, 3'-Dcoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine 1803135-38-7P, 3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine 1803135-39-8P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine 1803135-40-1P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-41-2P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-42-3P , 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-43-4P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-44-5P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-45-6P , 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-46-7P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-47-8P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-48-9P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-49-0P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803135-50-3P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine 1803135-51-4P, 5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine 1803135-52-5P, 3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine 1803135-53-6P , 3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-phenyl-N-(S)-1-

(isopropoxycarbonyl)ethyl phosphoramida 1803135-54-7P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramide 1803135-55-8P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803135-56-9P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-57-0P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803135-58-1P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-59-2P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-60-5P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-61-6P
, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-
benzodioxaphosphorin-2-yl)xyloadenosine 1803135-62-7P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-
benzodioxaphosphorin-2-yl)xyloade 1803135-63-8P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)phosphinyl]xyloadenosine 1803135-64-9P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl]xyloadenosine 1803135-65-0P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine 1803135-66-1P
, 3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylphosphoramidate 1803135-67-2P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-68-3P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803135-69-4P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-70-7P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803135-71-8P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-72-9P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-73-0P,
3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-74-1P
, 3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-
benzodioxaphosphorin-2-yl)xyloguanosine 1803135-75-2P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-
benzodioxaphosphorin-2-yl)xyloguanosine 1803135-76-3P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-
methoxyphenoxy)phosphinyl]xyloguanosine 1803135-77-4P,
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-[-3-[bis(4-
methoxyphenoxy)thiophosphinyl]xyloguanosine 1803135-78-5P,
4'-Difluoromethylxylouridine 1803135-79-6P,
4'-Difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramida 1803135-80-9P,
4'-Difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-81-0P,
4'-Difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803135-82-1P,
4'-Difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-

(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-83-2P, 4'-Difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-84-3P, 4'-Difluoromethylxylouridine-5'-[[-3-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-85-4P, 4'-Difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803135-86-5P, 4'-Difluoromethylxylouridine-5'-[O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803135-87-6P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803135-88-7P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylouridine 1803135-89-8P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylouridine 1803135-90-1P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylouridine 1803135-93-4P, 4'-Difluoromethyl-5-fluoroxylouridine 1803135-94-5P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of difluoromethyl substituted nucleoside derivs. as inhibitors of influenza RNA replication)


RN 1803133-53-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803133-54-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-55-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-56-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-57-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-60-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-61-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-62-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-63-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-64-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-65-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-66-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-67-6 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



RN 1803133-68-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803133-69-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX


NAME)

Absolute stereochemistry.




RN 1803133-70-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-71-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-72-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-75-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-76-7 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-77-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-78-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-79-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-80-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-81-4 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-82-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803133-83-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-84-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-85-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-86-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-89-2 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-90-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-91-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-92-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-93-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-94-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-95-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-96-1 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-97-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803133-98-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803133-99-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-00-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-03-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-04-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-05-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-06-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-07-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-08-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-09-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-10-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-11-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803134-12-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX


NAME)

Absolute stereochemistry.




RN 1803134-13-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-14-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-15-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-18-0 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-19-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-20-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-21-5 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-22-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-23-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-24-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-25-9 CAPLUS


CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-26-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803134-27-1 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-28-2 CAPLUS


CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-29-3 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-30-6 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-33-9 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-34-0 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-35-1 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-36-2 CAPLUS


CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-37-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-38-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-39-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-40-8 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-41-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803134-42-0 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-43-1 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-44-2 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-45-3 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-48-6 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-49-7 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-50-0 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-51-1 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-52-2 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-53-3 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-54-4 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-55-5 CAPLUS
CN L-Alanine, N,N'-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-56-6 CAPLUS
CN L-Alanine, N,N'-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-57-7 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-58-8 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-59-9 CAPLUS
CN 5'-Uridylic acid, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-60-2 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-61-3 CAPLUS
CN Cytidine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-62-4 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-phenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-63-5 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-phenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-64-6 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-1-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-65-7 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-1-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-66-8 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P-2-naphthalenyl-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-67-9 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-P(O)-2-naphthalenyl-P-thio-5'-cytidylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-68-0 CAPLUS
CN L-Alanine, N,N'-[3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-cytidylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-69-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803134-70-4 CAPLUS
CN L-Alanine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-71-5 CAPLUS
CN L-Alanine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-72-6 CAPLUS


CN 5'-Cytidylic acid, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-73-7 CAPLUS
CN Cytidine, 3'-deoxy-4'-C-(difluoromethyl)-3'-fluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-74-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-75-9 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-


2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-76-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-77-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-78-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-79-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-80-6 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-81-7 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-82-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803134-83-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-84-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-85-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-86-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-87-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-88-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-89-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-90-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-91-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-92-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-93-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-94-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-95-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803134-96-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803134-97-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803134-98-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803134-99-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-


(CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-00-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803135-01-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)


Absolute stereochemistry.



RN 1803135-02-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester,


5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-03-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-04-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-05-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-06-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-07-0 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-08-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-09-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-10-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-11-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-12-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-13-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-14-9 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-15-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-16-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-17-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-18-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-19-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-20-7 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-21-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-22-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-23-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-24-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-25-2 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-26-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-27-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-28-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-29-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-30-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-31-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-32-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-33-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-34-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-35-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-36-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803135-37-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803135-38-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-fluoro-


(CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-39-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803135-40-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)


Absolute stereochemistry.



RN 1803135-41-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester,


5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-42-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-43-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-44-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-45-6 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-46-7 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-47-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-48-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-49-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-50-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-51-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-52-5 CAPLUS
CN 9H-Purin-6-amine, 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-53-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-54-7 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-55-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-56-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-57-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-58-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-59-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-60-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-61-6 CAPLUS
CN 9H-Purin-6-amine, 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-62-7 CAPLUS
CN 9H-Purin-6-amine, 9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-63-8 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-64-9 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-65-0 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-66-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-67-2 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-68-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-69-4 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-70-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.



RN 1803135-71-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)


Absolute stereochemistry.



RN 1803135-72-9 CAPLUS


CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-73-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-74-1 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-75-2 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[3-deoxy-4-C-(difluoromethyl)-3-fluoro-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-76-3 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-77-4 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-3-deoxy-4-C-(difluoromethyl)-3-fluoro-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-78-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-79-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-80-9 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-81-0 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-82-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-83-2 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-84-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-85-4 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-86-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803135-87-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-88-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-89-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-90-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-93-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803135-94-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.



IT 1803135-95-6P, 4'-Difluoromethyl-5-fluororxylouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-96-7P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-97-8P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803135-98-9P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803135-99-0P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-00-6P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-O-[bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-01-7P, 4'-Difluoromethyl-5-fluoroxylouridine-5'-O-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-02-8P, 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine 1803136-03-9P, 4'-Difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxy]ouridine 1803136-04-0P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxy]ouridine 1803136-05-1P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine 1803136-08-4P, 5-Chloro-4'-difluoromethylxylouridine 1803136-09-5P, 5-Chloro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-

(isopropoxycarbonyl)ethyl phosphoramidate 1803136-10-8P,
5-Chloro-4'-difluoromethylxylouridine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-11-9P,
5-Chloro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-12-0P,
5-Chloro-4'-difluoromethylxylouridine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-13-1P,
5-Chloro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-14-2P,
5-Chloro-4'-difluoromethylxylouridine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-15-3P,
5-Chloro-4'-difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-16-4P,
5-Chloro-4'-difluoromethylxylouridine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-17-5P
, 5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-
yl)xylouridine 1803136-18-6P,
5-Chloro-4'-difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-
2-yl)xylouridine 1803136-19-7P,
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)phosphinyl]xylouridine 1803136-20-0P,
5-Chloro-4'-difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl]xylouridine 1803136-23-3P,
4'-Difluoromethylxylocytidine 1803136-24-4P,
4'-Difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-25-5P,
4'-Difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-26-6P,
4'-Difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-27-7P,
4'-Difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-28-8P,
4'-Difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-29-9P,
4'-Difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-30-2P,
[4'-Difluoromethylxylocytidine-5'-[N,N'-bis(S)-1-
(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-31-3P,
4'-Difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-
(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-32-4P
, 4'-Difluoromethyl-5'-O-[2-oxido-4H-1,3,2-benzodioxaphosphorin-2-
yl]xylocytidine 1803136-33-5P,
4'-Difluoromethyl-5'-O-[3-(2-sulfidc-4H-1,3,2-benzodioxaphosphorin-2-
yl]xylocytidine 1803136-34-6P,
4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
1803136-35-7P, 4'-Difluoromethyl-5'-O-[bis(4-
methoxyphenoxy)thiophosphinyl] xylocytidine 1803136-38-0P,
4'-Difluoromethyl-5-fluoroxylocytidine 1803136-39-1P,
4'-Difluoromethyl-5-fluoroxylocytidine-5'-[O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethyl phosphoramidate 1803136-40-4P,
(4'-Difluoromethyl-5-fluororxylocytidine-5'-f-O-phenyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-41-5P,
4'-Difluoromethyl-5-fluoroxylocytidine-5'-(O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylphosphoramidate 1803136-42-6P,
4'-Difluoromethyl-5-fluoroxylocytidine-5'-[O-1-naphthyl-N-(S)-1-
(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-43-7P,

4'-Difluoromethyl-5-fluoroxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-44-8P, 4'-Difluoromethyl-5-fluoroxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-45-9P, 4'-Difluoromethyl-5-fluoroxylocytidine-5'-[N,N'bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-46-0P, 4'-Difluoromethyl-5-fluororxylocytidine-5'-[Λ,Λ'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-47-1P , 4'-Difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine 1803136-48-2P, 4'-Difluoromethyl-5'-[-3-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxy]ocytidine 1803136-49-3P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxy]ocytidine 1803136-50-6P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine 1803136-53-9P, 5-Chloro-4'-difluoromethylxylocytidine 1803136-54-0P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-55-1P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-56-2P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-57-3P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-58-4P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803136-59-5P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-60-8P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-61-9P, 5-Chloro-4'-difluoromethylxylocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-62-0P , 5-Chloro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803136-63-1P, 5-Chloro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)xylocytidine 1803136-64-2P, 5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine 1803136-65-3P, 5-Chloro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xylocytidine 1803136-68-6P, 4'-Difluoromethylxyloadenosine 1803136-69-7P, 4'-Difluoromethylxyloadenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-70-0P, 4'-Difluoromethylxyloadenosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-71-1P, 4'-Difluoromethylxyloadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-72-2P, 4'-Difluoromethylxyloadenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-73-3P, 4'-Difluoromethylxyloadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-74-4P, 4'-Difluoromethylxyloadenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-75-5P, 4'-Difluoromethylxyloadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-76-6P,

4'-Difluoromethylxyloadenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-77-7P, 4'-Difluoromethyl-5'-O-[2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl]xyloadenosine 1803136-78-8P, 4'-Difluoromethyl-5'-[-3-[2-sulflde-4-H-1,3,2-benzodioxaphosphorin-2-yl]xyloadenosine 1803136-79-9P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine 1803136-80-2P, 4'-Difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]xyloadenosine 1803136-83-5P, 4'-Difluoromethylxyloguanosine 1803136-84-6P, 4'-Difluoromethylxyloguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-85-7P, 4'-Difluoromethylxyloguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-86-8P, 4'-Difluoromethylxyloguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-87-9P, 4'-Difluoromethylxyloguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-88-0P, 4'-Difluoromethylxyloguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803136-89-1P, 4'-Difluoromethylxyloguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803136-90-4P, 4'-Difluoromethylxyloguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803136-91-5P, 4'-Difluoromethylxyloguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803136-92-6P, 4'-Difluoromethyl-5'-O-[2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl]xyloguanosine 1803136-93-7P, 4'-Difluoromethyl-5'-O-[2-sulflde-4-H-1,3,2-benzodioxaphosphorin-2-yl]xyloguanosine 1803136-94-8P 1803136-95-9P, 4'-Difluoromethyl-5 '-O-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine 1803136-98-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine 1803136-99-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-00-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-01-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-02-1P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-03-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-04-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-05-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-06-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-07-6P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-08-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulflde-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-09-8P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803137-10-1P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-

methoxyphenoxy)thiophosphinyl]-5-fluorouridine 1803137-11-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine 1803137-12-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803137-13-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-14-5P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-15-6P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-16-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-17-8P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-18-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-19-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-20-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-21-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-22-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine 1803137-23-6P , 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine 1803137-24-7P, 5-Chloro-3'-deoxy-3'-3'-difluoro-4'-difluoromethyluridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-25-8P, 5-Chloro-3'-deoxy-3'-3'-difluoro-4'-difluoromethyluridine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-26-9P , 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-27-0P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-28-1P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-29-2P , 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-30-5P, (5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[N,N'-bis(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-31-6P, (5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-[N,N'-bis(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-32-7P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-33-8P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-O-(2-sulflde-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-34-9P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]uridine 1803137-35-0P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difhroromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine 1803137-36-1P,


3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine 1803137-37-2P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-38-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-39-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-40-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-41-8P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803137-42-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-43-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-44-1P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-45-2P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(1-2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803137-46-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)cytidine 1803137-47-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine 1803137-48-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine 1803137-49-6P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine 1803137-50-9P, 3'-Deoxy-3'-3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-51-0P, 3'-Deoxy-3'-3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-52-1P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-53-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-54-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-55-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-56-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-58-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-59-8P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803137-60-1P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine 1803137-61-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine 1803137-62-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine 1803137-63-4P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine 1803137-64-5P, 5-Chloro-3'-deoxy-3',3'-difluoro-4''-

difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-65-6P
, 5-Chloro-3'-deoxy-3',3'-difluoro-4''-difluoromethylcytidine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-66-7P
, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-67-8P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-68-9P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-69-0P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-70-3P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-71-4P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-72-5P
, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-74-7P, 5-Chloro-3'-deoxy-3',3'-difluoro-4''-difluoromethylcytidine-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)uridine 1803137-75-8P
, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine 1803137-76-9P, 5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]cytidine 1803137-77-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine 1803137-78-1P
, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-79-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-80-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-81-6P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-82-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-83-8P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-84-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-85-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-86-1P
, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(1-2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)adenosine 1803137-87-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)adenosine 1803137-88-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine 1803137-89-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]adenosine 1803137-90-7P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine 1803137-91-8P
, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethylphosphoramidate 1803137-92-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(O-phenyl-N-(S)-1-

(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-93-0P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-94-1P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-95-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate 1803137-96-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethylthiophosphoramidate 1803137-97-4P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]phosphorodiamidate 1803137-98-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-[N,N'-bis[(S)-1-(isopropoxy)carbonyl]ethyl]thiophosphorodiamidate 1803137-99-6P , 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(1-2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803138-00-2P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)guanosine 1803138-01-3P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)phosphinyl] guanosine 1803138-03-5P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine 1803138-05-7P 1803138-06-8P, 4'-Difluoromethyl-5'-O-(2-sulfide-4H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine 1803139-96-9P, 3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-O-[bis(4-methoxyphenoxy)thiophosphinyl]uridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of difluoromethyl substituted nucleoside derivs. as inhibitors of influenza RNA replication)


RN 1803135-95-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-96-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-97-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-98-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803135-99-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-00-6 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-01-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-02-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-03-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-04-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-05-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-08-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-09-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-10-8 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-11-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-12-0 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-13-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-14-2 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-15-3 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2,4(1H,3H)-pyrimidinedione (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-16-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-17-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-18-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-19-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-20-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803136-23-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803136-24-4 CAPLUS


CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-25-5 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-26-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-27-7 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-28-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-29-9 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-30-2 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-32-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-33-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-34-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-35-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-38-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-39-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-40-4 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-41-5 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-42-6 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-43-7 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-44-8 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-45-9 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-46-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-47-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-48-2 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-49-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-50-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-53-9 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-54-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-55-1 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-56-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-57-3 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-58-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-59-5 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-60-8 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 4-amino-5-chloro-1-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-2(1H)-pyrimidinone (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-62-0 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-63-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-64-2 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-65-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-68-6 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-69-7 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-70-0 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-71-1 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-72-2 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-73-3 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-74-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-75-5 CAPLUS
CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-9H-purin-6-amine (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-76-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-77-7 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-78-8 CAPLUS
CN 9H-Purin-6-amine, 9-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803136-79-9 CAPLUS
CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1803136-80-2 CAPLUS


CN 9H-Purin-6-amine, 9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-83-5 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803136-84-6 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)


Absolute stereochemistry.



RN 1803136-85-7 CAPLUS


CN L-Alanine, N-(hydroxyphenoxyphosphinothioyl)-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-86-8 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-87-9 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-88-0 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.



RN 1803136-89-1 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinothioyl]-, 1-methylethyl ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)


Absolute stereochemistry.



RN 1803136-90-4 CAPLUS


CN L-Alanine, N,N'-phosphinicobis-, 1,1'-bis(1-methylethyl) ester, 5'-ester with 2-amino-9-[4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro-6H-purin-6-one (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-91-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803136-92-6 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-5-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-93-7 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-94-8 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-95-9 CAPLUS
CN 6H-Purin-6-one, 2-amino-9-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-4-C-(difluoromethyl)-β-D-xylofuranosyl]-1,9-dihydro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-98-2 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803136-99-3 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-00-9 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-01-0 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-02-1 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-03-2 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-04-3 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-05-4 CAPLUS
CN L-Alanine, N,N'-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-06-5 CAPLUS
CN L-Alanine, N,N'-[3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-P-thio-5'-uridylylidene]bis-, 1,1'-bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-07-6 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-5'-O-(2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-08-7 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-5'-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-09-8 CAPLUS
CN 5'-Uridylic acid, 3'-deoxy-4'-C-(difluoromethyl)-3',3'-difluoro-, bis(4-methoxyphenyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-10-1 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-, 5'-[O,O-bis(4-methoxyphenyl) phosphorothioate] (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-11-2 CAPLUS
CN Uridine, 3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-12-3 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P-phenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-13-4 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P(O)-phenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-14-5 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P-1-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-15-6 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P(O)-1-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-16-7 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P-2-naphthalenyl-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-17-8 CAPLUS
CN L-Alanine, N-[3'-deoxy-4'-C-(difluoromethyl)-3',3',5-trifluoro-P(O)-2-naphthalenyl-P-thio-5'-uridylyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803137-18-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-19-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-20-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-21-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-22-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-23-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-24-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-25-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-26-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-27-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-28-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-29-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-30-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-31-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-32-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-33-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-34-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-35-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-36-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-37-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-38-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-40-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-41-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-42-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803137-43-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803137-44-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-45-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-46-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-47-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-48-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-49-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-50-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-51-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-52-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-53-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-54-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803137-55-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803137-56-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-58-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-59-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-60-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-61-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-62-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-63-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-64-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-66-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-67-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-68-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-69-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-70-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-72-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-74-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-75-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-76-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-77-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-78-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-79-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-80-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-81-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-82-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-83-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-84-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-85-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-86-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803137-87-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803137-88-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-89-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803137-90-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803137-91-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-92-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1803137-93-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1803137-94-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-96-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-97-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-98-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803137-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803138-00-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803138-01-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803138-03-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1803138-05-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-O-[bis(4-methoxyphenoxy)phosphinothioyl]-2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-arabinofuranosyl]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803138-06-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-5-O-(2-sulfido-4H-1,3,2-benzodioxaphosphorin-2-yl)-β-D-arabinofuranosyl]-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803139-96-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 1803126-02-4P, (2R,3R,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-5-(difluorom-ethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate 1803126-03-5P, 1-[(2R,3R,4S,5R)-5-(Difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 1803126-05-7P 1803126-06-8P 1803126-07-9P, (2R,3R,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydropurin-9-yl)tetrahydrofuran-3-yl acetate 1803126-08-0P 1803126-11-5P 1803126-13-7P, (2R,3R,4S,5R)-2-(4-Amino-5-chloro-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)tetrahydrofuran-3-yl acetate 1803126-14-8P 1803126-16-0P, 1-[(2R,3R,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 1803126-18-2P 1803126-19-3P, (2R,3S,4S,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate 1803126-20-6P, (2R,3S,4S,5R)-2-(4-Amino-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)tetrahydrofuran-3-yl acetate 1803126-21-7P 1803126-23-9P, 1-[(2R,3R,4R,5R)-4-(Benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 1803126-24-0P, 4-Amino-1-[(2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 1803126-25-1P 1803126-26-2P 1803126-28-4P 1803138-04-6P 1803138-07-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of difluoromethyl substituted nucleoside derivs. as inhibitors of influenza RNA replication)

RN 1803126-02-4 CAPLUS


CN Uridine, 4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)-, 2'-acetate (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-03-5 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-05-7 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-, 2',3',5'-triacetate (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-06-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-chloro-1-[2,3,5-tri-O-acetyl-4-C-(difluoromethyl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-07-9 CAPLUS
CN Guanosine, 4'-C-(difluoromethyl)-N-(2-methyl-1-oxopropyl)-3',5'-bis-O-(phenylmethyl)-, 2'-acetate (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-08-0 CAPLUS
CN Guanosine, 4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-11-5 CAPLUS
CN Adenosine, 4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-13-7 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)-, 2'-acetate (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-14-8 CAPLUS
CN Cytidine, 5-chloro-4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-16-0 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-18-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[4-C-(difluoromethyl)-3,5-bis-O-(phenylmethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-19-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-O-acetyl-4-C-(difluoromethyl)-3,5-bis-O-(phenylmethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-20-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-O-acetyl-4-C-(difluoromethyl)-3,5-bis-O-(phenylmethyl)-β-D-arabinofuranosyl]-4-amino- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-21-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-[4-C-(difluoromethyl)-3,5-bis-O-(phenylmethyl)-β-D-arabinofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-23-9 CAPLUS
CN Uridine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-24-0 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro-3',5'-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1803126-25-1 CAPLUS
CN Cytidine, 2',3'-O-cyclopentylidene-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803126-26-2 CAPLUS
CN L-Alanine, N-[2',3'-O-cyclopentylidene-4'-C-(difluoromethyl)-P-phenyl-5'-cytidylyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1803126-28-4 CAPLUS


CN L-Alanine, N-[2',3'-O-cyclopentylidene-4'-C-(difluoromethyl)-P-phenyl-5'-cytidylyl]-, 2,2-dimethylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1803138-04-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-chloro-1-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-3,5-bis-O-(phenylmethyl)-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1803138-07-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN

AN 2015:656201 CAPLUS
DN 162:550756
TI prepn of substituted nucleosides, nucleotides and analogs thereof as antiviral agents
IN Beigelman, Leonid; Wang, Guangyi; Smith, David Bernard; Prhavc, Marija; Jekle, Christian Andreas; Deval, Jerome
PA Alios Biopharma, Inc., USA
SO PCT Int. Appl., 854pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2015054465	A1	20150416	WO 2014-US59849	20141009
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 20150105341	A1	20150416	US 2014-14510451	20141009
PRAI US 2013-61890136	P	20131011		
US 2014-62016288	P	20140624		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 162:550756
IT 1643968-81-3P 1701427-53-3P 1702841-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of substituted nucleosides nucleotides and analogs thereof as antiviral agents)
RN 1643968-81-3 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1701427-53-3 CAPLUS
CN Uridine, 4'-C-(difluoromethyl)-2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1702841-23-3 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate),
4'-C-(difluoromethyl)-2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 1702842-46-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn of substituted nucleosides nucleotides and analogs thereof as antiviral agents)
RN 1702842-46-3 CAPLUS
CN Cytidine, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




IT 1701427-52-2P 1702842-48-5P 1702843-38-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn of substituted nucleosides nucleotides and analogs thereof as antiviral agents)

RN 1701427-52-2 CAPLUS

CN Uridine, 4'-C-(difluoromethyl)-2'-C-methyl-, 2',3',5'-tribenzoate (CA INDEX NAME)


Absolute stereochemistry.



RN 1702842-48-5 CAPLUS

CN 5'-Cytidylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1702843-38-6 CAPLUS

CN 5'-Uridylic acid, 4'-C-(difluoromethyl)-2'-C-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2015:259020 CAPLUS
DN 162:320182
TI Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection
AU Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo
CS Alios BioPharma, Inc., South San Francisco, CA, 94080, USA
SO Journal of Medicinal Chemistry (2015), 58(4), 1862-1878
CODEN: JMCMAR; ISSN: 0022-2623
DOI 10.1021/jm5017279
PB American Chemical Society
DT Journal; (online computer file)
LA English
OS CASREACT 162:320182
IT 1643968-81-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection)
RN 1643968-81-3 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2014:2181636 CAPLUS
DN 162:161199
TI Preparation of substituted nucleosides, nucleotides and analogs thereof as antiviral agents
IN Beigelman, Leonid; Deval, Jerome; Jin, Zhinan

PA Alios Biopharma, Inc., USA
SO PCT Int. Appl., 582pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2014209979	A1	20141231	WO 2014-US43836	20140624
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 20150011497	A1	20150108	US 2014-14313043	20140624


PRAI US 2013-61839711 P 20130626
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 162:161199
IT 1643968-81-3P 1643969-82-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted nucleosides, nucleotides and analogs thereof as antiviral agents)
RN 1643968-81-3 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1643969-82-7 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-4'-C-(difluoromethyl)-2'-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 2013:1470317 CAPLUS
DN 159:526750
TI 2'-Substituted carbanucleoside analogs for antiviral treatment
IN Clarke, Michael O' Neil Hanrahan
PA Gilead Sciences , Inc., USA
SO PCT Int. Appl., 94pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2013138236	A1	20130919	WO 2013-US30196	20130311
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
	CA 2866381	A1	20130919	CA 2013-2866381	20130311
	US 20130243725	A1	20130919	US 2013-13793557	20130311
	AU 2013232378	A1	20140925	AU 2013-232378	20130311
	IL 234586	A	20141030	IL 2013-234586	20130311
	KR 2014135820	A	20141126	KR 2014-7028523	20130311
	CN 104185638	A	20141203	CN 2013-80014318	20130311
	EP 2834258	A1	20150211	EP 2013-712043	20130311
	R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BA, ME				
	MD 20140112	A2	20150228	MD 2014-112	20130311
	JP 2015509983	T	20150402	JP 2015-500493	20130311
	MX 2014011009	A	20141013	MX 2014-11009	20140912
	IN 2014DN08505	A	20150515	IN 2014-DN8505	20141010
PRAI	US 2012-61610411	P	20120313		
	WO 2013-US30196	W	20130311		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 159:526750; MARPAT 159:526750
IT 1456712-54-1 1456712-62-1 1456712-70-1
1456712-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted carbanucleoside analogs for antiviral treatment)
RN 1456712-54-1 CAPLUS
CN D-Ribitol, 1-C-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-1,4-anhydro-2-deoxy-4-C-(difluoromethyl)-2-fluoro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1456712-62-1 CAPLUS
CN Imidazo[2,1-f][1,2,4]triazin-4(1H)-one, 2-amino-7-[2-deoxy-4-C-(difluoromethyl)-2-fluoro-β-D-ribofuranosyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1456712-70-1 CAPLUS
CN D-Ribitol, 1-C-(4-amino-2-fluoroimidazo[2,1-f][1,2,4]triazin-7-yl)-1,4-anhydro-2-deoxy-4-C-(difluoromethyl)-2-fluoro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1456712-78-9 CAPLUS
CN D-Ribitol, 1,4-anhydro-2-deoxy-1-C-(2,4-diaminoimidazo[2,1-f][1,2,4]triazin-7-yl)-4-C-(difluoromethyl)-2-fluoro-, (1S)- (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 1997:192727 CAPLUS
DN 126:293562
OREF 126:56857a,56860a
TI Through-space 7JHF and 6JCF spin-spin couplings in 2',3'-dideoxy-4'-fluoroalkylnucleosides. The role of sugar ring conformation and solvent effect
AU Mele, Andrea; Salani, Giuliana; Viani, Fiorenza; Bravo, Pierfrancesco
CS Dip. Chimica Politecnico, Milan, I-20131, Italy
SO Magnetic Resonance in Chemistry (1997), 35(3), 168-174
CODEN: MRCHEG; ISSN: 0749-1581
DOI 10.1002/(SICI)1097-458X(199703)35:3<168::AID-OMR58>3.0.CO;2-2
PB Wiley
DT Journal
LA English
IT 171108-83-1 171108-88-6 171335-18-5
189154-02-7
RL: PRP (Properties)
(mol structure and conformation of 2',3'-dideoxy-4'-fluoroalkylnucleosides by NMR)
RN 171108-83-1 CAPLUS


CN Thymidine, 3'-deoxy-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 171108-88-6 CAPLUS
CN Uridine, 2',3'-dideoxy-4'-C-(difluoromethyl)-5-fluoro-5'-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171335-18-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-(difluoromethyl)tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189154-02-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2S,5S)-5-(difluoromethyl)tetrahydro-5-[(phenylmethoxy)methyl]-2-furanyl]-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



OSC.G 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)


=> d bib hitstr 7

L13 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2015 ACS on STN
AN 1995:755465 CAPLUS
DN 124:30216
OREF 124:5807a,5810a
TI Synthesis of 4'-fluoroalkyl nucleoside analog
AU Bravo, Pierfrancesco; Mele, Andrea; Salani, Giuliana; Viani, Fiorenza; La Colla, Paolo
CS Dip. Chim., Politecnico Milano, Milan, I-20131, Italy
SO Gazzetta Chimica Italiana (1995), 125(7), 295-303
CODEN: GCITA9; ISSN: 0016-5603
PB Societa Chimica Italiana
DT Journal
LA English
OS CASREACT 124:30216
IT 171108-81-9P 171108-88-6P 171335-16-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of fluoroalkyl nucleoside analogs from β-keto-γ-fluoro-substituted sulfoxides via dideoxyfluoroalkylriboses)
RN 171108-81-9 CAPLUS
CN Thymidine, 3'-deoxy-4'-C-(difluoromethyl)-5'-O-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 171108-88-6 CAPLUS
CN Uridine, 2',3'-dideoxy-4'-C-(difluoromethyl)-5-fluoro-5'-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171335-16-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-(difluoromethyl)tetrahydro-5-[(phenylmethoxy)methyl]-2-furanyl]-5-methyl-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 171108-83-1P 171335-18-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of fluoroalkyl nucleoside analogs from β-keto-γ-fluoro-substituted sulfoxides via dideoxyfluoroalkylriboses)
RN 171108-83-1 CAPLUS
CN Thymidine, 3'-deoxy-4'-C-(difluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 171335-18-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-(difluoromethyl)tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14615928	SMITH ET AL.
	Examiner	Art Unit
	TRAVISS C MCINTOSH III	1673

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
palm - inventor	11/3/15	tcm
google/pubmed	11/3/15	tcm
east	11/3/15	tcm
stn	11/3/15	tcm

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/615,928	02/06/2015	Mark Smith	596000-00410

CONFIRMATION NO. 4203

115777
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

PUBLICATION NOTICE

OC00000076847799

Title:4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

Publication No.US-2015-0225441-A1
Publication Date:08/13/2015

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
14/615,928	02/06/2015	1629	3200	596000-00410	20	3

CONFIRMATION NO. 4203

UPDATED FILING RECEIPT

115777
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

OC000000074879121

Date Mailed: 04/29/2015

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Mark Smith, San Francisco, CA;
Klaus G. Klumpp, West Chester, PA;

Applicant(s)

Riboscience LLC, Palo Alto, CA

Power of Attorney: The patent practitioners associated with Customer Number 115777

Domestic Priority data as claimed by applicant

This appln claims benefit of 61/936,569 02/06/2014

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 02/23/2015

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 14/615,928**

Projected Publication Date: 08/06/2015

Non-Publication Request: No

Early Publication Request: No

Title

4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 14/615,928

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	280
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	600
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	720
TOTAL CLAIMS (37 CFR 1.16(i))	20 minus 20 =	*			OR	x 80 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	*				x 420 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						1600
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	3200

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/615,928	02/06/2015	Mark Smith	596000-00410

CONFIRMATION NO. 4203

POA ACCEPTANCE LETTER

115777
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

OC000000074879169

Date Mailed: 04/29/2015

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 04/24/2015.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/eruga/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
14/615,928	02/06/2015	

ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **04/29/2015**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	X $80 =	0
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $420 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/KAREN VESTAL/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Mark Smith et al.	
Serial No. **14/615,928**	Art Unit: **1629**
Filing Date: **February 6,2015**	Conf. No. **4203**
For: **4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication**	Attorney Docket No. **596000-00410**

VIA EFS WEB

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows.

The Commissioner is authorized to charge or credit any discrepancies in fee amounts to Deposit Account No. 501678.

In the Claims:

1. (Original) A compound of Formula I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

3. (Original) The compound of claim 1, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

4. (Original) The compound of claim 1, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

5. (Original) The compound of claim 1, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

6. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

7. (Original) The compound of claim 1, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

8. (Original) The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

9. (Original) The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

10. (Original) The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

11-12. (Cancelled)

13. (Original) The compound of claim 1, wherein X is O.

14. (Original) The compound of claim 1, wherein X is S.

15. (Cancelled)

16. (Original) The compound of claim 1, wherein R is O-R^1, and R^1 is naphthylenyl.

17. (Original) The compound of claim 1, wherein R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

18-22. (Cancelled)

23. (Original) A compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylcytidine;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorocytidine;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorocytidine;

4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorocytidine;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-chlorocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-chlorocytidine;

4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyladenosine;

4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-7-adenosine;

4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylguanosine;

4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2,2''-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylarauridine;

4'-Difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroarauridine;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4'-difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;

4'-Difluoromethyl—5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine;

4'-Difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;

4'-Difluoromethyl—5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine;

4'-Difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadensoine;

4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraguanosine;

4'-Difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxylouridine;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylouridine;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylouridine;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxylocytidine;

4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxyloadenosine;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxyloguanosine;

4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;

3'-Deoxy-3'.3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy -5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine; and

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine.


24. (Original) A method of preventing or treating Influenza comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

25. (Original) A composition comprising the compound of claim 1, admixed with at least one carrier, diluent or excipient.

26. (Original) A composition comprising the compound of claim 1 in combination with one or more antiviral compounds.

27-30. (Cancelled)

31. (Original) A method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, $-OP(=O)(OH)OP(=O)(OH)OH$, or $-OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S; and

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

or a pharmacologically acceptable salt thereof.

32. (Cancelled)

33. (Original) A method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 23.

Remarks

Original Claims 11, 12, 15, 18-22, 27-30 and 32 have been cancelled. Claims 1-10, 13-14, 16-17, 23-26, 31 and 33 remain in the case.

No new matter has been added by this amendment.

If further prosecution of this application can be facilitated through a telephone conference between the Examiner and the undersigned, the Examiner is requested to telephone the undersigned at the Examiner's convenience.

Respectfully submitted,

/Jennifer L. Kisko J.D., Ph.D./
Jennifer L. Kisko J.D., Ph.D.
Reg. No. 56907
GrayRobinson, P.A.
P.O. Box 3068
Orlando, FL 32802-3068
Telephone: (407) 244-5681
jennifer.kisko@gray-robinson.com

8582227 v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Mark Smith et al.	Conf. No. **4203**
Serial No. **14/615,928**	Attorney Docket No. **596000-00410**
Filing Date: **February 6, 2015**	
For: **4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication**	

VIA EFS WEB
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Responsive to the Notice to File Missing Parts mailed February 24, 2015, Applicant encloses the following:

1. Preliminary Amendment reducing the total number of claims to 20 thus eliminating the additional claim fee charge referenced in the Notice to File Missing Parts.

2. Power of Attorney.

The Commissioner is authorized to charge or credit any discrepancies in fee amounts to Deposit Account No. 501678.

Respectfully submitted,

/Jennifer L. Kisko J.D., Ph.D./

Jennifer L. Kisko J.D., Ph.D.
Reg. No. 56907
GrayRobinson, P.A.
P.O. Box 3068
Orlando, FL 32802-3068
Telephone: (407) 244-5681
Email: jennifer.kisko@gray-robinson.com

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date
14/615,928	2/6/2015

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 115777

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Riboscience, LLC

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	/M. Smith/	Date (Optional)	
Name	MARK SMITH		
Title	SECRETARY OF RIBOSCIENCE, LLC		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

Electronic Acknowledgement Receipt

EFS ID:	22157216
Application Number:	14615928
International Application Number:	
Confirmation Number:	4203
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Customer Number:	115777
Filer:	Jennifer Kisko/Lynnette Dewitz
Filer Authorized By:	Jennifer Kisko
Attorney Docket Number:	596000-00410
Receipt Date:	24-APR-2015
Filing Date:	06-FEB-2015
Time Stamp:	10:10:46
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Applicant Response to Pre-Exam Formalities Notice	RNFMP.pdf	79864 6a17ae192afee0fb2993459ea66b7803736b799a	no	1

Warnings:	
Information:	

2	Preliminary Amendment	Prel_Amd.pdf	245264 b77ca7e126d76fe6896c5018c2c87801b6b05353	no	69
Warnings:					
Information:					
3	Power of Attorney	POA.pdf	300628 f9bbe64a5d1bea140dc31dc5a38e4c0bb8c667ea	no	1
Warnings:					
Information:					
			Total Files Size (in bytes):	625756	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/615,928	02/06/2015	Mark Smith	596000-00410

CONFIRMATION NO. 4203

115777
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

FORMALITIES LETTER

OC000000073545667

Date Mailed: 02/24/2015

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing.

Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- Additional claim fees of $ **1040** as an undiscounted entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

The fee(s) required within **TWO MONTHS** from the date of this Notice to avoid abandonment is/are itemized below. No entity status discount is in effect. If applicant is qualified for small entity status, a written assertion of small entity status must be submitted to establish small entity status. (See 37 CFR 1.27). If applicant is qualified for micro entity status, an acceptable Certification of Micro Entity Status must be submitted to establish micro entity status. (See 37 CFR 1.29 and forms PTO/SB/15A and 15B.)

- $ **1040** for **13** total claims over 20.
- $(**0**) previous unapplied payment amount.
- $ **1040** TOTAL FEE BALANCE DUE.

Replies must be received in the USPTO within the set time period or must include a proper Certificate of Mailing or Transmission under 37 CFR 1.8 with a mailing or transmission date within the set time period. For more information and a suggested format, see Form PTO/SB/92 and MPEP 512.

Replies should be mailed to:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web, including a copy of this Notice and selecting the document description "Applicant response to Pre-Exam Formalities Notice". https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/atesfaye/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 14/615,928

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	280
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	600
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	720
TOTAL CLAIMS (37 CFR 1.16(i))	33 minus 20 =	* 13			OR	x 80 =	1040
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	*				x 420 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						1600
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	4240

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
14/615,928	02/06/2015	1629	3200	596000-00410	33	3

CONFIRMATION NO. 4203

115777
Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

FILING RECEIPT

OC000000073545666

Date Mailed: 02/24/2015

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Mark Smith, San Francisco, CA;
Klaus G. Klumpp, West Chester, PA;

Applicant(s)

Riboscience LLC, Palo Alto, CA

Power of Attorney: None

Domestic Priority data as claimed by applicant

This appln claims benefit of 61/936,569 02/06/2014

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 02/23/2015

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 14/615,928**

Projected Publication Date: 08/06/2015

Non-Publication Request: No

Early Publication Request: No

Title

4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

PTO/AIA/14 (03-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	596000-00410
	Application Number	
Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Mark		Smith	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	San Francisco	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	1080 Sutter Street, #401		
Address 2			
City	San Francisco	State/Province	CA
Postal Code	94109	Country i	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Klaus	G.	Klumpp	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	West Chester	State/Province	PA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	611 Winston Lane		
Address 2			
City	West Chester	State/Province	PA
Postal Code	19382	Country i	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

PTO/AIA/14 (03-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	596000-00410
	Application Number	
Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication	

☐ **An Address is being provided for the correspondence Information of this application.**			
Customer Number	115777		
Email Address	IPteam@gray-robinson.com	Add Email	Remove Email

Application Information:

Title of the Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication		
Attorney Docket Number	596000-00410	**Small Entity Status Claimed**	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		**Suggested Figure for Publication (if any)**	

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	115777		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	non provisional of	61/936569	2014-02-06

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button. Add

PTO/AIA/14 (03-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	596000-00410
	Application Number	
Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication	

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX) [i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country [i]	Filing Date (YYYY-MM-DD)	Access Code [i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button. Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.

Authorization to Permit Access:

☐ Authorization to Permit Access to the Instant Application by the Participating Offices

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the instant patent application is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the instant patent application is filed to have access to the instant patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is sought in the instant patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.

PTO/AIA/14 (03-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	596000-00410
	Application Number	
Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

◉ Assignee	○ Legal Representative under 35 U.S.C. 117	○ Joint Inventor
○ Person to whom the inventor is obligated to assign.	○ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor :

If the Applicant is an Organization check here. ☒

Organization Name	Riboscience LLC		
Mailing Address Information:			
Address 1	3901 Laguna Avenue		
Address 2			
City	Palo Alto	**State/Province**	CA
Country [i]	US	Postal Code	94306
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Non-Applicant Assignee Information:

Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

PTO/AIA/14 (03-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	596000-00410
	Application Number	
Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication	

Assignee 1

Complete this section only if non-applicant assignee information is desired to be included on the patent application publication in accordance with 37 CFR 1.215(b). Do not include in this section an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest), as the patent application publication will include the name of the applicant(s).

Remove

If the Assignee is an Organization check here. ☐

Prefix	**Given Name**	Middle Name	**Family Name**	Suffix

Mailing Address Information:

Address 1	
Address 2	

City		**State/Province**	
Country i		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Assignee Data may be generated within this form by selecting the Add button. Add

Signature:

Remove

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications

Signature	/Jennifer L. Kisko/			Date (YYYY-MM-DD)	2015-02-06
First Name	Jennifer L	Last Name	Kisko	Registration Number	56907

Additional Signature may be generated within this form by selecting the Add button. Add

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION

FIELD OF THE INVENTION

[0001] The invention relates to nucleoside derivatives as inhibitors of Influenza RNA replication. In particular, the invention is concerned with the use of purine and pyrimidine nucleoside derivatives as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.

[0002] Influenza virus is causing seasonal epidemics of respiratory disease throughout the world. Approved treatment options for Influenza infection fall into two classes, neuraminidase inhibitors (Oseltamivir, Zanamivir) and M2 inhibitors (Amantadine, Rimantadine). However, the yearly influenza epidemics are still associated with a significant number of excess deaths every year. The occurrence of yearly deaths due to influenza and pneumonia correlates with circulating influenza virus and with the relative pathogenicity of the particular circulating influenza strain. In addition, new virus strains for which little or no population resistance exists can emerge through gene reassortment with viruses from a large animal reservoir and cause pandemics, which are a serious global public health issue. The available treatments of influenza virus infection have limited efficacy because of widespread resistance (amantadine, rimantadine) or requirement for early start of treatment (neuraminidase inhibitors). In addition, naturally resistant viruses have emerged that are resistant to both classes of inhibitors.

[0003] Many of the drugs approved for the treatment of viral infections are nucleosides or nucleoside analogues and most of these nucleoside analogue drugs inhibit viral replication, following conversion to the corresponding triphosphates, through inhibition of the viral polymerase enzymes. The influenza virus polymerase is essential for viral replication, and its inhibition by nucleoside triphosphate analogs results in the shut-down of virus production. Only very few nucleoside analogs have been previously found that can inhibit the influenza virus polymerase.


[0004] Influenza virus belongs to the family of Orthomyxoviridae. It is an RNA virus with a segmented negative sense RNA genome. The synthesis of viral messenger RNA and of viral genomic RNA in infected cells is performed by the trimeric influenza virus polymerase. Three

virus encoded polymerase subunits (PA, PB1, PB2) and a virus encoded single stranded RNA binding protein (NP) are necessary and sufficient to perform RNA replication.

SUMMARY OF THE INVENTION

[0005] The compounds of Formula I are useful for the treatment of diseases mediated by Influenza and for pharmaceutical compositions comprising such compounds.

[0006] The application provides a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

[0007] The application provides the compounds of Formula I which are useful for the treatment of diseases mediated by Influenza, pharmaceutical compositions comprising such compounds of Formula I, or result in the formation of such compounds of Formula I in vivo during said treatment.

[0008] The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I or a compound resulting in the formation of a compound of Formula I in vivo.

[0009] The application provides a composition comprising a compound of Formula I and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION OF THE INVENTION

[0010] The compounds of Formula I have been shown to be inhibitors of the influenza virus RNA polymerase or result in the formation of inhibitors of the influenza virus polymerase after metabolic conversion in human cells.

[0011] The term "alkyl" as used herein denotes a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms. Preferably, the term "alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms. Most preferred are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert. -butyl or pentyl. The alkyl may be unsubstituted or substituted. The substituents are selected from one or more of cycloalkyl, nitro, amino, alkyl amino, dialkyl amino, alkyl carbonyl and cycloalkyl carbonyl.

[0012] The term "cycloalkyl" as used herein denotes an optionally substituted cycloalkyl group containing 3 to 7 carbon atoms, e. g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

[0013] The term "alkoxy" as used herein denotes an optionally substituted straight or branched chain alkyl-oxy group wherein the "alkyl" portion is as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, tert. -butyloxy, pentyloxy, hexyloxy, heptyloxy including their isomers.

[0014] The term "alkoxyalkyl" as used herein denotes an alkoxy group as defined above which is bonded to an alkyl group as defined above. Examples are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propyloxypropyl, methoxybutyl, ethoxybutyl, propyloxybutyl, butyloxybutyl, tert. -butyloxybutyl, methoxypentyl, ethoxypentyl, propyloxypentyl including their isomers.

[0015] The term "alkenyl" as used herein denotes an unsubstituted or substituted hydrocarbon chain radical having from 2 to 7 carbon atoms, preferably from 2 to 4 carbon atoms, and having one or two olefinic double bonds, preferably one olefinic double bond. Examples are vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

[0016] The term "alkynyl" as used herein denotes to unsubstituted or substituted hydrocarbon chain radical having from 2 to 7 carbon atoms, preferably 2 to 4 carbon atoms, and having one or where possible two triple bonds, preferably one triple bond. Examples are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

[0017] The term "H" as used herein refers to hydrogen, including deuterium.

[0018] The term "hydroxyalkyl" as used herein denotes a straight or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a hydroxy group. Examples are hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, hydroxyisopropyl, hydroxybutyl and the like.

[0019] The term "haloalkyl" as used herein denotes a straight or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl and the like.

[0020] The term "alkylthio" as used herein denotes a straight or branched chain (alkyl)S-group wherein the "alkyl" portion is as defined above. Examples are methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio or tert.-butylthio.

[0021] The term "aryl" as used herein denotes an optionally substituted phenyl and naphthyl (also referred to as naphthylenyl") (e. g. 1-naphthyl, 2-naphthyl or 3-naphthyl). Suitable substituents for aryl can be selected from those named for alkyl, in addition however, halogen, hydroxy and optionally substituted alkyl, haloalkyl, alkenyl, alkynyl and aryloxy are substituents which can be added to the selection.

[0022] The term "heterocyclyl" or "heterocycloalkyl" or "heterocycle" as used herein denotes an optionally substituted saturated, partially unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic systems which contain one or more hetero atoms selected from nitrogen, oxygen and sulfur which can also be fused to an optionally substituted saturated, partially unsaturated or aromatic monocyclic carbocycle or heterocycle.

[0023] Examples of suitable heterocycles are oxazolyl, isoxazolyl, furyl, tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, 2-thienyl, 3-thienyl, pyrazinyl, isothiazolyl, dihydrooxazolyl, pyrimidinyl, tetrazolyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinonyl, (N-oxide)-pyridinyl, 1-pyrrolyl, 2-pyrrolyl, triazolyl e. g. 1,2,3-triazolyl or 1,2,4-triazolyl, 1-pyrazolyl, 2-pyrazolyl, 4-pyrazolyl, piperidinyl, morpholinyl (e. g. 4-morpholinyl), thiomorpholinyl (e. g. 4-thiomorpholinyl), thiazolyl, pyridinyl, dihydrothiazolyl, imidazolidinyl, pyrazolinyl, piperazinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, thiadiazolyl e. g. 1,2,3-thiadiazolyl, 4-methylpiperazinyl, 4-hydroxypiperidin-1-yl.

[0024] Suitable substituents for heterocycloalkyls can be selected from those named for alkyl, in addition however, optionally substituted alkyl, alkenyl, alkynyl, an oxo group (=O) or aminosulphonyl are substituents which can be added to the selection.

[0025] The term “acyl” ("alkylcarbonyl")as used herein denotes a group of formula C(=O)R wherein R is hydrogen, an unsubstituted or substituted straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms or a phenyl group. Most preferred acyl groups are those wherein R is hydrogen, an unsubstituted straight chain or branched hydrocarbon residue containing 1 to 4 carbon atoms or a phenyl group.

[0026] The term “halogen” or “halo” stands for fluorine, chlorine, bromine or iodine, preferable fluorine, chlorine, bromine.

[0027] In the pictorial representation of the compounds given throughout this application, a thickened tapered line ( ) indicates a substituent which is above the plane of the ring to which the asymmetric carbon belongs and a dotted line ( ) indicates a substituent which is below the plane of the ring to which the asymmetric carbon belongs.

[0028] Compounds of formula I may exhibit stereoisomerism. These compounds can be any isomer of the compound of formula I or mixtures of these isomers. The compounds and intermediates of the present invention having one or more asymmetric carbon atoms may be obtained as racemic mixtures of stereoisomers which can be resolved.


[0029] Compounds of formula I may exhibit tautomerism which means that the compounds of this invention can exist as two or more chemical compounds that are capable of facile interconversion. In many cases it merely means the exchange of a hydrogen atom between two other atoms, to either of which it forms a covalent bond. Tautomeric compounds exist in a mobile equilibrium with each other, so that attempts to prepare the separate substances usually result in the formation of a mixture that shows all the chemical and physical properties to be expected on the basis of the structures of the components.

[0030] The most common type of tautomerism is that involving carbonyl, or keto, compounds and unsaturated hydroxyl compounds, or enols. The structural change is the shift of a hydrogen atom between atoms of carbon and oxygen, with the rearrangement of bonds. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form is the predominant one; in phenols, the enol form is the major component.

[0031] Compounds of formula I which are basic can form pharmaceutically acceptable salts with inorganic acids such as hydrohalic acids (e.g. hydrochloric acid and hydrobromic acid), sulphuric acid, nitric acid and phosphoric acid, and the like, and with organic acids (e.g. with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulphonic acid and p-toluene sulphonic acid, and the like). The formation and isolation of such salts can be carried out according to methods known in the art.

Inhibitors of Influenza

[0032] The application provides a compound of Formula I



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is -$C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or –OR^3;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, -$N(R^{1a})_2$, acylamino, -$SO_2N(R^{1a})_2$, -$C(=O)R^{1b}$, -$SO_2(R^{1c})$, -$NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently -OR^{1a} or -$N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, -$(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, -CH_2SH, -$(CH_2)S(O)_pMe$, -$(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, -$(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and

with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;

or a pharmacologically acceptable salt thereof.

[0033] The application provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

[0034] The application alternatively provides the above compound of Formula I, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

[0035] The application alternatively provides the above compound of Formula I, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

[0036] The application alternatively provides the above compound of Formula I, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

[0037] The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

[0038] The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

[0039] The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

[0040] The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

[0041] The application alternatively provides the above compound of Formula I, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

[0042] The application provides the compound of Formula I, wherein R^z is H.

[0043] The application provides the compound of Formula I, wherein R^y is OH.

[0044] The application provides the compound of Formula I, wherein R^W is H.

[0045] The application provides the compound of Formula I, wherein R^x is OH.

[0046] The application provides the compound of Formula I, wherein R' is O-R^3, R^3 is lower alkyl, R is $-OR^1$, and R^1 and R^x together form a bond.

[0047] The application provides the compound of Formula I, wherein R is $-OR^1$, R^1 is phenyl substituted with $R^{1''}$, R' is $-OR^3$, and R^3 and $R^{1''}$ together form CH_2.

[0048] The application provides the compound of Formula I, wherein X is O.

[0049] The application provides the compound of Formula I, wherein X is S.

[0050] The application provides the compound of Formula I, wherein R is O-R^1, and R^1 is phenyl optionally substituted with methoxy.

[0051] The application provides the compound of Formula I, wherein R is O-R^1, and R^1 is naphthylenyl.

[0052] The application provides the compound of Formula I, wherein R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

[0053] The application provides the compound of Formula I, wherein R' is -OP(=O)(OH)OP(=O)(OH)OH.

[0054] The application provides the compound of Formula I, wherein Base is cytidine optionally substituted with halo.

[0055] The application provides the compound of Formula I, wherein Base is uridine optionally substituted with halo.

[0056] The application provides the compound of Formula I, wherein Base is guanosine.

[0057] The application provides the compound of Formula I, wherein Base is adenosine.

[0058] The application provides the compound of Formula I, wherein R^w is F if R^w is not H or OH.

[0059] The application provides the compound of Formula I, wherein R^y is F if R^y is not H or OH.

[0060] The application provides the compound of Formula I, wherein R^z is F if R^z is not H or OH.

[0061] The application provides the compound of Formula I, wherein both R^y and R^z are F if both R^y and R^z are not H or OH.

[0062] The application provides the compound of Formula I, wherein R^y is H and R^z is OH if R^y is not OH or F and R^z is not H or F.

[0063] The application provides a compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl5-fluorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorouridine;

4’-Difluoromethyl-5-fluorouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluorouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorouridine;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

4’-Difluoromethyl-5-chlorouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylcytidine;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

4’-Difluoromethylcytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};
4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};
4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorocytidine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorocytidine;
4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-5-chlorocytidine;
4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl-5-chlorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-chlorocytidine;

4’-Difluoromethyl-5-chlorocytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyladenosine;

4’-Difluoromethyladenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine;
4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylguanosine;
4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

4’-Difluoromethylguanosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylguanosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;
2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;
2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;
4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Dideoxy-2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Dideoxy-2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;
2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2,2''-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylarauridine;

4'-Difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

4’-Difluoromethylarauridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylarauridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroarauridine;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4’-difluoromethyl-5-fluoroarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;

4’-Difluoromethyl—5-fluoroarauridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroarauridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine;
5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro -4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;
5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;
5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylaracytidine;
4'-Difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;

4'-Difluoromethyl—5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine;

4'-Difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadensoine;

4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraguanosine;

4'-Difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;
4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;
3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxylouridine;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylouridine;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;
5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;
5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxylocytidine;
4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluoroxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethyl-5-fluororxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;

4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;
5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;
5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine;
4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;
4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;
4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;
4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;
4'-Difluoromethylxyloguanosine;
4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine;

3'-Deoxy-3'.3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethy -5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine; and
3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine.

[0064] The application provides a composition comprising the compound of Formula I.

[0065] The application provides the above composition, admixed with at least one carrier, diluent or excipient.

[0066] The application provides a composition comprising the compound of Formula I in combination with one or more antiviral compounds.


[0067] The application provides a composition comprising the compound of Formula I in combination with one or more anti-Influenza compounds.

[0068] The application provides a composition comprising the compound of Formula I in combination with one or more antiviral compounds, admixed with at least one carrier, diluent or excipient.

[0069] The application provides a composition comprising the compound of Formula I in combination with one or more anti-Influenza compounds, admixed with at least one carrier, diluent or excipient.

[0070] The application provides a method of preventing or treating a virus comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;


X is O or S;

Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano; and

with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H;

or a pharmacologically acceptable salt thereof.

The application provides a method for treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;
or R^{2b} and R^4 together form $(CH_2)_3$;
R^w, R^y, and R^z are each independently H, OH or F;
R^x is H, OH, or F;
or R^3 and R^x together form a bond;
or R^1 and R^x together form a bond;
X is O or S; and
Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
or a pharmacologically acceptable salt thereof.

[0071] The application provides a method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I or a compound resulting in the formation of a compound of Formula I in vivo.

[0072] The application provides the use of a compound of Formula I in the preparation of a medicament for the treatment of a viral infection.

[0073] The application provides the use of the compound of Formula I in the preparation of a medicament for the treatment of an Influenza infection.

[0074] The application provides any compound, composition, method, or use as described herein.

[0075] The application provides the above method, further comprising administering an immune system modulator or one or more antiviral agents that inhibits replication of Influenza, or a combination thereof.

[0076] The application provides the above method for inhibiting replication of Influenza in a cell comprising administering a compound of Formula I.

[0077] Examples of representative compounds encompassed by the present invention and within the scope of the invention are provided in the following Tables. These examples and preparations which follow are provided to enable those skilled in the art to more clearly

understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

[0078] In general, the nomenclature used in this Application is based on standard nucleic acid nomenclature common to one of ordinary skill in the art. If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

Table 1. Examples of compounds of generic Formula I.





Compound Number	Structure	Name
I-1		4'-Difluoromethyluridine
I-2		4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-3		4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-4		4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-5		4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-6		4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-7		4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-8		4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-9		4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-10		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-11		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-12		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-13		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-14		4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester
I-15		4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-16		4'-Difluoromethyl-5-fluorouridine
I-17		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-18		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-19		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-20		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-21		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-22		4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-23		4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-24		4'-Difluoromethyl5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-25		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-26		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-27		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine
I-28		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-29		4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-30		4'-Difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-31		4'-Difluoromethyl-5-chlorouridine
I-32		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-33		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-34		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-35		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-36		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-37		4'-Difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-38		4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-39		4'-Difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-40		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-41		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-42		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine
I-43		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-44		4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-45		4'-Difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-46		4'-Difluoromethylcytidine
I-47		4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-48		4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate
I-49		4'-Difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-50		4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-51		4'-Difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-52		4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-53		4'-Difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-54		4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-55		4'-Difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-56		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-57		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-58		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-59		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-60		4'-Difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-61		4'-Difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-62		4'-Difluoromethyl-5-fluorocytidine
I-63		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-64		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-65		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-656		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-67		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-68		4'-Difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-69		4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-70		4'-Difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-71		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-72		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-73		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-74		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-75		4'-Difluoromethyl-5-fluorcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-76		4'-Difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-77		4'-Difluoromethyl-5-chlorocytidine
I-78		4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-79		4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-80		4'-Difluoromethyl5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-81		4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-82		4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-83		4'-Difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-84		4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-85		4'-Difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-86		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-87		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-88		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine
I-89		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-chlorocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-90		4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-91		4'-Difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-92		4'-Difluoromethyladenosine
I-93		4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-94		4'-Difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-95		4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-96		4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-97		4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-98		4'-Difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-99		4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-100		4'-Difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-101		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-102		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-103		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-104		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine
I-105		4'-Difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-106		4'-Difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-107		4'-Difluoromethyl-7-adenosine
I-108		4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-109		4'-Difluoromethyl-7-adenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-110		4'-Difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-111		4'-Difluoromethyl-7-adenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-112		4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-113		4'-Difluoromethyl-7-adenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-114		4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-115		4'-Difluoromethyl-7-adenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-116		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine
I-117		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine
I-118		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine
I-119		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine
I-120		4'-Difluoromethyl-7-adenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-121		4'-Difluoromethyl-7-adenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-122		4'-Difluoromethylguanosine
I-123		4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-124		4'-Difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-125		4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-126		4'-Difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-127		4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-128		4'-Difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-129		4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-130		4'-Difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-131		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-132		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-133		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-134		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine
I-135		4'-Difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-136		4'-Difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-137		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-138		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-139		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-140		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-141		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-142		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-143		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-144		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-145		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-146		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-147		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-148		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-149		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine
I-150		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester
I-151		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-152		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine
I-153		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-154		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-155		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-156		2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-157		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-158		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-159		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-160		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-161		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-162		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-163		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-164		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine
I-165		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-166		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-167		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine
I-168		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-169		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-170		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-171		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-172		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-173		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-174		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-175		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-176		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-177		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-178		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-179		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine
I-180		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-181		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-182		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine
I-183		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-184		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-185		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-186		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-187		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-188		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-189		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-190		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-191		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-192		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-193		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-194		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-195		2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-196		2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-197		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine
I-198		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-199		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-200		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-201		2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-202		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-203		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-204		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-205		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-206		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-207		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-208		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-209		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-210		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-211		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-212		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine
I-213		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-214		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-215		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-216		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-217		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-218		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-219		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-220		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-221		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-222		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine
I-223		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine
I-224		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-225		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-226		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-227		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine
I-228		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-229		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-230		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-231		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-232		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-233		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-234		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-235		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-236		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-237		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-238		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-239		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine
I-240		2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-241		2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-242		2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine
I-243		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-244		2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-245		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-246		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-247		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-248		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-249		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-250		2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-251		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-252		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-253		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-254		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine
I-255		2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-256		2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-257		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-258		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-259		2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-260		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-261		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-262		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-263		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-264		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-265		2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-266		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-267		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-268		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine
I-269		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine
I-270		2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-271		2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-272		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine
I-273		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-274		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-275		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-276		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-277		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-278		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-279		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-280		2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-281		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-282		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-283		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-284		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine
I-285		2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-286		2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-287		4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylarauridine
I-28		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-289		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-290		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-291		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-292		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-293		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-294		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-295		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-296		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-297		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-298		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-299		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine
I-300		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-301		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-302		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine
I-303		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-304		2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-305		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-306		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-307		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-308		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-309		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-310		2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-311		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-312		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-313		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine
I-314		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-315		2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-316		2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-317		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine
I-318		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-319		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-320		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-321		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-322		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-323		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-324		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-325		2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-326		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-327		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-328		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-329		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-330		2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-331		2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-332		4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine
I-333		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-334		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-335		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-336		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-337		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-338		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-339		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-340		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-341		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-342		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-343		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-344		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-345		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-346		4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-347		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine
I-348		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-349		2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-350		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-351		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-352		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-353		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-354		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-355		2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-356		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-357		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-358		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine
I-359		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadenosine
I-360		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-361		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-362		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine
I-363		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-364		2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-365		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-366		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-367		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-368		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-369		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-370		2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-371		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-372		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-373		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine
I-374		2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine
I-375		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-376		2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-377		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-378		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-379		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-380		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-381		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-382		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-383		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-384		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-385		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-386		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-387		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-388		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-389		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine
I-390		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester
I-391		2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-392		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine
I-393		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-394		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-395		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-396		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-397		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-398		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-399		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-400		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-401		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-402		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine
I-403		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-404		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine
I-405		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-406		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-407		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine
I-408		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-409		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-410		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-411		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-412		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-413		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-414		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-415		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-416		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-417		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine
I-418		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-419		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine
I-420		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-421		2'-Deoxy-2',2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-422		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine
I-423		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-424		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-425		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-426		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-427		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-428		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-429		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-430		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-431		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-432		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-433		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-434		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-435		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytdine-3',5'-cyclic phosphoric acid isopropyl ester
I-436		2'-Deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-437		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine
I-438		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-439		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-440		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-441		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-442		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-443		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-444		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-445		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-446		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine
I-447		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-448		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine
I-449		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-450		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-451		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-452		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine
I-453		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-454		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-455		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-456		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-457		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-458		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-459		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-460		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-461		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine
I-462		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine
I-463		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-464		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-465		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-466		5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-467		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine
I-468		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-469		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-470		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-471		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-472		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-473		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-474		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-475		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-476		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-477		2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-478		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-479		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine
I-480		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-481		2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-482		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine
I-483		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-484		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-485		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-486		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-487		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-488		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-489		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-490		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-491		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-492		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-493		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-494		2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine
I-495		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-496		2'-Deoxy-2',2'-difluoro-4'-difluoromethylguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-497		4'-Difluoromethylarauridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-498		4'-Difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-499		4'-Difluoromethlarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-500		4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-501		4'-Difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-502		4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-503		4'-Difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-504		4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate}
I-505		4'-Difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate}
I-506		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-507		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-508		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine
I-509		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine
I-510		4'-Difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-511		4'-Difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-512		4'-Difluoromethyl-5-fluoroarauridine
I-513		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-514		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-515		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-516		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-517		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-518		4'-Difluoromethyl-5-fluoroarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-519		4'-difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-520		4'-Difluoromethyl-5-fluoroarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-521		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine
I-522		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine
I-523		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-524		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine
I-525		4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-526		4'-Difluoromethyl-5-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-527		5-Chloro-4'-difluoromethylarauridine
I-528		5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-529		5-Chloro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-530		5-Chloro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-531		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-532		5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-533		5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-534		5-Chloro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-535		5-Chloro -4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-536		5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-537		5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine
I-538		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-539		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine
I-540		5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester
I-541		5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-542		4'-Difluoromethylaracytidine
I-543		4'-Difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-544		4'-Difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-545		4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-546		4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-547		4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-548		4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-549		4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-550		4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-551		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-552		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-553		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine
I-554		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-555		4'-Difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-556		4'-Difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-557		4'-Difluoromethyl-5-fluoroaracytidine
I-558		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-559		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-560		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-561		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-562		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-563		4'-Difluoromethyl-5-fluoroaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-564		4'-difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-565		4'-Difluoromethyl-5-fluoroaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-566		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine
I-567		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine
I-568		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine
I-569		2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-570		4'-Difluoromethyl—5-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-571		4'-Difluoromethyl-5-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-572		5-Chloro-4'-difluoromethylaracytidine
I-574		5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-575		5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-576		5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-577		4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-578		5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-579		5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-580		5-Chloro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-581		5-Chloro -4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-582		5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-583		5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine
I-584		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine
I-585		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-586		5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-587		5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-588		4'-Difluoromethylaraadenosine
I-589		4'-Difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-590		4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-591		4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-592		4'-Difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-593		4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-594		4'-Difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-595		4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-596		4'-Difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-597		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-598		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine
I-599		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine
I-600		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadensoine
I-601		4'-Difluoromethylaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-602		4'-Difluoromethylaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-603		4'-Difluoromethylaraguanosine
I-604		4'-Difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-605		4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-606		4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-607		4'-Difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-608		4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-609		4'-Difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-610		4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-611		4'-Difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-612		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-613		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine
I-614		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine
I-615		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine
I-616		4'-Difluoromethylaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-617		4'-Difluoromethylaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-618		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-619		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-620		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-621		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-622		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-623		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-624		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-625		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-626		3'-Deoxy-3'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-627		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-628		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-629		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-630		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine
I-631		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine
I-632		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-633		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-634		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-635		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-636		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-637		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-638		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-639		3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-640		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-641		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-642		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-643		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-644		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine
I-645		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-646		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-647		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-648		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-649		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-650		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-651		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-652		3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-653		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-654		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-655		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-656		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine
I-657		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-658		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-659		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-660		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-661		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-662		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-663		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-664		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-665		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-666		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-667		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-668		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-669		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine
I-670		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylouridine
I-671		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-672		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-673		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-674		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-675		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-676		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-677		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-678		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-679		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-680		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-681		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]xylouridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-682		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine
I-683		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine
I-684		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-685		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-686		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-687		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-688		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-689		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-690		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-691		3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-692		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-693		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-694		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-695		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-696		3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine
I-697		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-698		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-699		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-700		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-701		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-702		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-703		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-704		3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-705		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-706		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-707		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-708		3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine
I-709		5-Chloro-3'-deoxy-3'-fluoro-4'-difluoromethylxylocytidine
I-710		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-711		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-712		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-713		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-714		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-715		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-716		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-717		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-718		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-719		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-720		5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]xylocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-721		5-Chloro-3'-deoxy 3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine
I-722		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine
I-723		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-724		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-725		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-726		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-727		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-728		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-729		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-730		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-731		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-732		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine
I-733		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-734		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine
I-735		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine
I-736		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-737		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-738		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-739		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-740		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-741		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-742		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-743		3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-744		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine
I-745		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine
I-746		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine
I-747		3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine
I-748		4'-Difluoromethylxylouridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-749		4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-750		4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-751		4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-752		4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-753		4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-754		4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-755		4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-756		4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-757		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-758		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-759		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine
I-760		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine
I-761		4'-Difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-762		4'-Difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-763		4'-Difluoromethyl-5-fluoroxylouridine
I-764		4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-765		4'-Difluoromethyl-5-fluororxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-766		4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-767		4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-768		4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-769		4'-Difluoromethyl-5-fluoroxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-770		4'-Difluoromethyl-5-fluoroxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-771		4'-Difluoromethyl-5-fluororxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-772		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine
I-773		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine
I-774		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-775		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine
I-776		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-777		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-778		5-Chloro-4'-difluoromethylxylouridine
I-779		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-780		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-781		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-782		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-783		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-784		5-Chloro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-785		5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-786		5-Chloro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-787		5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-788		5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine
I-789		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]xylouridine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-790		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine
I-791		5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-792		5-Chloro-4'-difluoromethylxylouridine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-793		4'-Difluoromethylxylocytidine
I-794		4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-795		4'-Difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-796		4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-797		4'-Difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-798		4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-799		4'-Difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-800		4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-801		4'-Difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-802		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-603		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine
I-804		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-805		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-806		4'-Difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-807		4'-Difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-808		4'-Difluoromethyl-5-fluoroxylocytidine
I-809		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-810		4'-Difluoromethyl-5-fluororxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-811		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-812		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-813		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-814		4'-Difluoromethyl-5-fluoroxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-815		4'-Difluoromethyl-5-fluoroxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-816		4'-Difluoromethyl-5-fluororxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-817		4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine
I-818		4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine
I-819		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine
I-820		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-821		4'-Difluoromethyl-5-fluoroxylouridine-3',5'-cyclic phosphoric acid isopropyl ester
I-822		4'-Difluoromethyl-5-fluoroxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-823		5-Chloro-4'-difluoromethylxylocytidine
I-824		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-825		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-826		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-827		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-828		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-829		5-Chloro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-830		5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-831		5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-832		5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-833		5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine
I-834		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine
I-835		5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-836		5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester
I-837		5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-838		4'-Difluoromethylxyloadenosine
I-839		4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-840		4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-841		4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-842		4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-843		4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-844		4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-845		4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-846		4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-847		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-848		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine
I-849		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine
I-850		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine
I-851		4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester
I-852		4'-Difluoromethylxyloadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-853		4'-Difluoromethylxyloguanosine
I-854		4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-855		4'-Difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-856		4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-857		4'-Difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-858		4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-859		4'-Difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-860		4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-861		4'-Difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-862		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-863		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine
I-864		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine
I-865		4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine
I-866		4'-Difluoromethylxyloguanosine-3',5'-cyclic phosphoric acid isopropyl ester
I-867		4'-Difluoromethylxyloguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester
I-868		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-869		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-870		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-871		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-872		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-873		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-874		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-875		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-876		3'-Deoxy-3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-877		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-878		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-879		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-880		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine
I-881		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine
I-882		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-883		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-884		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-885		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-886		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-887		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-888		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-889		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-890		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-891		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-892		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-893		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine
I-894		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine
I-895		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-896		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-897		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-898		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-899		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-900		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-901		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-902		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-903		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-904		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-905		5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine
I-906		5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-907		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine
I-908		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-909		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-910		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-911		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-912		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-913		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-914		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-915		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-916		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-917		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine
I-918		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-919		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine
I-920		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine
I-921		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-922		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-923		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-924		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-925		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-926		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-927		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-928		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-929		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-930		3'-Deoxy-3',3'-difluoro-4'-difluoromethy -5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine
I-931		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-932		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine
I-933		5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine
I-934		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-935		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-936		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate





Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-937		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-938		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-939		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-940		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate







Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-941		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-942		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-943		5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine
I-944		5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine
I-945		5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine
I-946		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-947		3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-948		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-949		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-950		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-951		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-952		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-953		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate
I-954		3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-955		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine
I-956		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine






Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-957		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine
I-958		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine
I-959		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine
I-960		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-961		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate











Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-962		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-963		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-964		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate
I-965		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate
I-966		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate

Table 1. Examples of compounds of generic Formula I.		
Compound Number	**Structure**	**Name**
I-967		3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate
I-968		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-969		3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine
I-970		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine
I-971		3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine

EXAMPLES

[0079] Abbreviations used in this application include: acetyl (Ac), acetic acid (HOAc), azo-*bis*-isobutyrylnitrile (AIBN), 1-N-hydroxybenzotriazole (HOBt), atmospheres (Atm), high pressure liquid chromatography (HPLC), 9-borabicyclo[3.3.1]nonane (9-BBN or BBN), methyl (Me), *tert*-butoxycarbonyl (Boc), acetonitrile (MeCN), di-*tert*-butyl pyrocarbonate or boc anhydride (BOC_2O), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), benzoyl (Bz), benzyl (Bn), *m*-chloroperbenzoic acid (MCPBA), butyl (Bu), methanol (MeOH), benzyloxycarbonyl (cbz or Z), melting point (mp), carbonyl diimidazole (CDI), $MeSO_2$- (mesyl or Ms), 1,4-diazabicyclo[2.2.2]octane (DABCO), mass spectrum (ms) diethylaminosulfur trifluoride (DAST), methyl *t*-butyl ether (MTBE), dibenzylideneacetone (Dba), N-carboxyanhydride (NCA), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), N-bromosuccinimide (NBS), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), 1,2-dichloroethane (DCE), pyridinium chlorochromate (PCC), N,N'-dicyclohexylcarbodiimide (DCC), pyridinium dichromate (PDC), dichloromethane (DCM), propyl (Pr), diethyl azodicarboxylate (DEAD), phenyl (Ph), di-*iso*-propylazodicarboxylate , DIAD, pounds per square inch (psi), di-iso-propylethylamine (DIPEA), pyridine (pyr), di-*iso*-butylaluminumhydride , DIBAL-H, room temperature, rt or RT, N,N-dimethyl acetamide (DMA), *tert*-butyldimethylsilyl or *t*-$BuMe_2Si$, (TBDMS), 4-N,N-dimethylaminopyridine (DMAP), triethylamine (Et_3N or TEA), N,N-dimethylformamide (DMF), triflate or CF_3SO_2-(Tf), dimethyl sulfoxide (DMSO), trifluoroacetic acid (TFA), 1,1'-*bis*-(diphenylphosphino)ethane (dppe), 2,2,6,6-tetramethylheptane-2,6-dione (TMHD), 1,1'-*bis*-(diphenylphosphino)ferrocene (dppf), thin layer chromatography (TLC), ethyl acetate (EtOAc), tetrahydrofuran (THF), diethyl ether (Et_2O), trimethylsilyl or Me_3Si (TMS), ethyl (Et), *p*-toluenesulfonic acid monohydrate (TsOH or pTsOH), lithium hexamethyl disilazane (LiHMDS), 4-Me-$C_6H_4SO_2$- or tosyl (Ts), *iso*-propyl (*i*-Pr), N-urethane-N-carboxyanhydride (UNCA), ethanol (EtOH). Conventional nomenclature including the prefixes *normal* (*n*), *iso* (*i*-), *secondary* (*sec*-), *tertiary* (*tert*-) and *neo* have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, *Nomenclature in Organic Chemistry,* IUPAC **1979** Pergamon Press, Oxford.).

General Conditions

[0080] Compounds of the invention can be made by a variety of methods depicted in the illustrative synthetic reactions described below in the Examples section.

[0081] The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's *Reagents for Organic Synthesis*; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's *Chemistry of Carbon Compounds*, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplementals; and *Organic Reactions*, Wiley & Sons: New York, 1991, Volumes 1-40. It should be appreciated that the synthetic reaction schemes shown in the Examples section are merely illustrative of some methods by which the compounds of the invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this application.

[0082] The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.


[0083] Unless specified to the contrary, the reactions described herein are typically conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, often from about 0 °C to about 125 °C, and more often and conveniently at about room (or ambient) temperature, e.g., about 20 °C.

[0084] Various substituents on the compounds of the invention can be present in the starting compounds, added to any one of the intermediates or added after formation of the final products by known methods of substitution or conversion reactions. If the substituents themselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups are known in the art, and can be employed. Examples of many of the possible groups can be found in "*Protective Groups in Organic Synthesis*" by Green et al., John Wiley and Sons, 1999. For example, nitro groups can be added by nitration and the nitro group can be converted to other groups, such as amino by reduction, and halogen by diazotization of the amino group and replacement of the diazo group with halogen. Acyl groups

can be added by Friedel-Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product, including isolated products.

[0085] The starting material **1** can be purchased through numerous vendors (CAS: 63593-03-3). Selective benzyl protection followed by oxidation, under Swern conditions, provided aldehyde intermediate **3**. Fluorination with DAST, followed by treatment with acetic anhydride under acidic conditions provided the diacetate intermediate **5**. Vorbrüggen reaction followed by deprotection, under standard conditions, provided 4'-difluoromethyluridine **7** (**Scheme 1**).


Scheme 1



i) NaH, BnBr, DMF; ii) DMSO, $(ClCO_2)$, -78 °C, iii) DAST, CH_2Cl_2; iv) Ac_2O, cat. H_2SO_4, AcOH; v) Uridine, BSA, $SnCl_4$, MeCN; vi) $NH_3.H_2O$, MeCN; vii) $Pd(OH)_2/C$, cat. HCl.

[0086] Compound **8** can be prepared, from the uridine analogue **7**, by those skilled in the art of organic synthesis following the synthetic sequence outlined below (**Scheme 2**).

Scheme 2




7 **8**

i) Ac_2O, AcOH; ii) 4-Cl-CPhOP(O)Cl_2, 1-H-tetrazole, pyriidine; iii) $NH_3.H_2O$; iv) NH_3, MeOH

[0087] Phosphoramidate compounds of the present invention can be prepared by condensation of nucleoside **7**, **8** or **9** with a suitably substituted phosphochloridate, or its sulfur analogue, of type **10** in the presence of a strong base (**Scheme 3**). The coupled product **11** of formula I is obtained as a mixture of two diastereomers initially under the coupling reaction and can be separated into their corresponding chiral enantiomers by chiral column, chiral HPLC, or chiral SFC chromatography.

Scheme 3




7, 8 or 9 **10** **11**

R^1 = H, OH or F X = O or S

[0088] Phosphorodiamidate compounds of formula I in the present invention can be prepared by condensation of nucleoside **7**, **8** or **9** with a suitably substituted phosphorodiamidic chloride, or phosphorodiamidothioic chloride, of type **12** in the presence of a strong base (**Scheme 4**).

Scheme 4




7, 8 or 9 **12** **13**

R^1 = H, OH or F

X = O or S

[0089] Cyclic phosphates of the present invention can be prepared by condensation of nucleoside **4** or **5** with isopropyl N,N,N,N-tetraisopropylphosphorodiamidite **14** (**Scheme 5**). Conversion to the thio derivative can be performed by heating the crude reaction mixture with bis(3-triethoxylsilyl)propyl-tetrasulfide (TEST).

Scheme 5




7, 8 or 9 **14** **15**

R^1 = H, OH or F

X = S or O

[0090] An alternative cyclic phosphate can be furnished from the reaction of the nucleoside **7**, **8** or **9** with the appropriate chlorophosphite **16** in the presence of a base and Oxone **(Scheme 6).**

Scheme 6




7, 8 or 9 **16** **17**

R^1 = H, OH or F

[0091] Phosphate prodrugs of type **19** are readily prepared from the reaction of compounds **7**, **8** or **9** with chlorophosphates of type **18** (**Scheme 7**).


Scheme 7



R^1 = H, OH or F

[0092] The synthesis of 4'-difluoromethylguanidine is outlined in **Scheme 8.** Herein, the ribose intermediate **5** undergoes a Vorbrüggen reaction with **20** to give the guanidine **23** derivative, following deprotection.


Scheme 8



i) BSA, TMSOTf, MeCN; vi) $NH_3.H_2O$, MeCN; vii) $HCOONH_4$, MeOH

[0093] The synthesis of 4'-difluoromethyladenosine is outlined in **Scheme 9.** Herein, the ribose intermediate **5** undergoes a Vorbrüggen reaction with **24** to give the adenosine derivative **27**, following deprotection.


Scheme 9



i) BSA, $SnCl_4$MeCN; vi) $NH_3.H_2O$, MeCN; vii) $Pd(OH)_2/C$, MeOH

[0094] Synthesis of 4'-difluoromethyl-5-chlorocytidine is outlined in **Scheme 10**. Herein, the ribose intermediate **5** undergoes a Vorbrüggen reaction with **28** to give the cytidine derivative **31**, following deprotection.


Scheme 10



i) BSA, $SnCl_4$MeCN; ii) NH_3, MeOH; iii) BCl_3, CH_2Cl_2, -78 °C

[0095] 4'-Difluoromethylaracytidine synthesis is outlined in **Scheme 11**. Herein, the uridine intermediate **6** is reacted with diphenyl carbonate to provide the anhydro compound **33**. Hydrolysis and deprotection yield the arabinocytidine **38**, following deprotection.


Scheme 11



i) $NH_3.H_2O$, dioxane; ii) $(Ph_2O)CO$, $NaHCO_3$, DMF; iii) NaOH, EtOH; iv) Ac_2O, Pyridine;
v) 1H-tetrazole, pyridine, $POCl_3$, $NH_3.H_2O$, dioxane; vi) $NH_3.H_2O$, dioxane, 60 °C; vii) BCl_3, CH_2Cl_2, -78 °C

[0096] The arabinouridine intermediate **34** was converted to its 2'-deoxy-2'-fluoro derivative **39** through a reaction with DAST. Subsequent base conversion and deprotection provides the 2'-deoxy-2'-fluorocytidine **41** (**Scheme 12**).


Scheme 12



i) DAST, THF, 25-60 °C; $NH_3.H_2O$, dioxane; ii) 1H-tetrazole,4-Cl-PhOP(O)Cl_2, pyridine; iii) $NH_3.H_2O$, dioxane; iv) $Pd(OH)_2/C$, MeOH, H_2.


[0097] The phosphoramidate compound **47** was synthesized following standard coupling methods as shown in **Scheme 13**. The neopently ester derivative was synthesized in a similar manner and outlined in **Scheme 14**.

Scheme 13.



i) BnOH, $SOCl_2$; ii) $PhOP(O)Cl_2$, Et_3N, CH_2Cl_2; iii) 1,1-dimethoxycyclopentane, 4-$MePhSO_3H$, DCE, 65 °C;
iv) **44**, t-BuMgCl, THF; v) HCO_2H (80%).


Scheme 14.



i) 48, t-BuMgCl, THF; ii) HCO_2H (80%).

General Preparations

Synthesis of compound ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-2,2 -dimethyl-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol (2)




2

[0098] To a solution of compound **1** (0.5 g, 1.61 mmol) in dry DMF (20 mL), was added NaH (77.6 mg, 1.94 mmol). After the mixture stirred at room temperature for 0.5 h, BnBr (355 mg, 2.09 mmol) was added drop-wise. The mixture was allowed to stir at r.t. for 4 hrs. TLC (Petroleum ether:Ethyl acetate; 1:3) showed the reaction was complete. The reaction was quenched with water and extracted with ethyl acetate. The organic phase was dried over Na_2SO_4 and then evaporated to dryness under reduced pressure. Purification by silica gel

chromatography [ethyl acetate:petroleum ether (1:10 to 1:3)] provided the product **2** (0.42 g, 65%) as a colorless oil. LC-MS $(M+H)^+ = 401.0$


Synthesis of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-2,2 -dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde (3)



3

[0099] DMSO (1.65 mL, 23.6 mmol) was added drop-wise to a cold (–78 °C) solution of oxalyl chloride (1.05mL, 12.0mmol) in dichloromethane (50 mL). After stirring for 30 min, a solution of compound **2** (3 g, 7.5 mmol) in dichloromethane (25 mL) was added to the reaction. The stirring was continued for 45 min at –78 °C, and triethylamine (3.5 mL, 25.0 mmol) was added to the reaction. The reaction was stirred at –78 °C for 15 min, after which the ice-bath was removed and the reaction was allowed to gradually warm over 45 min. The reaction was diluted with dichloromethane and the organic phase was sequentially washed with 5% aqueous HCl solution, saturated aqueous $NaHCO_3$ solution, brine, dried (Na_2SO_4) and concentrated under reduced pressure to provide **3** (2.2 g, crude), which was used without any further purification. LC-MS $(M+H)^+ = 399.1$

Synthesis of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-5 -(difluoromethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole (4)




4

[00100] To a solution of compound **3** (2.2 g, 5.5 mmol) in dichloromethane (20 mL) was added DAST (4.45 g, 27.6 mmol). The mixture was stirred at room temperature for 14 hrs and

then quenched by the addition of saturated $NaHCO_3$, extracted with EtOAc, dried (Na_2SO_4) and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] to afford **4** (1.0 g, 43%) as an oil. LC-MS $(M+H)^+ = 421.1$


Synthesis of (3R, 4S, 5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-2,3-diyl diacetate (5)



5

[00101] To a solution of compound (3aR,5R,6S,6aR)-6-(benzyloxy)-5-(benzyloxymethyl)-5 -(difluoromethyl)-2,2-dimethyl-tetrahydrofuro[2,3-d][1,3]dioxole (1.0 g, 6.3 mmol) in Ac2O (2.5 mL) and AcOH (10 mL) was added H2SO4 (3 drops). The mixture was stirred at room temperature for 3 hrs. TLC showed the reaction was complete. The mixture was poured to water, extracted with EtOAc , dried (Na2SO4) and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:3)] to afford compound 5 (1.0 g, crude) as a light-color oil. LC-MS (M+H)+ = 465.1

Synthesis of compound(2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluorom -ethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl acetate (6)




6

[00102] The mixture of uracil (482 mg, 4.32 mmol) and BSA (1.75 g, 8.64 mmol) in MeCN (20 ml) was stirred at room temperature for 3 hrs. Compound **5** (1.0 g, 2.16 mmol) and $SnCl_4$ (2.4 g, 9.3 mmol) was added respective, then stirred at 65 °C for 12 hrs. The mixture was quenched with saturated $NaHCO_3$ solution, extracted with EtOAc (200 mL × 3), dried over

Na_2SO_4 and purified by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] to afford the product (450 mg, 40%) as a yellow solid. LC-MS $(M+H)^+$ = 517.1

Synthesis of compound 1-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5 -(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (7)




7

[00103] The mixture of compound 1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5 -(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (450 mg 0.87 mmol) in CH_3CN (10 mL) was added $NH_3.H_2O$ (10 mL) stirred at room temperature overnight. The mixture was concentrated and concentrated and dissolved in methanol (30mL). To this was added $Pd(OH)_2/C$ (1.0g). The reaction mixture was stirred under an atmosphere of hydrogen and at room temperature overnight, the mixture was concentrated and purified by Prep-HPLC to afford **7** (100 mg, 40%) as white solid. LC-MS $(M+H)^+$ = 295.0

^{1}H NMR (300 MHz, DMSO-*d*6): δ 11.42 (s, 1H), 7.89–7.86 (d, 1H, J = 8.1 Hz), 6.30–5.94 (m, 2H), 5.78–5.64 (m, 2H), 5.56–5.51 (m, 2H), 4.31–4.25 (m, 1H), 4.21–4.18 (m, 1H), 3.75–3.71 (m, 1H), 3.62–3.57 (m, 1H).

Synthesis of compound4-amino-1-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy -5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one（8）




8

[00104] To a solution of **7** (0.1 g, 0.34 mmol) in dry pyridine (15 mL) was added Ac_2O (5 mL). The mixture was stirred at room temperature overnight and then evaporated to dyness under reduced pressure. The residue was treated with saturated aqueous $NaHCO_3$ solution extracted with ethyl acetate. The organic phase was separated, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Puriication by silica gel chromatography [ethyl acetate:petroleum ether (1:10)] gave the acetylated intermediate (0.12 g, 84%) as a white solid. MS $[M+H]^+$ = 420.1. The acetylated intermediate (0.12 g, 0.286 mmol) and 1*H*-tetrazole (0.02 g, 0.429 mmol) were azeotroped with pyridine and then dissolved in anhydrous pyridine (20 mL). The solution was cooled by an ice-water bath, and 4-chlorophenylphosphorodichloridate (84 mg, 0.343 mmol) was added. The reaction mixture was stirred at 0-5 °C for 5 min and then allowed to warm to room temperature. After 5 h, the reaction mixture was evaporated to dryness under reduced pressure and the residue was partitioned between CH_2Cl_2 and saturated aqueous $NaHCO_3$ solution. The organic phase was separated, dried (Na_2SO_4), and evaporated to dryness under reduced pressure. The crude product was treated with $NH_3.H_2O$ (10 mL) in 1,4-dioxane (20 mL) for 16 h at room temperature and then evaporated to dryness under reduced pressure. The crude material was dissolved in NH_3 in MeOH (7N, 30 mL) and the mixture was stirred for 18 h at room temperature and then evaporated to dryness under reduced pressure. Purification by preparative HPLC column purification gave **8** (51 mg, 61%) as a white solid. MS $[M+H]^+$ = 294.0

^{1}H NMR (300 MHz, DMSO-*d*6) δ 7.80–7.78 (d, *J*=7.8Hz, 1H), 7.28–7.24 (brs, 2H), 6.28–5.92 (m, 2H), 5.81–5.78(d, *J*=7.5Hz, 1H), 5.53–5.38 (m, 3H), 4.30–4.19 (m, 2H), 3.68–3.60 (m, 2H).


Synthesis of compound (2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoro methyl)-2-(2-isobutyramido-6-oxo-1,6-dihydropurin-9-yl)-tetrahydrofuran-3-yl acetate (21)



21

[00105] To a solution of compound *N*-(6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide (0.57 g, 2.58 mmol) in anhydrous CH_3CN (50 mL) was added BSA (1.26 mL, 5.17 mmol) portion-wise while maintaining the reaction temperature at 25 °C. Then the reaction was stirred at 40 °C for 1 h until a clear solution persisted. Compound **5** (0.6 g, 1.29 mmol) in CH_3CN (5 mL) was added into the mixture at 0 °C followed by TMSOTf (0.94 mL, 5.17 mmol). The mixture was stirred at 40 °C for 2 h and then poured into saturated $NaHCO_3$ solution (10 mL) at 0 °C, extracted with ethyl acetate, washed with water, brine solution, dried over Na_2SO_4 and evaporated to dryness under reduced pressure. The crude compound was purified by silica gel chromatography [petroleum ether:ethyl acetate (5:1 to 1:1)] to provide the product **21** as a white foam (0.5 g, 60%). LC-MS: $(M+H)^+ = 626$

Synthesis of compound 2-amino-9-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one (22)




22

[00106] A mixture of compound **21** (0.5 g, crude) in $NH_3 \cdot MeOH$ (7 N, 40 mL) was stirred at 35 °C for 16 h and then evaporated to dryness. Purification by silica gel chromatography

[dichloromethane:methanol (100:1 to 20:1)] to give the product **22** as a white foam (0.22 g, 53%). LC-MS $(M+H)^+$ = 514

Synthesis of compound 2-amino-9-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydro xy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one (23)




23

[00107] To a solution of compound **22** (0.22 g, 0.42 mmol) in methanol (30 mL) was added HCO_2NH_4 (600 mg, 9.52 mmol), followed by $Pd(OH)_2/C$ (500 mg). The reaction mixture was stirred at 80 °C for 15 h, then cooled to 25 °C, filtered and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (20:1 to 5:1)] and prep-HPLC provided the product **23** (0.046 g, 33%) as a white solid. LC-MS $(M+H)^+$ = 334.1

^{1}H NMR (300MHz, d_6-DMSO) δ 10.64 (s, 1 H), 7.93 (s, 1 H), 6.50 (s, 2 H), 6.28–5.92 (dd, J = 52.8, 56.4 Hz, 1 H), 5.87–5.83 (d, J = 14.7 Hz, 1 H), 5.62–5.45 (m, 3 H), 4.73–4.67 (m, 1 H), 4.27–4.24 (m, 1 H), 3.72–3.58 (m, 2 H).

Synthesis of (2R,3R,4S,5R)-2-(6-benzamido-9H-purin-9-yl)-4-(benzyloxy)-5-(benz yloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (25)




25

[00108] To a solution of compound **5** (1.44 g, 6.02 mmol) in anhydrous CH_3CN (15 mL) was added BSA (7.2 mL, 30.1 mmol) portion-wise while maintaining the reaction temperature at 25

°C. After the reaction mixture became clear, compound **1** (0.4 g, 0.86 mmol) in CH_3CN (5 mL) and $SnCl_4$ (0.42 mL, 3.5 mmol) was added into the mixture. The mixture was stirred at 85 °C for 20 h, then it was poured into saturated $NaHCO_3$ (10 mL) at 0 °C, extracted with ethyl acetate, the combined organic layer was washed with H_2O (100 mL), brine solution (100 mL), dried over Na_2SO_4 and evaporated to dryness. Purification by silica gel chromatography column [dichloromethane:methanol; (30:1)] to give product **25** as an colorless oil (0.225 g, 25%). LC-MS: $(M+H)^+ = 393$


Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-4-(benzyloxy)-5-(benzyloxy methyl)-5-(difluoromethyl)-tetrahydrofuran-3-ol (26)



26

[00109] A mixture of compound **25** (0.225 g, 0.35 mmol) in $NH_3 \cdot MeOH$ (40 mL) was stirred in a sealed tube at 65 °C for 16 hrs, warmed to 25 °C and stirred for 3 hrs. TLC showed the reaction was completed, the reaction solution was concentrated and the crude compound was purified by silica gel chromatography column [dichloromethan:methanol (30:1)] to give product **26** as an colorless oil (0.16 g, 92%).
LC-MS $(M+H)^+ = 469$

Synthesis of (2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(difluoromethyl)-2-(hydroxyl methyl)-tetrahydrofuran-3,4-diol (27)




27

[00110] Concentrated HCl (37%) 1 drop was added into the mixture of compound **3** (0.048 g, 0.1 mmol) and $Pd(OH)_2/C$ (0.8g) in MeOH (5 mL), after addition, the whole mixture was stirred at 25 °C under hydrogen atmosphere. After 2 h, the reaction mixture was filtered and evaporated to dryness under reduced pressure. Purification by prep-HPLC afforded **27** (0.024 g, 85%) as a white solid. L-MS $(M+H)^+ = 318$.

^1H NMR (300 MHz, d_6-DMSO) δ 8.52 (s, 1 H), 8.24 (s, 1 H), 6.94 (br s, 2 H), 6.47–6.11 (m, 1 H), 5.99 (d, $J = 7.8$ Hz, 1 H), 5.81–5.79 (m, 2 H), 5.59 (br s, 1 H), 4.46 (br s, 1 H), 4.32 (br s, 1 H), 3.74 (br s, 1 H), and 3.65 (br s, 1 H).


Synthesis of (2R,3R,4S,5R)-2-(4-amino-5-chloro-2-oxopyrimidin-1(2H)-yl)-4-(benzy loxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (29).



29

[00111] To a solution of 4-amino-5-chloropyrimidin-2(1H)-one **28** (0.336 g, 2.33 mmol) in anhydrous CH_3CN (10 mL) was added BSA (0.945 g, 4.64 mmol) portion-wise while maintaining the reaction temperature at 25 °C. After the reaction mixture became clear, compound **5** (0.54 g, 1.16 mmol) in CH_3CN (2 mL) and $SnCl_4$ (1.2 g, 4.64 mmol) was added into the mixture. The mixture was stirred at 65 °C for 1 h, then cooled and poured into saturated $NaHCO_3$ solution (20 mL). The organic phase was extracted with ethyl acetate, washed with water, brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by flash silica gel chromatography [dichloromethane:methanol (40:1)] gave **29** as a white solid (0.24 g, 31%). LC-MS: $(M+H)^+ = 550.1$


Synthesis of 4-amino-1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(diflu oromethyl)-3-hydroxy-tetrahydrofuran-2-yl)-5-chloropyrimidin-2(1H)-one (30).



30

[00112] A mixture of compound **29** (0.235 g, 0.43 mmol) in NH_3·MeOH (10 mL) was stirred at r.t for 3 h and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography column [dichloromethane:methanol (40:1)] gave **30** as a white solid (0.135 g, 62%). LC-MS: $(M+H)^+$ = 508.1

Synthesis of 4-amino-5-chloro-1-((2R,3R,4S,5R)-5-(difluoromethyl)-3,4-dihydro xy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (31)




31

[00113] BCl_3 (2.46 mL, 2.46 mmol) was added to a cooled (–78 °C) solution of compound **30** (0.125 g, 0.246 mmol) in dry dichloromethane (10 mL). The mixture was cooled to 0 °C and pyridine (0.5 mL) and MeOH (2 mL) were added. The reaction mixture was evaporated to dryness under reduced pressure. Purification by prep-HPLC provided **31** (0.035 g, 44 %) as a white solid. LC-MS $(M+H)^+$ = 328.1

^{1}H NMR (300 MHz, DMSO-d_6) δ 8.12 (s, 1 H), 7.99 (s, 1 H), 7.35 (s, 1 H), 6.27–5.91 (m, 2 H), 5.57 (m, 2 H), 5.44–5.42 (d, J = 6.3 Hz, 1 H), 4.25–4.16 (m, 2 H), 3.62 (m, 2 H).


Synthesis of 1-((2R,3R,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (32).



32

[00114] A solution of compound **6** (0.52 g, 1 mmol) in NH_3·MeOH/dioxane (6 mL/6 mL) was stirred at 20 °C. After 18 h the reaction mixture was evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1 to 1.5:1)] provided **32** (0.314 g, 61%) as a white solid.
LC-MS: $(M+H)^+$ = 475.1


Synthesis of 2,2'-anhydro-4'-difluoromethyl-1-(β-arabinofuranosyl)uracil (33).



33

[00115] Diphenyl carbonate (0.258 g, 1.2 mmol) and sodium hydrogen carbonate (0.184 g, 2.2 mmol) were added to a solution of **32** (0.52 g, 1.1 mmol) in dry DMF (10 mL). The reaction mixture was stirred at 110 °C for 2 h, then cooled and evaporated to dryness under reduced pressure. The residue was dissolved with dichloromethane and washed with water, brine, dried (Na_2SO_4) and then evaporated to dryness under reduced pressure to give the crude product **33** (0.45 g) as a white solid, which was used directly without further purification. LC-MS: $(M+H)^+$ = 457.2


Synthesis of 1-((2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (34).



34

[00116] A solution of aqueous NaOH (1N, 5 mL) was added to a solution of compound **33** (0.45 g) in ethanol (10 mL). After stirring at 20 °C for 3 h, the reaction mixture was adjusted to pH = 7 by strong-acid cation-exchange resin, filtered and evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichlormethane:methanol (40:1)] provided **34** (0.12 g, 25%) as a white solid. LC-MS: $(M+H)^+$ = 475.2


Synthesis of (2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl acetate (35).



35

[00117] Ac_2O (0.5 mL) was added into a solution of compound **34** (0.114 g, 0.24 mmol) in dry pyridine (4 mL). The reaction mixture was stirred at 20 °C for 3 h and then quenched by saturated aqueous $NaHCO_3$ solution (2 mL). The organic phase was extracted with dichloromethane and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1)] afforded **35** (0.12 g, 88%) as a white solid. LC-MS: $(M+H)^+$ = 517.2


Synthesis of (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-tetrahydrofuran-3-yl acetate (36).



36

[00118] 4-Chlorophenylphosphonic dichloride (0.4 g, 0.81 mmol) was added to a cooled (0 °C) solution of 1-*H*-tetrazole (0.056 g, 0.81 mmol) and **35** (0.113 g, 0.22 mmol) in dry pyridine (5 mL). The reaction mixture was left to stir under a nitrogen atmosphere at 20 °C for 3 h and then evaporated to dryness under reduced pressure. The residue was dissolved in dioxane and $NH_3 \cdot H_2O$ (5 mL) was added. After stirring for 5 h at 20 °C, the reaction mixture was evaporated to dryness under reduced pressure to afford **36** (0.2 g, crude).


Synthesis of 4-amino-1-((2R,3S,4S,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-hydroxy-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (37).



37

[00119] A solution of compound **36** (0.112 g, 0.21 mmol) in $NH_3 \cdot MeOH$ (4 mL) was stirred at 60 °C for 12 h and then cooled and evaporated to dryness under reduced pressure to give **37** as a white solid. LC-MS: $(M+H)^+ = 474.2$

Synthesis of 4-amino-1-((2R,3S,4S,5R)-5-(difluoromethyl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (38).




38

[00120] BCl_3 (3.7 mL, 3.7 mmol) was added to a solution of compound **37** (0.175 g, 0.37 mmol) in dichloromethane (10 mL) cooled to –78 °C. The reaction was stirred at –78 °C for 3 h, then warmed to 25 °C and stirred for a further 12 h. The reaction mixture was cooled to 0 °C and then pyridine was added into the mixture, followed by methanol. The reaction mixture was evaporated to dryness under reduced pressure. Purification by prep-HPLC afforded the product **38** (0.052 g, 41 %) as a white solid. LC-MS $(M+H)^+ = 294.1$

^{1}H NMR (300MHz, DMSO-d_6) δ 7.59–7.56 (d, J = 7.5 Hz, 1 H), 7.13–7.06 (d, J = 21.3 Hz, 2 H), 6.24–6.23 (d, J = 5.7 Hz, 1 H), 6.07 (s, 1 H), 5.92-5.90 (d, J = 5.1 Hz, 1 H), 5.67–5.62 (m, 2 H), 5.41–5.38 (m, 1 H), 4.30–4.28 (m, 1 H), 4.15–4.14 (m, 1 H), 3.64–3.59 (m, 2 H).

Synthesis of compound 1-((2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxymethyl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (39).




39

[00121] Diethylaminosulfur trifluoride (7.6 g, 47.4 mmol) was added to a suspension of compound **34** (1.5 g, 3.16 mmol) in dry THF (150 mL). The mixture was stirred at 60 °C for 16 h and then cooled to room temperature. The mixture was quenched by the addition of saturated aqueous $NaHCO_3$ solution and then extracted with ethyl acetate. The organic phase was washed

with brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (4:1)] afforded **39** as a brown solid (700 mg, 46%). LC-MS $(M+H)^+ = 477.4$


Synthesis of compound 4-amino-1-((2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxymeth yl)-5-(difluoromethyl)-3-fluoro-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (40).



40

[00122] 4-Chlorophenyl phosphorodichloridate (0.68 g, 2.77 mmol) was added to a solution of compound **39** (0.22 g, 0.462 mmol) and 1-*H*-tetrazole (0.485 g, 6.93 mmol) in dry pyridine (100 mL) at 0 °C. After stirring at room temperature for 3 h, the reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane and washed with saturated aqueous $NaHCO_3$ solution, brine, dried (Na_2SO_4) and evaporated to dryness under reduced pressure. Purification by silica gel chromatography (petroleum ether:ethyl acetate (4:1)] provided the intermediate as an red oil. The intermediate was dissolved in dioxane (40 mL) and $NH_3 \cdot H_2O$ (2 mL) was added. After stirring for 30 min, the reaction mixture was evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (10:1)] provided **40** as a brown solid (180 mg, 81%).
LC-MS $(M+H)^+ = 476.1$


Synthesis of compound 4-amino-1-((2R,3R,4R,5R)-5-(difluoromethyl)-3-fluoro-4-hydro xy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (41).



41

[00123] A mixture of compound **40** (160 mg, 0.34 mmol), $Pd(OH)_2/C$ (0.8 g) and concentrated aqueous HCl (2 drops, 37%) in methanol (10 mL) was stirred under an atmosphere of hydrogen for 10 min, filtered and evaporated to dryness under reduced pressure. Purification by preparative HPLC afforded **41** as a white solid (26 mg, 25%). LC-MS $(M+H)^+ = 296.1$ ^1H NMR (300MHz, d_6-DMSO) δ 7.79 (d, J = 7.2 Hz, 1 H), 7.33 (d, J = 10.4 Hz, 2 H), 6.26–5.99 (m, 3 H), 5.77 (d, J = 7.6 Hz, 1 H), 5.44 (t, J = 5.2 Hz, 1 H), 5.15 (dt, J_1 = 53.6 Hz, J_2 = 5.2 Hz, 1 H), 4.58–4.53 (m, 1 H), 3.70–3.58 (m, 2 H).


Synthesis of (S)-1-(benzyloxy)-1-oxopropan-2-aminium chloride (43).



43

[00124] Thionyl chloride (27 mL) was added drop-wise to a solution L-alanine (**42**) (6.83 g, 76.6 mmol) in benzyl alcohol (120 mL). After stirring at 0 °C for 2 h, the reaction mixture was warmed to room temperature and stirred for a further 24 h and then evaporated to dryness under reduced pressure. Trituration with diethyl ether, followed by filtration and evaporation under reduced pressure, provided the crude product **43** (3.5 g), which was used directly without further purification. LC-MS $(M-Cl)^+ = 180$


Synthesis of (2S)-benzyl 2-(chloro(phenoxy)phosphorylamino)propanoate (44).



44

[00125] Phenyl phosphorodichloridate (1.17 g, 2 N) was added to a solution of **43** (1 g, 5.58 mmol) in dichloromethane at –78 °C. Triethylamine (1.13 g, 11.173 mmol) was then added drop-wise. Once complete, the reaction mixture was allowed to warm to room temperature and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [petroleum ether:ethyl acetate (3:1)] provided **44** as an colorless oil (1.2 g, 60%). LC-MS $(M+H)^+ = 354$


Synthesis of compound (45).



45

[00126] To a mixture of compound **8** (0.11 g, 0.375 mmol) and compound 1,1-dimethoxycyclopentane (0.495 g, 3.8 mmol) in dichloromethane was added PTSA (0.01 g). The resulting mixture was stirred at 65 °C for 1 h and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (10:1)] afforded **45** as a white solid (0.17 g, 90%). LC-MS $(M+H)^+ = 360.2$


Synthesis of compound (46).



46

[00127] To a suspension of compound **45** (0.08 g, 0.223 mmol) in dry THF was added t-BuMgBr (1.3 mL, 1.34 mmol) at 0 °C under nitrogen atmosphere, then warmed to 25 °C and stirred for 30 min. The reaction mixture was then cooled to 0 °C and then (2S)-Benzyl 2-(chloro(phenoxy)phosphorylamino)propanoate (0.236 g, 0.668 mmol) was added drop-wise. The reaction mixture was stirred at room temperature for 2 h and then quenched by the addition of methanol (1 mL). The mixture was then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (10:1)] afforded **46** as a white solid (0.19 g). LC-MS $(M+H)^+ = 677.1$

Synthesis of compound (S)-benzyl 2-((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimid in-1(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (47).




47

[00128] A solution of compound **46** (0.18 g, 0.26 mmol) in formic acid (80%, v/v) was stirred at 25 °C for 18 h and then evaporated to dryness under reduced pressure. Purification by prep-HPLC provided **47** as a white solid (12.8 mg, 5%). LC-MS $(M+H)^+ = 611.1$

^{1}H NMR (300MHz, DMSO-d_6) δ 7.55–7.16 (m, 13 H), 6.33–5.97 (m, 3 H), 5.78–5.77 (m, 2 H), 5.47–5.46 (m, 1 H), 5.15–5.06 (m, 2 H), 4.23–3.95 (m, 5 H), 1.28–1.23 (t, J = 7.5 Hz, 3 H).


Synthesis of compound (49).



49

[00129] To a suspension of compound **45** (0.2 g, 0.5 mmol) in dry THF was added t-BuMgBr (3 mL, 3 mmol) at 0 °C under nitrogen atmosphere, then warmed to 25 °C and stirred for 30 min, compound (2S)-neopentyl 2-(chloro(phenoxy)phosphorylamino)propanoate (0.5 g, 1.5 mmol) was added drop wise at 0 °C over 10 min, after addition, the whole mixture was stirred at 25 °C. After 2 hrs, the reaction mixture was quenched with 1 mL MeOH and then evaporated to dryness under reduced pressure. Purification by silica gel chromatography [dichloromethane:methanol (20:1 to 15:1)], provided **49** as a white solid (0.3 g, crude). LC-MS $(M+H)^+$ = 657

Synthesis of compound (S)-neopentyl 2-((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrim idin-1(2H)-yl)-2-(difluoromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (50)



50

[00130] A solution of compound 49 (0.3 g, crude) in HCOOH (80%, v/v, 30 mL) was stirred at room temperature. After 12 h the reaction mixture was cooled to 0 °C and neutralized with 1M

aqueous NaHCO3 solution. The organic phase was extracted with ethyl acetate, washed with water, brine solution, dried (Na2SO4) and evaporated to dryness under reduced pressure. Purification by prep-HPLC provided 50 (17 mg, 9.8%) as a white solid. LC-MS $(M+H)^+$ = 590.9 ^{1}H NMR (300MHz, DMSO-d_6) δ 7.54–7.18 (m, 8 H), 6.32–6.06 (m, 3 H), 5.81–5.65 (m, 2 H), 5.48–5.46 (m, 1 H), 4.24–4.12 (m, 4 H), 3.95–3.89 (dd, 1 H), 3.79–3.69 (m, 2 H), 1.29–1.24 (m, 3 H), 0.88 (s, 9 H).

Biological Examples

Influenza Assay

[00131] This assay measures the ability of the active compounds derived from the compounds of formula I to inhibit the essential influenza RNA polymerase. The influenza polymerase was obtained from purified influenza virus particles and the rate of nucleotide incorporation was measured from the quantitation of a radiolabeled nucleotide tracer during the polymerase reaction.

Metabolism Assay

[00132] This assay measures the ability of human cells to generate the active compounds from the compounds of formula I. The active compounds are the triphosphate (TP) derivatives of the nucleoside analogs. The assay is determining the concentration of specific nucleoside triphosphates formed in human cells exposed to compounds of formula I after methanol extraction of cells and analysis of soluble nucleoside triphosphate using LC-MS.

Table 2. Activity of nucleotide triphosphates in influenza polymerase assay.


Compound Number	Structure	Activity IC_{50} µM
TPP-1		B










Table 2. Activity of nucleotide triphosphates in influenza polymerase assay.		
Compound Number	**Structure**	**Activity IC_{50} μM**
TPP-2		B
TPP-3		B
TPP-4		A
TPP-5		B
TPP-6		A
TPP-7		C
TPP-8		A

Table 2. Activity of nucleotide triphosphates in influenza polymerase assay.		
Compound Number	**Structure**	**Activity IC_{50} μM**
TPP-9		A
TPP-10		A

Activity in influenza polymerase assay is as follows: A = IC_{50} < 10 μM; B = IC_{50} 10-100 μM; C = IC_{50} >100 μM

Dosage and Administration

[00133] As shown in above Table the compounds of formula I have the potential to be efficacious as antiviral drugs for the treatment of influenza infections in humans, or are metabolized to a compound that exhibit such activity.

[00134] In another embodiment of the invention, the active compound or its prodrug derivative or salt can be administered in combination with another antiviral agent, such as an anti-influenza agent or an immunomodulatory compound, including those of formula I. When the active compound or its derivative or salt are administered in combination with another antiviral or immunomodulatory agent the activity may be increased over the parent compound. This can easily be assessed by preparing the derivative and testing its anti-influenza activity according to the method described herein.

[00135] Administration of the active compound may range from continuous (intravenous drip) to several or single administrations per day (for example, Q.I.D) or less frequent administrations and may include oral, topical parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration.

[00136] The 4'-difluoromethyl substituted nucleoside derivatives as well as their pharmaceutically useable salts, can be used as medicaments in the form of any pharmaceutical formulation. The pharmaceutical formulation can be administered enterally, either orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions, syrups, or suspensions, or rectally, e.g. in the form of suppositories. They can also be administered parenterally (intramuscularly, intravenously, subcutaneously or intrasternal injection or infusion techniques), e.g. in the form of injection solutions, nasally, e.g. in the form of nasal sprays, or inhalation spray, topically and so forth.

[00137] For the manufacture of pharmaceutical preparations, the 4'-substituted nucleoside derivatives, as well as their pharmaceutically useable salts, can be formulated with a therapeutically inert, inorganic or organic excipient for the production of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.

[00138] The compounds of formula I can be formulated in admixture with a pharmaceutically acceptable carrier. For example, the compounds of the present invention can be administered orally as pharmacologically acceptable salts. Because the compounds of the present invention are mostly water soluble, they can be administered intravenously in physiological saline solution (e.g., buffered to a pH of about 7.2 to 7.5). Conventional buffers such as phosphates, bicarbonates or citrates can be used for this purpose. Of course, one of ordinary skill in the art may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity. In particular, the modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.) which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

[00139] For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, though other ingredients including those which aid dispersion may be included. Of course, where sterile water is to be used and maintained as sterile, the compositions

and carriers must also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.

[00140] Suitable excipients for tablets, coated tablets, dragées, and hard gelatin capsules are, for example, lactose, corn starch and derivatives thereof, talc, and stearic acid or its salts.

[00141] If desired, the tablets or capsules may be enteric-coated or sustained release by standard techniques.

[00142] Suitable excipients for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols.

[00143] Suitable excipients for injection solutions are, for example, water, saline, alcohols, polyols, glycerin or vegetable oils.

[00144] Suitable excipients for suppositories are, for example, natural and hardened oils, waxes, fats, semi-liquid or liquid polyols.

[00145] Suitable excipients for solutions and syrups for enteral use are, for example, water, polyols, saccharose, invert sugar and glucose.

[00146] The pharmaceutical preparations of the present invention may also be provided as sustained release formulations or other appropriate formulations.

[00147] The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavourants, salts for adjustment of the osmotic pressure, buffers, masking agents or antioxidants.

[00148] The pharmaceutical preparations may also contain other therapeutically active agents known in the art.

[00149] The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case. For oral administration, a daily dosage of between about 0.01 and about 100 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 100 mg/kg body weight per day. A typical preparation will contain from about 5% to about 95% active compound (w/w). The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day.

[00150] In certain pharmaceutical dosage forms, the pro-drug form of the compounds, especially including acylated (acetylated or other) derivatives, pyridine esters and various salt

forms of the present compounds are preferred. One of ordinary skill in the art will recognize how to readily modify the present compounds to pro-drug forms to facilitate delivery of active compounds to a target site within the host organism or patient. One of ordinary skill in the art will also take advantage of favorable pharmacokinetic parameters of the pro-drug forms, where applicable, in delivering the present compounds to targeted site within the host organism or patient to maximize the intended effect of the compound.

Indications and Method of Treatment

[00151] The application provides a method for treating a Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I.

[00152] The application provides the above method, further comprising administering an immune system modulator or one or more antiviral agents that inhibits replication of Influenza, or a combination thereof.

[00153] The application provides the above method for inhibiting replication of Influenza in a cell comprising administering a compound of Formula I.

Combination Therapy

[00154] The compounds of the invention and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing influenza infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the influenza lifecycle. Classes of compounds useful in the invention include, without limitation, all classes of influenza antivirals.

[00155] The present invention is not limited to the aforementioned classes or compounds and contemplates known and new compounds and combinations of biologically active agents. It is intended that combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds of the inventive group or other compounds outside of the inventive group, as long as the combination does not eliminate the anti-viral activity of the compound of this inventive group or the anti-viral activity of the pharmaceutical composition itself.

[00156] Combination therapy can be sequential, that is treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be treatment with both agents at the same time (concurrently). Sequential therapy can include a reasonable time after the completion of the first therapy before beginning the second therapy. Treatment with both agents at the same time can be in the same daily dose or in separate doses. Combination therapy need not be limited to two agents and may include three or more agents. The dosages for both concurrent and sequential combination therapy will depend on absorption, distribution, metabolism and excretion rates of the components of the combination therapy as well as other factors known to one of skill in the art. Dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules may be adjusted over time according to the individual's need and the judgment of the one skilled in the art administering or supervising the administration of the combination therapy.

[00157] It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions, and that the treatment of animals includes the treatment of humans as well as other mammals. Furthermore, treatment of an Influenza infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by Influenza infection, or the clinical symptoms thereof.

[00158] The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.

[00159] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the

above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

[00160] All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

WE CLAIM:

1. A compound of Formula I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl, (1*H*-indol-4-yl)methyl, $-(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;
or R^3 and R^x together form a bond;
or R^1 and R^x together form a bond;
X is O or S;
Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
with the proviso that if R^w is H, R^y is H, and R^z is H, then R^x is not H; and
with the proviso that Formula I is not ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(difluoromethyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;
or a pharmacologically acceptable salt thereof.

2. The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is OH.

3. The compound of claim 1, wherein R^W is F, R^y is H, R^x is F, and R^z is OH.

4. The compound of claim 1, wherein R^W is OH, R^y is H, R^x is H, and R^z is OH.

5. The compound of claim 1, wherein R^W is F, R^y is H, R^x is H, and R^z is OH.

6. The compound of claim 1, wherein R^W is H, R^y is H, R^x is F, and R^z is OH.

7. The compound of claim 1, wherein R^W is H, R^y is OH, R^x is OH, and R^z is H.

8. The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is F.

9. The compound of claim 1, wherein R^W is H, R^y is F, R^x is OH, and R^z is H.

10. The compound of claim 1, wherein R^W is H, R^y is H, R^x is OH, and R^z is F.

11. The compound of claim 1, wherein R' is O-R^3, R^3 is lower alkyl, R is $-OR^1$, and R^1 and R^x together form a bond.

12. The compound of claim 1, wherein R is $-OR^1$, R^1 is phenyl substituted with $R^{1''}$, R' is $-OR^3$, and R^3 and $R^{1''}$ together form CH_2.

13. The compound of claim 1, wherein X is O.

14. The compound of claim 1, wherein X is S.

15. The compound of claim 1, wherein R is O-R^1, and R^1 is phenyl optionally substituted with methoxy.

16. The compound of claim 1, wherein R is O-R^1, and R^1 is naphthylenyl.

17. The compound of claim 1, wherein R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, R^4 is H, R^{2a} is H, R^{2b} is methyl, and R^3 is isopropyl.

18. The compound of claim 1, wherein R' is -OP(=O)(OH)OP(=O)(OH)OH.

19. The compound of claim 1, wherein Base is cytidine optionally substituted with halo.

20. The compound of claim 1, wherein Base is uridine optionally substituted with halo.

21. The compound of claim 1, wherein Base is guanosine.

22. The compound of claim 1, wherein Base is adenosine.

23. A compound selected from the list consisting of:

4'-Difluoromethyluridine;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4'-Difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

4'-Difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

4'-Difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethyl-5-fluorouridine;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl5-fluorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorouridine;

4’-Difluoromethyl-5-fluorouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluorouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorouridine;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

4’-Difluoromethyl-5-chlorouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylcytidine;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

4’-Difluoromethylcytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylcytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluorocytidine;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl-5-fluorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-fluorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-fluorocytidine;

4’-Difluoromethyl-5-fluorcytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluorocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorocytidine;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl5-chlorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-chlorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethyl-5-chlorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] -5-chlorocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] -5-chlorocytidine;

4’-Difluoromethyl-5-chlorocytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-chlorocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyladenosine;

4’-Difluoromethyladenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4’-Difluoromethyladenosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyladenosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-7-adenosine;

4’-Difluoromethyl-7-adenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-7-adenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-7-adenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-7-adenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-7-adenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-7-adenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-7-adenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-7-adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-7-adenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

4’-Difluoromethyl-7-adenosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-7-adenosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylguanosine;

4’-Difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

4’-Difluoromethylguanosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylguanosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-fluorouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-fluorouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5-chlorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’-fluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-fluorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorocytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5-chlorocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethyladenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

2'-Deoxy-2',5-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2',5-difluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-2'fluoro-4'-difluoromethylaracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

4-Chloro-2'-deoxy-4'-difluoromethyl-2'-fluoroaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadenosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraadenosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethlaraguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethylaraguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

2'-Deoxy-2'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-4'-difluoromethyl-2'-fluoroaraguanosine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyluridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyluridine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Dideoxy-2’-difluoro-4’-difluoromethyluridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Dideoxy-2’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-uridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-fluorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-chlorouridine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5-chlorouridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethylcytdine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethylcytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroucytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluorocytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5-fluorocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2’-deoxy-2,2’’-difluoro-4’-difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethylcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2’-deoxy-2’,2’-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl) cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

5-Chloro-2'-deoxy-2',2'-difluoro-4'-difluoromethylcytidine-3',5'-cyclic phosphoric acid isopropyl ester;

2'-Deoxy-2',2'-fluoro-4'-difluoromethylcytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

2'-Deoxy-2'2'-difluoro-4'-difluoromethyladenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyladenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

2'-Deoxy-2',2'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethyladenosine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethyladenosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine;

2’-Deoxy-2’,2’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-3’,5’-cyclic phosphoric acid isopropyl ester;

2’-Deoxy-2’,2’-difluoro-4’-difluoromethylguanosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylarauridine;

4’-Difluoromethylarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethlarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate};

4’-Difluoromethylarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate};

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] arauridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] arauridine;

4’-Difluoromethylarauridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylarauridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroarauridine;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate

4’-Difluoromethyl-5-fluoroarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate

4’-difluoromethyl-5-fluoroarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-5-fluoroarauridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroarauridine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroarauridine;

4’-Difluoromethyl—5-fluoroarauridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroarauridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4’-difluoromethylarauridine;

5-Chloro-4’-difluoromethylarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylarauridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2’-deoxy-2’-fluoro-4’-difluoromethylarauridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylarauridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylarauridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-arauridine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-arauridine;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylarauridine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaracytidine;

4'-Difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] aracytidine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] aracytidine;

4’-Difluoromethylaracytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylaracytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroaracytidine;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-difluoromethyl-5-fluoroaracytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-5-fluoroaracytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroaracytidine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroaracytidine;

2’-Deoxy-2’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluoroaracytidine;

4’-Difluoromethyl—5-fluoroaracytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroaracytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4-Chloro-2'-deoxy-2'-fluoro-4'-difluoromethylaracytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro -4'-difluoromethylaracytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-aracytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-aracytidine;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylaracytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylaraadenosine;

4'-Difluoromethylaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethlaraadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraadenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylaraadenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraadenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylaraadenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraadenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylaraadenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araadenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] araadenosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araadensoine;

4’-Difluoromethylaraadenosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylaraadenosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylaraguanosine;

4’-Difluoromethylaraguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethlaraadenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylaraguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylaraguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylaraguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylaraguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-araguanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] araguanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] araguanosine;

4’-Difluoromethylaraguanosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylaraguanosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3’-Deoxy-3’-fluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethylxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-3’-deoxy-3’-fluoro-4’-difluoromethylxylouridine;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-3'-deoxy -3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3'-Deoxy-3'5-difluoro-4'-difluoromethylxylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3'-Deoxy-3',5-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

3’-Deoxy-3’,5-difluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-3’-deoxy-3’-fluoro-4’-difluoromethylxylocytidine;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethylxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3’-deoxy-3’-fluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-3’-deoxy -3’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-3’-deoxy 3’-fluoro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

3’-Deoxy-3’-fluoro-4’-difluoromethylxyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethylxyloguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

3'-Deoxy-3'-fluoro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4'-Difluoromethylxylouridine;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxylouridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxylouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

4’-Difluoromethylxylouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylxylouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroxylouridine;

4’-Difluoromethyl-5-fluoroxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluororxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-5-fluororxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylouridine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylouridine;

4’-Difluoromethyl-5-fluoroxylouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroxylouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4’-difluoromethylxylouridine;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4’-difluoromethylxylouridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylouridine;

5-Chloro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylouridine;

5-Chloro-4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylouridine;

5-Chloro-4’-difluoromethylxylouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

5-Chloro-4’-difluoromethylxylouridine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylxylocytidine;

4’-Difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

4’-Difluoromethylxylocytidine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylxylocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroxylocytidine;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluororxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethyl-5-fluoroxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethyl-5-fluororxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4’-Difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-5-fluoroxylocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluoroxylocytidine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluororxylocytidine;

4’-Difluoromethyl-5-fluoroxylouridine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethyl-5-fluoroxylocytidine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

5-Chloro-4’-difluoromethylxylocytidine;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-4’-difluoromethylxylocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-4'-difluoromethylxylocytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xylocytidine;

5-Chloro-4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xylocytidine;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic phosphoric acid isopropyl ester;

5-Chloro-4'-difluoromethylxylocytidine-3',5'-cyclic thiophosphoric acid isopropyl ester;

4'-Difluoromethylxyloadenosine;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl; phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4'-Difluoromethylxyloadenosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4'-Difluoromethylxyloadenosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloadenosine;

4'-Difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloadenosine;

4'-Difluoromethylxyloadenosine-3',5'-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylxyloadenosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

4’-Difluoromethylxyloguanosine;

4’-Difluoromethylxyloguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxyloguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxyloguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxyloguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxyloguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

4’-Difluoromethylxyloguanosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

4’-Difluoromethylxyloguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

4’-Difluoromethylxyloguanosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] xyloguanosine;

4’-Difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] xyloguanosine;

4’-Difluoromethylxyloguanosine-3’,5’-cyclic phosphoric acid isopropyl ester;

4’-Difluoromethylxyloguanosine-3’,5’-cyclic thiophosphoric acid isopropyl ester;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyluridine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorouridine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluororuridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5-fluorouridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorouridine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorouridine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethyluridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethyluridine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] uridine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine;

3’-Deoxy-3’.3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluororcytidine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluororcytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5-fluorocytidine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethy -5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)- 5-fluorocytidine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl]-5-fluorocytidine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl]-5-fluorocytidine;

5-Chloro-3'-deoxy-3',3'-difluoro-4'-difluoromethylcytidine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro-4'-difluoromethylcytidine-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] cytidine;

5-Chloro-3'-deoxy -3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] cytidine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyladenosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylcytidine-5'-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyladenosine-5’-{*N,N’*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethyl-5’-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)phosphinyl] adenosine;

3’-Deoxy-3’,3’-difluoro -4’-difluoromethyl-5’-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] adenosine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethylguanosine;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethylguanosine-5’-(*O*-phenyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3’-Deoxy-3’,3’-difluoro-4’-difluoromethylguanosine-5’-(*O*-1-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-(*O*-2-naphthyl-*N*-(S)-1-(isopropoxycarbonyl)ethyl thiophosphoramidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]phosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethylguanosine-5'-{*N,N'*-bis[(S)-1-(isopropoxylcarbonyl)ethyl]thiophosphorodiamidate;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro-4'-difluoromethyl-5'-*O*-(2-sulfide-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)phosphinyl] guanosine; and

3'-Deoxy-3',3'-difluoro -4'-difluoromethyl-5'-*O*-[bis(4-methoxyphenoxy)thiophosphinyl] guanosine.

24. A method of preventing or treating Influenza comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

25. A composition comprising the compound of claim 1, admixed with at least one carrier, diluent or excipient.

26. A composition comprising the compound of claim 1 in combination with one or more antiviral compounds.


27. A composition comprising the compound of claim 1 in combination with one or more anti-Influenza compounds.

28. A composition comprising the compound of claim 1 in combination with one or more antiviral compounds, admixed with at least one carrier, diluent or excipient.

29. A composition comprising the compound of claim 1 in combination with one or more anti-Influenza compounds, admixed with at least one carrier, diluent or excipient.

30. A method of preventing or treating a viral infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

31. A method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a compound resulting in the formation of a compound of Formula I in vivo,



I

wherein:

Y is H or P(=X)(R')(R);

R is O-R^1 or $NHR^{1'}$;

$R^{1'}$ is $-C(R^{2a})(R^{2b})C(=O)OR^3$;

R' is $N(R^4)C(R^{2a})(R^{2b})C(=O)OR^3$, –OP(=O)(OH)OP(=O)(OH)OH, or $–OR^3$;

R^1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, $-N(R^{1a})_2$, acylamino, $-SO_2N(R^{1a})_2$, $-C(=O)R^{1b}$, $-SO_2(R^{1c})$, $-NHSO_2(R^{1c})$, nitro, cyano, or $R^{1''}$;

each R^{1a} is independently H or lower alkyl;

each R^{1b} is independently $-OR^{1a}$ or $-N(R^{1a})_2$;

each R^{1c} is lower alkyl;

each R^{2a} and R^{2b} is independently H, lower alkyl, $-(CH_2)_rN(R^{1a})_2$, lower hydroxyalkyl, $-CH_2SH$, $-(CH_2)S(O)_pMe$, $-(CH_2)_nNHC(=NH)NH_2$, (1*H*-indol-3-yl)methyl,

(1*H*-indol-4-yl)methyl, -$(CH2)_mC(=O)R^{1b}$, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

m is 0, 1, or 2;

n is 1, 2, or 3;

p is 1 or 2;

r is 1 or 2;

or R^{2a} is H and R^{2b} and R^4 together form $(CH_2)_n$;

each R^3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;

or R^3 and $R^{1''}$ together form CH_2;

each R^4 is independently H, lower alkyl;

or R^{2b} and R^4 together form $(CH_2)_3$;

R^w, R^y, and R^z are each independently H, OH or F;

R^x is H, OH, or F;

or R^3 and R^x together form a bond;

or R^1 and R^x together form a bond;

X is O or S; and


Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;

or a pharmacologically acceptable salt thereof.

32. A method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

33. A method for preventing or treating an Influenza infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 23.

ABSTRACT



I

The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [x] The attached application, or
- [ ] United States application or PCT international application number _____

  filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Mark Smith Date (Optional): 2/4/15

Signature: M Smith

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [■] The attached application, or
- [ ] United States application or PCT international application number _____

filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Klaus G. Klumpp Date (Optional): 02-04-2015

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Filer:	Jennifer Kisko/Lynnette Dewitz
Attorney Docket Number:	596000-00410

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Utility application filing	1011	1	280	280
Utility Search Fee	1111	1	600	600
Utility Examination Fee	1311	1	720	720
Pages:				
Utility Appl Size fee per 50 sheets >100	1081	4	400	1600
Claims:				
Miscellaneous-Filing:				
Petition:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
		Total in USD ($)		**3200**

Electronic Acknowledgement Receipt

EFS ID:	21423171
Application Number:	14615928
International Application Number:	
Confirmation Number:	4203
Title of Invention:	4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
First Named Inventor/Applicant Name:	Mark Smith
Customer Number:	115777
Filer:	Jennifer Kisko/Lynnette Dewitz
Filer Authorized By:	Jennifer Kisko
Attorney Docket Number:	596000-00410
Receipt Date:	06-FEB-2015
Filing Date:	
Time Stamp:	14:48:20
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$3200
RAM confirmation Number	1189
Deposit Account	501678
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	ADS.pdf	1503261 d9996ea1bdd427472f215485edfa986ed8ee542f	no	6
Warnings:					
Information:					
2		Spec_US.pdf	5334139 c5f05707460c102fb04d073dd93a88dfea0df909	yes	354

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Specification	1	291
	Claims	292	353
	Abstract	354	354

Warnings:					
Information:					
3	Oath or Declaration filed	Decl.pdf	881641 ce36c8631310cf011bfb6197f9dc10a340d84825	no	2
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	36920 db9ce0a01ec7b0e41504a93e5edfdd838b8ec317	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	7755961		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

115777 7590 02/18/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

EXAMINER
MCINTOSH III, TRAVISS C

ART UNIT	PAPER NUMBER
1673	

DATE MAILED: 02/18/2016

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TITLE OF INVENTION: 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	05/18/2016

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

115777 7590 02/18/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

TITLE OF INVENTION: 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	05/18/2016

EXAMINER	ART UNIT	CLASS-SUBCLASS
MCINTOSH III, TRAVISS C	1673	514-047000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:

❑ Issue Fee

❑ Publication Fee (No small entity discount permitted)

❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**

❑ A check is enclosed.

❑ Payment by credit card. Form PTO-2038 is attached.

❑ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

❑ Applicant asserting small entity status. See 37 CFR 1.27

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

❑ Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

PTOL-85 Part B (10-13) Approved for use through 10/31/2013. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/615,928	02/06/2015	Mark Smith	596000-00410	4203

115777 7590 02/18/2016

Jennifer L. Kisko
GrayRobinson, P.A.
301 E. Pine Street
Suite 1400
Orlando, FL 32801

EXAMINER	
MCINTOSH III, TRAVISS C	
ART UNIT	PAPER NUMBER
1673	

DATE MAILED: 02/18/2016

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 14/615,928	Applicant(s) SMITH ET AL.	
	Examiner TRAVISS C. MCINTOSH III	Art Unit 1673	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *amendment filed 12/3/2015*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *1-10,13,14,16,17,23-26,31 and 33*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov .
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
   Certified copies:
   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
5. ☐ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/TRAVISS C MCINTOSH III/
Primary Examiner, Art Unit 1673

REASONS FOR ALLOWANCE

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

The following is an examiner's statement of reasons for allowance: applicant's amendments and arguments have overcome the rejections set forth in the 11/9/2015 office action. The prior art is not seen to teach or fairly suggest the instantly claimed compounds which require a 4'-CF_2H group and also has the claimed bases. The closest art is seen to be 2015/0011497 (of record) – but the compounds therein comprise either a 4'-CH_2CHF_2 or are delimited by the proviso set forth in the instant claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/TRAVISS C MCINTOSH III/
Primary Examiner, Art Unit 1673